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INTRODUCTION
Viral quasispecies evolution refers to the fact that RNA viralpopulations consist of mutant spectra (or mutant clouds)
rather than genomes with the same nucleotide sequence. Mutant
spectra and not individual genomes are the target of evolutionary
events. Quasispecies evolution is decisively influenced by high
mutation rates (rate of nucleotide misincorporation per nucleo-
tide copied) during viral replication and in some cases also by
molecular recombination and genome segment reassortment.
Mutation rates are such that it is unlikely to produce inside any
infected cell a progeny viral RNA molecule identical to its imme-
diate parental template. Viral genomic sequences would rapidly
expand in sequence space and lose biological information were it
not for continuous elimination of unfit genomes, a process known
as negative selection.Mutant spectra are the source of virus adapt-
ability because they constitute dynamic (continuously changing)
repositories of genotypic and phenotypic viral variants.
Major events in the biology of RNA viruses, such as their ca-
pacity to change their cell tropism or host range or to overcome
internal or external selective constraints (immune responses, an-
tiviral agents, etc.), have their origin in the repertoire of variants
present and arising in mutant spectra. Major difficulties for dis-
ease prevention and treatment stem from quasispecies dynamics,
and we examine strategies that have been proposed to overcome
the adaptive potential of RNAviruses.Mutant clouds are notmere
aggregates of independently acting mutants. Rather, internal in-
teractions of cooperativity or interference can be established
among components of a mutant spectrum, mainly through their
expression products. As a consequence of such interactions, an
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ensemble of mutants (not an individual mutant) can frequently
determine the biological behavior of a viral population. Recogni-
tion of intraquasispecies interactions has influenced research on
an antiviral strategy that aims at extinguishing viruses through
intensification of negative intrapopulation interactions, which
may contribute to deterioration of viral functions. This new strat-
egy is termed lethalmutagenesis, and it is gradually finding its way
toward a clinical application.
This review is centered on the principles of viral quasispecies
and their relevance for the behavior of viruses, with emphasis on
medical implications. Field observations and experiments in cell
culture and in vivo are reviewed and discussed, with the main
objective of establishing concepts relevant to the understanding of
viruses that display error-prone replication. We address the qua-
sispecies-derived mechanisms that mediate adaptability for per-
sistence, both within individual hosts and also at the host popula-
tion level. Highly variable RNA viruses are among the most
important human, animal, and plant pathogens, and the penulti-
mate section covers quasispecies dynamics for three salient hu-
man pathogens: human immunodeficiency virus type 1 (HIV-1),
hepatitis B virus (HBV), and hepatitis C virus (HCV). In the con-
clusion of the article, extensions of quasispecies to nonviral sys-
tems and some possible course of events and future developments
are addressed.
Some terms and parameters relevant to the characterization of
viral quasispecies are given in Table 1.
THEORETICAL AND EXPERIMENTAL ORIGINS OF
QUASISPECIES
Quasispecies Theory and Its Adequacy for Viruses
Virologists adopted the term “quasispecies” from a theory on the
adaptability of self-replicative entities that might have been key
components at the origin of primitive forms of life. A pioneer
study by Manfred Eigen on a quantitative treatment of the evolu-
tion of biological macromolecules (encouraged by Francis Crick
and inspired by early in vitro RNA replication experiments by Sol
Spiegelman and colleagues) had the merit of integrating for the
first time concepts of information theory with Darwinian natural
selection (237). The study represented the first theoretical treat-
ment of self-instructive behavior required for template activity, as
a necessity for the origin of inheritable information. According to
Eigen’s theory, a master copy of the self-replicative molecule pro-
ducesmutant versions with a certain probability distribution. The
production of mutant copies is dependent on a quality factor that
determines the fraction of copying processes that leads to an exact
copy of the template and the fraction that leads to error copies of
the template. Eigen used the term “comet tail” to refer to error
copies, and the terms “quasispecies” and “mutant spectrum,” now
used in virology, were introduced later (240–242). Thus, the initial
study by Eigen was a quantitative treatment of error-prone repli-
cation, an important achievement in evolutionary biology in-
tended to explain the events involved in the origin of life (237).
The theory represented the introduction of a molecular view into
evolutionary biology.
Quasispecies theory was further developed by Manfred Eigen
and Peter Schuster in a series of theoretical papers that defined
quasispecies as steady-state mutant distributions, dominated by a
master sequence that displays the highest replication rate among
the components of the mutant spectrum (243). Furthermore, the
theory defined “hypercycles” as a principle of natural self-organi-
zation, to integrate different quasispecies into higher-order orga-
nizations that facilitated evolution into more complex forms, ide-
ally combining the coding capacity of nucleic acids with the
catalytic activities of proteins (243).
In addition to defining in quantitative terms a replicative sys-
tem with a high mutational input, quasispecies theory established
a condition needed to ensure the stable conservation of genetic
information. Such a condition was formulated as an error thresh-
old relationship. The error threshold means that for any given
complexity (amount of nonredundant genetic information con-
veyed by a replicative system), there is amaximumerror rate com-
patible with the maintenance of that genetic information. The
error threshold value depends on the replication accuracy and the
fitness of the dominant or master sequence relative to the mean
fitness value of the error copies (243). The error threshold corre-
sponds to the (mean) mutation rate (per site and replication) at
which the frequency of the master sequence becomes very small
and vanishes for practical purposes (Fig. 1) (789). The two funda-
mental equations of quasispecies theory are the dynamics of error
TABLE 1 Some terms and parameters relevant to the characterization of
viral quasispecies
Term (definition) Comment or implication
Mutation ratea (the frequency
of occurrence of a
mutation during genome
replication)
It is a biochemical event, independent of
the fitness of parental and mutated
genomes
Mutation frequencyb (the
proportion of mutations
[any mutation, a mutation
at a specific genome site, or
a mutation type] in a
population of genomes)
It is a population number, dependent on
the relative fitness of the genomes
harboring the mutations relative to
nonmutated genomes
Rate of evolutionc (the
number of mutations that
accumulate in viral
genomes as a function of
time)
The key difference from the mutation
rate and frequency is that it includes a
time factor
Mutant spectrum or mutant
cloudd (the ensemble of
genomes that constitute a
viral quasispecies)
Its complexity and composition are
highly relevant biologically
a Expressed as substitutions per nucleotide copied. Several genetic and biochemical
procedures have been used to determine mutation rates, with a general agreement that
for RNA viruses they are in the range of 103 to 105 mutation introduced per
nucleotide copied (see text for references).
b Expressed as substitutions per nucleotide. Mutation frequencies are influenced by
many biochemical and environmental factors, with one being the fidelity of the viral
polymerases, which determines the mutation rate (see text).
c Often expressed as substitutions per site per year. It may refer to intrahost or interhost
replication of viral populations.
d The complexity of a mutant spectrum can be calculated from nucleotide sequences
obtained either by classic molecular cloning and Sanger sequencing or by ultradeep
sequencing. The classic method involves biological or molecular cloning, partial or
complete nucleotide sequence determination, sequence alignment (generally 10 to 100
sequences per sample), and calculation of average genetic distances (average number of
mutations that distinguish any two genomic sequences), mutation frequency (number
of different mutations divided by total number of nucleotides sequenced), and Shannon
entropy (proportion of sequences that are identical). Ultradeep sequencing involves
amplification of short nucleotide sequences from a viral population and derivation of
corrected reads (generally 105 to 106 sequences per genomic region) to calculate
complexity (see text).
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copy production and the error threshold relationship (Fig. 1).
They convey concepts that have exerted a great influence in de-
scribing, understanding, and at times even predicting the behavior
of viral populations, including strategies for controlling virus dis-
ease (reviewed in references 187, 192, 211, 236, 238, and 466).
Quasispecies theory as formulated initially was a “determinis-
tic” theory. That is, when numerical values are assigned to a num-
ber of parameters, the system described by the equation that re-
lates the different parameters is predictable. Deterministic
theoretical models are usually articulated first because they can be
solved mathematically. Determinism in quasispecies means that
the theory assumed mutant distributions of infinite size in equi-
librium (239, 243). Some geneticists have argued that the origi-
nally deterministic nature of quasispecies theory invalidated its
adequacy for RNA viruses. However, it must be considered that a
common procedure in theoretical studies is to extend determin-
istic models to incorporate stochastic (chance) events and that
many generalized theories in physics, chemistry, and biologymust
be modified to fit real systems. In the case of quasispecies, several
extensions to finite replicon (meaning any type of replicating en-
tity) populations under nonequilibrium conditions (that is, in
variable fitness landscapes) have been elaborated by Eigen and
other authors (17, 234, 605, 608, 611, 636, 712–714, 741, 794, 863).
The extensions to finite populations of the core concepts embod-
ied in quasispecies theory justify even more the current use of the
term “quasispecies” in virology (206, 373, 652). It is unlikely that
the primitive replicons that quasispecies theory intended to rep-
resent fulfilled the conditions of equilibrium.
Viral quasispecies are perceived differently by physicists, chem-
ists, biologists, and medical experts in infectious diseases. To
physicists, a quasispecies is regarded as a cloud in sequence space,
and viral quasispecies represented an experimental verification of
the theory. To chemists, quasispecies are distributions of related
but nonidentical nucleotide sequences, a definition familiar to
virologists. To biologists a quasispecies is the target of selection,
and the term does not imply a modification of the biological spe-
cies concept (despite some ambiguity in the early literature on
quasispecies). To experts in infectious diseases, quasispecies are
the dynamic swarms of mutant viruses (particularly drug-resis-
tant mutants) that they have to confront during antiviral therapy
(these views on quasispecies and the adequacy of the term quasi-
species in virology were previously discussed [206]).
Quasispecies theory and the supporting mathematical equa-
tions (Fig. 1) are closely connected with equations that describe
other models of evolutionary dynamics (625). There is no funda-
mental conflict between quasispecies and the mutation-selection
models of population genetics (578, 861). However, in contrast to
population genetics, quasispecies theory has no problems in in-
cluding epigenetic effects or RNA interference in the process of
template copying, provided the mechanisms are known. Alterna-
tive terms to quasispecies, such as intrahost variation, intrahost
diversity, mixture of mutants, nucleotide degeneracy, hyperp-
loidy, heterospecies, or heteropopulations, have been proposed
(commented on in reference 206). Any terminology is acceptable
provided it transmits the true nature of viral populations. How-
ever, alternative terms fail to recognize quasispecies theory as the
conceptual origin of mutant spectra. We do not consider it neces-
sary to revisit arguments on why quasispecies theory has been
more influential on experimental virology than classical popula-
tion genetics (a point discussed in references 619 and 652). Our
aim is to analyze some of the biological implications of viruses
replicating as highly complex mutant distributions, including
how this point of view on viral populations can contribute to the
control of viral disease. We acknowledge considerable literature
on theoretical aspects connected with quasispecies, which com-
prises extensions of quasispecies theory to finite populations in
variable environments, effects of replication models on the distri-
bution ofmutations, dynamics of infection, coinfection, and virus
spread, compartmentalization of infection, cooperation versus
defection, attenuation and virulence, complexity, self-organiza-
tion, and error catastrophe. Despite their importance, we quote
only a limited number of theoretical studies either to assist in the
interpretation of experimental observations or to reinforce mu-
tual support between theory and experiment in reaching a key
conclusion.
Early Research on Reverse Genetics of Bacteriophage Q
and Quasispecies Dynamics
During the second half of the 20th century, RNA viruses became
well established as research objects following the discovery of RNA
bacteriophages (492). Soon after, there were indications that their
geneticsmight be unusual in the sense that some phenotypic traits
(temperature sensitivity, plaque size, etc.) did not remain invari-
ant (for review of evidence of RNA virus variability from the pre-
genomics era, see reference [203]). Someof these early suggestions
concerned the RNA bacteriophages that infect Escherichia coli,
notably MS2 (the first biological entity whose entire genome was
sequenced [278]) and Q, an attractive system to study RNA ge-
nome replication, regulation of gene expression, and formation of
RNA viral particles (855). Specifically, in 1969, Raymond C. Val-
entine and colleagues reported that a stock of bacteriophage Q
FIG 1 The two fundamental equations of quasispecies theory (243). The first
equation describes the concentration of mutant i as a function of time, xi(t),
and accordingly, xk(t) describes the concentration of mutant k. Ai,Di, andWik
are reaction rate parameters for the replication of i, for the degradation of i,
and for the error-prone synthesis of i on k being the template, respectively. The
factor Qi expresses the fraction of correct replications producing i through
copying of template i.i is a function which describes the flux of molecules as
a consequence of the embedding of the replication-mutation system in some
environment. In a simple flow reactor, i would be proportional to the con-
centration of i. This equation describes the dynamics of mutant generation
within mutant spectra, as represented schematically in Fig. 2, 3, and 5. Exten-
sions of the original equation have been developed, as described in references
quoted in the text. The second equation is the error threshold relationship, in
which max is themaximum genetic complexity that can bemaintained during
replication,0 is the selectivity or superiority of themaster sequence relative to
the sequences of the mutant spectrum, and q is the average copying fidelity of
the replicative system, with 1  q being the average error rate per site and
replication. The equation shows two important conditions: (i) the existence of
a maximal sequence length max for constant replication accuracy (left side)
and (ii) the existence of a maximal error rate for constant sequence length
(right side). Exceeding the limiting values leads to a breakdown of inheritance.
The second case is of particular importance in virology since a drug-induced
increase of the mutation rate may drive a virus population beyond the error
threshold. This lies at the basis of lethal mutagenesis, depicted schematically in
Fig. 12 and discussed in the text.
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contained 8% temperature-sensitive mutants (821). They con-
cluded that “replication errors constantly replenished the mutant
pool” and that “roughly one base in 3 104 was misread.” Early
evidence of phenotypic variation of RNA bacteriophages was re-
viewed by Horiuchi (382). In the course of the first nucleotide
sequencing studies, two different 5=-terminal sequences were
found in bacteriophage Q (182), and Charles Weissmann, Mar-
tin Billeter, and colleagues suggested that “an apparently pheno-
typically homogeneous phage stock might contain multiple vari-
ants at various sites on the RNA” (856).
The first calculation of amutation rate for anRNAvirus and the
demonstration of quasispecies dynamics using bacteriophage Q
were possible becauseWeissmann and colleagues were developing
in the 1970s the methodology that Weissmann coined “reverse
genetics.” It was based on the efficient copying of Q RNA by
purified Q replicase in vitro to synthesize a full-length comple-
mentary (minus) strand which, in turn, could be copied into in-
fectious plus strands. The unique properties of Q replicase al-
lowed a stepwise synthesis of the minus strand. A mutagenic
nucleotide analogue could be introduced into a preselected posi-
tion of the minus-strand RNA to give rise to a plus strand with a
mutation at the preselected site (283). An infectious extracistronic
mutant was constructed, and it reverted to the wild-type sequence
upon passage in E. coli (199). Serial passages of biological clones of
the mutant virus alone and growth competition experiments be-
tween wild-type and mutant clones permitted an estimate of the
mutation rate for the relevant G¡A transition, which yielded
104 mutation per genome doubling (53). This mutation rate was
104-fold higher than the values that at the time had been estimated
for some DNA bacteriophages and 106- to 108-fold higher than
values for bacteria and fungi (219). A high mutation rate was
consistent with the previously noted phenotypic plasticity of RNA
bacteriophage populations, which marked a difference from the
DNA bacteriophages.
In the course of the analyses of wild-type and extracistronic
mutant Q RNAs by T1-oligonucleotide fingerprinting (a two-
dimensional electrophoretic separation of the RNase T1-digested
products of labeled RNA, which was the only method available at
the time to screen for the presence of mutations), it was observed
that in some viral clones (a population derived from a single ge-
nome), typical, well-resolved oligonucleotides in the fingerprint
were occasionally altered (had shifted their position or were lost,
or new oligonucleotides were acquired). The modifications in the
fingerprint suggested that mutations occurred with high fre-
quency at multiple positions in the viral genome. This possibility
was confirmed by control experiments in which biological clones
were shown to diversify intomultiplemutant clones upon passage
in E. coli (215). It was concluded that “aQ phage population is in
a dynamic equilibrium, with viable genomes arising at a high rate
on the one hand, and being strongly selected against on the other.
The genome of Q phage cannot be described as a defined unique
structure, but rather as a weighted average of a large number of
different individual sequences” (215). These observations were
linked with quasispecies theory at a meeting of the Max-Planck
Society inKlosters (Switzerland), whereWeissmannpresented the
experimental data to Eigen and colleagues (for more-detailed ac-
counts of the initial connection between quasispecies theory and
the Q experiments, see references 192, 206, and 216). There can
be no doubt that Eigen and his colleagues regarded viral quasispe-
cies as an experimental verification of quasispecies theory. Obvi-
ously, quasispecies cannot be taken as a synonym of variation but
rather can be taken as a representation of the dynamics of genetic
variation, competition, and selection (69, 192, 233, 235, 236, 238).
The studies with infectious bacteriophage Q were comple-
mented with in vitro experiments on replication of small RNAs
derived from standard Q RNA, carried out by Christof K.
Biebricher. These kinetic analyses extended the in vitro Q RNA
replication studies by Spiegelman and colleagues, described quan-
titatively processes of mutation, competition, and selection, and
provided further experimental support to quasispecies dynamics
(64, 65, 68, 70, 71).
Unless the Q results were exceptional, quasispecies theory sig-
naled amajor change in our views on RNA viruses as populations.
The change was that what we generically term a “wild-type” virus
could no longer be equated with a genome with a defined nucle-
otide sequence. Rather, a replicating “wild type” would consist of
an ensemble ofmutants, the “mutant spectrum” or “comet tail” of
quasispecies theory. At the time this was an important conceptual
departure, which was soon recognized as having numerous bio-
logical and medical implications ranging from a general adapt-
ability of viral populations to consequences for viral pathogenesis
and disease control strategies (188, 209, 372, 376, 800). There has
been ample confirmation that the results with bacteriophage Q
apply to RNA viruses that infect animals and plants, as evidenced
by experiments carried out in cell culture and in vivo, in particular
many fundamental studies by John J. Holland and his colleagues
(reviewed in references 187, 192, and 596). Many references are
included in the following sections of this article, with emphasis on
animal viruses, our field of expertise. Error-prone replication is
now recognized as a feature shared by all RNA viruses, as evi-
denced not only by rapid generation of variants but also by the
fidelity properties of their RNA-dependent RNA polymerases
(141, 408, 476, 832). Not only viral polymerases and reverse trans-
criptases (RTs) but also the reverse transcriptases of cellular ret-
roelements are equally error prone (298, 400). Diversity and
spread of mobile elements may have contributed to cellular diver-
sification (566, 763) and also to disease (422).
It is not yet obvious to all virologists that an invariant consensus
sequence reflects not an absence of mutations but rather a contin-
uous replenishment of the mutant pool to yield the same average
(Fig. 2). The consensus sequence may change either as a conse-
quence of a random, bottleneck event or as result of modification
of an equilibrium (which is generally transient) of the mutant
spectrum. In viral evolution there is no such a thing as amolecular
clock that dictates constancy of incorporation of mutations (dis-
cussed in “Viral Quasispecies Dynamics In Vivo: Long-Term Vi-
rus Evolution” below). A virus variant that emerges to slowly in-
crease its frequency in a mutant spectrum need not be generated
with a lower-than-average mutation rate. The rhythm of fre-
quency gain depends on the fitness (or capacity to produce prog-
eny [defined in the next section]) of the newly arising mutant and
its surrounding cloud relative to those of the other components of
the mutant ensemble (Fig. 3). These are key issues which are ex-
tremely relevant to understanding virus behavior.
MAIN FEATURES OF VIRAL QUASISPECIES
Levels and Mechanisms of Genetic Variation, Competition,
and Selection
Virologists use the termviral quasispecies tomean distributions of
nonidentical but related genomes subjected to a continuous pro-
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cess of genetic variation, competition, and selection andwhich act
as a unit of selection (187, 652). Strictly speaking, a viral quasispe-
cies should be considered a single replicative unit in an infected
cell (177, 414, 444, 719). However, heterogeneous viral progeny
from a single cell will invade neighboring cells in culture or from
the same tissue or organ in vivo. This creates a second and succes-
sive level of competition among viral particles and viral genomes.
In viremia, competition for invasion of tissues and organs is es-
tablished among viruses that have originated in different replica-
tive units. Whether at the intracellular or extracellular (whole-
organism) level, the use of the term quasispecies is justified in vivo
since it conveys the concept of ensembles of similar genomic se-
quences generated by amutation-selection process (187, 215, 235,
236, 238, 466, 605, 606, 652, 861).
Although the emphasis for quasispecies has been on mutation
as the source of variant genomes (mechanisms of mutation are
reviewed in reference 294), the theory has been extended to in-
clude additional mechanisms of variation such as recombination,
gene duplication, genome segment reassortment, and gene trans-
fers (75, 204, 371, 398, 575, 635) (Fig. 4).
A seemingly complex and disorganized mutant spectrum
may nevertheless hide subcomponents that reflect prior evolu-
tion of sets of different parental genomes. Substructuring of
quasispecies may be revealed by groupings of reads of sufficient
length in ultradeep sequencing analyses (889) and by nonhier-
archical clustering methods such as partition analysis of quasi-
species (PAQ) (39, 40). This procedure can group closely re-
lated genomes from mutant spectra (Fig. 5) and can reveal
quasispecies expansions and compressions as a result of muta-
genic treatments (615).
Positive selection is the process by which a genotype (or set of
genotypes) becomes dominant in an evolving population as a re-
sult of positive evaluation of phenotypic traits expressed by the
individuals (or set of individuals) of that population. In complex
viral quasispecies, amutant distribution whose components share
the selectable trait, rather than a single individual, becomes dom-
inant, as shown by antibody selection acting on a reconstructed
foot-and-mouth disease virus (FMDV) quasispecies (653). The
fixed repertoire was enriched in the individuals that displayed rel-
atively higher fitness values (520), underscoring the influence of
relative fitness (and thus of the fitness landscape ofmutant clouds)
on the outcome of selective processes undergone by viral quasi-
species.
In contrast to positive selection, negative selection is the process
by which a genotype (or set of genotypes) is eliminated in an
evolving population as a result of negative evaluation of pheno-
typic traits expressed by individuals (or a set of individuals). A
point to note is that the distinction between positive and negative
selection may become fuzzy because in a competition process,
negative selection of genome subsets may have the same outcome
as positive selection of the remaining subsets and vice versa. Also,
negative selection need not result in the elimination of subsets of
genomes but may result in their maintenance at low frequencies.
These low-frequency genomes may be detectable or not, depend-
ing on the analytical procedures used (e.g., minority mutations
present at different frequencies revealed by ultradeep nucleotide
sequencing might have been subjected to negative selection of
different intensity). These arguments lead to the necessity of
quantifying relative selective advantages of viral populations
through fitness measurements, which is covered in the next sec-
tion.
Viral Fitness and the Effect of Population Size: Bottleneck
Events
Fitness is a major parameter in genetics that was also included in
the formulation of quasispecies theory and the error threshold
relationship (Fig. 1). It was adapted by virologists to quantify the
relative replication capacity of a virus, generally measured in
FIG 2 Schematic representation of the evolution (change in composition) of a viral quasispecies withoutmodification of the consensus sequence. Viral genomes
are represented as horizontal lines andmutations as different colored symbols on the lines. Discontinuous lines indicate genomes that have acquired five ormore
mutations and that cannot survive to act as the template for the next generation of genomes (large arrows). Other genomes can incorporate mutations during
replication (i.e., genome 2 in the distribution on the left generates genomes 2 and 3 in the second distribution, until an excess of mutations in genome 2 of the
third distribution impedes its replication). Thus, a constant evolution in the mutant spectrum can nevertheless yield the same consensus sequence, depicted as
a line devoid of mutations at the bottom. In a viral population the number of genomes in a single replicative unit in an infected cell can reach several thousand
rather than 27, implying a highly dynamic and indeterminate mutant spectrum or cloud, as discussed in the text.
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growth competition experiments with a reference virus isolate,
either in cell culture or in vivo (215, 374, 524; reviewed in refer-
ences 205, 527, and 684). Fitness measurements have been
equated to the determination of a selection coefficient (514).
Comparison of the consensus nucleotide sequence of a population
with those of individual components of the same population in-
dicates that quasispecies dynamics is basically reflected in varia-
tions of frequency (relative fitness) of subsets of genomes in re-
sponse to environmental changes (Fig. 2 and 3).
Mutations occur unavoidably whenever an RNA virus repli-
cates, including in the course of plaque formation on a cell mono-
layer. The generation of a plaque involves virus replication in an
initial cell, followed by the spread of progeny virus to neighbor
cells in the monolayer until resources are exhausted, virus inacti-
vated, or plaque development interrupted. Mutations while a vi-
rus replicates within a plaque were first described by John Yin,
working, interestingly, with a DNA bacteriophage (884). A pas-
sage regimen consisting of successive plaque-to-plaque transfers
should result in an accumulation ofmutations in the viral genome
and a fitness decrease (Fig. 6). Average fitness decreases were first
documented with bacteriophage 6 (112), although the underly-
ing genetic changes were not determined. The result was con-
firmedwith several RNA viruses (133, 168, 222, 253, 258, 364, 597,
601, 602, 888).
Studies with the animal pathogen foot-and-mouth disease virus
(FMDV) by Cristina Escarmís and her colleagues unveiled the
molecular basis of fitness loss associated with successive bottle-
neck events of biological clones of the virus. A number of unusual
mutations were observed, which had never been detected in field
isolates of FMDV or in the same FMDV clones subjected to large-
population passages. Atypicalmutations included those leading to
amino acid replacements at internal residues of the viral capsid
FIG 3 The selective advantage (relative fitness) of a mutant genome (with its associated cloud) alters the rate of dominance in a population. Mutant spectra are
depicted as in Fig. 2, withmutations on genomes indicated as colored symbols on the lines. In the uppermutant distribution, themutation highlighted by a black
asterisk in genome 8 of the first distribution confers a selective advantage that results in dominance of that mutation after a given number of replication rounds
(several large arrows, but only two are drawn). The selective advantage results in the dominance of genomes with the mutation in the mutant spectrum (upper
right distribution) and modification of the consensus sequence (below the upper right distribution). In the bottom mutant distribution, the same mutation in
genome 8 confers a modest selective advantage, and despite its frequency increasing in the population, it does not become dominant (bottom right distribution)
and the consensus sequence remains invariant (below the bottom right distribution). Themutations that accompanied the relevant one in the initial genomeneed
not bemaintained aftermultiple rounds of copying. This scheme illustrates that fitness gainmay not be reflected in amodification of the consensus sequence and,
consequently, that selective events can be overlooked if mutant spectra are not analyzed, as discussed in the text.
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(2), a point deletion within the L (leader protease)-coding region,
an elongation of an internal oligonucleotide tract that precedes
the second functional AUG, and even an amino acid substitution
in the FMDV capsid that adversely affected the processing of the
viral polyprotein despite the substitution being located far from
the relevant cleavage site (253, 258). Hundreds of bottleneck pas-
sages resulted in the evolution toward noncytopathic (NC) forms
of FMDV that displayed a 140-fold reduction in specific infectivity
(the ratio between PFU and the amount of viral RNA present in a
virus preparation) relative to that of the corresponding unpas-
saged parental clones (256). These remarkable NC forms of
FMDV remained, however, replication competent, and could es-
FIG 4 Simplified representation of several types of genetic modifications that can alter the composition of viral quasispecies. (A)Mutation is a universal class of
genetic variation and the basis of the original quasispecies formulation, as described in the text. (B) Hypermutation (generally biased toward some mutation
types) is a consequence of cellular editing activities acting on viral genomes. (C) Genome segment reassortment occurs in viruses with segmented genomes and
is responsible for the antigenic shift associated with new influenza pandemics. (D) Recombination results in formation of mosaic genomes, either by template
switching (replicative recombination [left]; the negative, complementary strand is depicted with darker color) or breakage and rejoining of RNA molecules
(nonreplicative recombination [right]). (E) A high multiplicity of infection passages of FMDV resulted in genome segmentation, as described in “Fitness Gain
and Genetic Change: Genome Segmentation” in the text (schemes are based on references 5, 189, and 306).
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tablish persistent infections in BHK-21 cells without a previous
phase of cytopathology (compare references 256 and 170, 365).
The increasing mutational load due to successive bottleneck
events of FMDV was associated with a biphasic and fluctuating
pattern of fitness decrease. Yet, the clones that attained very low
fitness displayed a remarkable resistance to extinction, with ge-
nomes rescued by compensatory mutations (255, 467, 468). Fur-
thermore, the pattern of fitness decrease adhered to a statistical
Weibull function (853), which probably reflects an intricate set of
interactions that must take place for a virus to give rise to progeny
and to generate a plaque on a cell monolayer (468).
The remarkable consequences of bottleneck events provide ad-
ditional evidence of genetic and phenotypic heterogeneity of viral
populations, as well as an experimental confirmation of “Muller’s
ratchet” (540, 571, 572).Hermann J.Muller proposed that asexual
organisms with a small population size and a high mutation rate
will tend to incorporate deleterious mutations in an irreversible,
ratchet-likemanner unless compensatorymechanisms such as re-
combination could restore the mutation-free class of genomes
(571, 572). Muller’s ratchet has been shown to operate not only in
RNA viruses but also in DNA-based cellular organisms such as
bacteria, protozoa, and plants, as well as mitochondrial DNA (15,
22, 58, 139, 248, 493, 560). Fitness decrease due to serial bottleneck
passages can be compensated for by subsequent large-population
passages, as anticipated by theoretical investigations (301, 342,
500, 785). However, studies with vesicular stomatitis virus (VSV)
showed that huge numbers of replication roundsmight be needed
to overcome the effect of Muller’s ratchet (223). The number of
clonal pools required to maintain a fitness value of VSV is depen-
dent on the fitness of the parental clone. For a clone displaying low
fitness, pools of five clones were sufficient to maintain or increase
fitness.When the initial fitness was high, pools of at least 30 clones
were needed to maintain the fitness level (602). Repeated genetic
bottlenecks in VSV resulted in adverse effects regarding subse-
FIG 5 A quasispecies distribution (represented as in Fig. 2 and 3, with each
genome identified with a letter) may hide distinguishable virus subpopula-
tions. Partition analysis of quasispecies (PAQ) is a nonhierarchical bioinfor-
matics procedure that groups components of viral quasispecies (39, 40). In this
example we depict mutant classes as spheres of sizes proportional to the num-
ber of genomes in each class.
FIG 6 Fitness evolution of RNA virus populations. Mutant distributions are represented as horizontal lines and colored symbols as in Fig. 2 and 3. Large
population passages in a constant environment generally result in a fitness increase (bottom trapezoid), which may or may not result in a modification of the
consensus sequence (lines below the distribution). In contrast, plaque-to-plaque transfers (discontinuous genome in the central mutant distribution and
discontinuous arrow) result in an accumulation of mutations, also reflected in the consensus sequence, and fitness decline. Plaque-to-plaque transfers decrease
the complexity of mutant spectra and mimic bottleneck events that occur during virus life cycles, as discussed in the text.
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quent adaptability of the virus (597). Compensation for the dele-
terious effects of Muller’s ratchet is one of the arguments in favor
of the evolution toward sex in ancestral asexual organisms (540,
541).
It is remarkable how profound can be the reductions in fitness
and the biological alterations in viruses subjected to repeated bot-
tleneck transfers. Such transfers mediate the surfacing ofminority
components present or generated in the mutant spectra of the
corresponding clonal populations (reviewed in references 197,
257, and 507). From all evidence, mutant spectra are far from
being distributions of neutral mutants. They can hide compo-
nents that in isolation would display dissimilar biological proper-
ties (512, 552). As expressed by Schuster: “Quasispecies are the
genetic reservoir of an asexually replicating species” (741).
Plaque-to-plaque transfers are an extreme case of population
bottleneck because a single infectious genome initiates replication
and diversification. Viruses can, however, be subjected to bottle-
necks of different intensity, depending on the number of genomes
from a larger ensemble that initiate replication. A small number of
genomes taken from a larger ensemble will include a limited rep-
ertoire of variants for further replication or to confront a selective
constraint (Fig. 7).
Current evidence is that bottleneck events are frequent in the
course of the life cycles of viruses, not only in the most obvious
case of host-to-host transmission, known for decades (35, 150),
but also during the intrahost spread of virus (14, 63, 93, 288, 338,
480, 680, 740, 772). Quantification of intrahost bottleneck inten-
sities would contribute to the understanding of intrahost evolu-
tionary events. Bottlenecks introduce an additional strong ele-
ment of stochasticity during short-term (intrahost) or long-term
(interhost) virus evolution (Fig. 6 and 7).
In contrast to the case for bottlenecks that lead to fitness de-
creases, viruses passaged as large populations in a given environ-
ment tend to gain fitness in that environment (254, 496, 600).
Fitness gain can be viewed as the result of competitive optimiza-
tion of a viral quasispecies in its tendency toward a mutation-
selection equilibrium in a given environment (861). The popula-
tion size attained by a virus in an infected host can be exceedingly
large, in the range of 109 to 1012 infectious particles (346, 700,
746). (Additional values are given in “Human Immunodeficiency
Virus Type 1,” “Hepatitis B Virus,” and “Hepatitis C Virus” be-
low.) It is not obvious how to calculate the proportion of replicat-
ing genomes at any given time, which would yield the effective
population size (a concept widely used in population genetics). A
virus particle may not be capable of initiating an infection and
producing progeny at a given time, but the same particle may
immediately be exposed to a different environment that triggers
its replication. Specific infectivities, similarly to efficiencies of
plating, are environment dependent. It may be anticipated that
the large population sizes attained after infection by a limited
number of particles (the usual situation in transmission from an
infected donor into a susceptible host) should result in high fitness
levels (254, 600). However, an infected organism is essentially a
mosaic of different environments (cells, tissues, organs, and phys-
iological conditions), and fitness is environment dependent (205,
457, 634, 684). Viruses specialized to replicate mainly in a specific
tissue (e.g., hepatitis viruses in the liver) are expected to increase
their fitness in that specific tissue as the infection advances, but for
viruses targeting different tissue types, compartmentalization of
fitness values is to be expected, although this is an area in need of
additional research.
Modification of the environment and limitations of population
FIG 7 Population size may affect the evolutionary outcome. The large rectangle represents a viral quasispecies. Each symbol (even of the same shape and color)
portrays a slightly different sequence. Three types of particles harboring mutations that can confer resistance to a selective agent are distinguished (red triangles,
white squares, and yellow stars) from other components of the mutant spectrum (blue circles). If a small population is analyzed (white inner circle on the left),
no resistant variants will be found. Further viral replication of that subpopulation will be needed to generate the resistant mutants. If an intermediate-size
population is analyzed (intermediate gray inner circle on the right), two of the resistant variants will be found. If a large population is analyzed (large circle), all
relevant variants will be represented. This scheme illustrates how the viral population size can condition the results of intrahost or interhost virus transmission,
or of experimental evolution, in relation to drug resistance or other phenotypic traits (see text).
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size (including bottleneck events) may perturb (delay or prevent)
the process of fitness gain (223, 603, 634). Thus, viral fitness is
environment and population size dependent, as well as prone to
stochastic fluctuations due to finite viral population sizes and to
the inherently heterogeneous and dynamic nature of viral popu-
lations (205, 506, 527, 684, 841).
Comparing the accumulation rates ofmutations in FMDV sub-
jected to plaque-to-plaque transfers (0.20 to 0.40 mutation per
genome and transfer) and in FMDV subjected to large-population
passages (0.10 to 0.25 mutation per passage in the consensus se-
quence) (Table 2) offers an interesting illustration of a counterin-
tuitive concept that can be phrased paradoxically as “a positive
outcomeof negative selection.” It ariseswhen the context inwhich
the virus is situated facilitates the survival of a minority subpopu-
lation. Hundreds of plaque-to-plaque transfers led to replication-
competent and plaque-forming clones that displayed a mutation
frequency of 1.5  102 substitution per nucleotide, measured
relative to the sequence of the parental virus (256). Yet, the same
FMDVpopulations subjected to lethalmutagenesis (deterioration
of virus replication due to an excessive mutational load) were
extinguished when their mutant spectra amenable to amplifica-
tion reached an average mutation frequency in the range of 4 
104 to 3  103 substitution per nucleotide (12, 634, 762) (the
consensus sequence in the progression toward virus extinction by
lethal mutagenesis remained invariant; see “Antiviral Approaches
to Counteract Quasispecies Adaptability: Lethal Defection and
Lethal Mutagenesis” below). The available evidence suggests that
the critical difference is that during plaque-to-plaque transfers,
selection for plaque formation rescues a tiny minority amid ama-
jority of genomes that have lost the capacity to form a plaque. In
contrast, no such opportunity for the rescuing of viable minority
genomes exists during lethal mutagenesis, and the entire popula-
tion collapses, probablywith the contribution ofmultiple negative
interactions established among components of the mutant spec-
trum (see “Complementation and Defection: Quasispecies as a
Unit of Selection” below).
Fitness Gain and Genetic Change: Genome Segmentation
In a study aimed at elucidating what could be the limits of fitness
gain of FMDV replicating in BHK-21 cells under standard cell
culture conditions, a biological clone of FMDV was subjected to
460 serial large-population passages. Initially, fitness gain oc-
curred as expected, with an accumulation of point mutations in
the consensus sequence of the viral genome (306, 307). However,
between passages 143 and 260 the virus underwent a remarkable
transition in which the standard full-length genome was replaced
by genomic forms with internal deletions that were infectious and
killed cells by complementation (306, 307). One of the deletions
was located in the L-coding region, and other deletions affected
the capsid-coding region. By passage 240 the standard virus was
not detected, whichmeans that its frequencywas lower than 104-
fold the frequency of genomes with deletions (306). Passage of the
population consisting of genomes with internal deletions at a low
multiplicity of infection (MOI) resulted in the rescuing of the
standard-size genome, originated by recombination between ge-
nomes with deletions (307). Comparison of the kinetics in the
major steps of the virus life cycle using standard and segmented
FMDV genome forms suggested that capsid stability (rather than
a more rapid replication of shorter RNAs or differences in viral
protein synthesis) conferred the selective advantage of the FMDV
genome version with internal deletions over the virus with the
standard-size genome (618). The increased stability of viral parti-
cles harboring shorter RNAs was possibly due to relaxation of
packaging constraints that affected the standard genome and that
were relieved when a shorter genomic RNA was encapsidated
(532, 618). This study with FMDV showed that conditions of rep-
lication that favor fitness increase can give rise to drastic genetic
modifications, even under a constant physical and biological en-
vironment. Internal deletions within RNA genomes under widely
different environments have been described, such as during rep-
lication of Venezuelan equine encephalitis virus in Vero cells
(284) or during replication of coxsackie B3 virus in cardiac tissue
of mice (432). Internal deletions characterize some strains of por-
cine reproductive and respiratory syndrome virus, although their
biological relevance is not known (347, 805).
It has been suggested that genome segmentationmay have been
favored during evolution because it introduces a form of sex that
permits counteracting the effect of deleterious mutations (111,
790). An alternative, mechanistic proposal is that segmentation
can result from selection of shorter genomes whose replication is
TABLE 2 Parameters in mutant spectra that are relevant to the adaptive
capacity of viral quasispecies
Parameter (values) Major reason for relevance
Population heterogeneity
(average number of
mutations per
genome; current
estimates range from 1
to 100, depending on
multiple factorsa)
Accessibility to different regions of sequence
space; heterogeneity enhances chances of
intra-mutant spectrum interactions
Virus population size or
viral load (very
variable but for some
viruses can reach 1012
infectious particles per
organism; may refer to
infectious or total
[infectious and
noninfectious] virus
Population size determines the numbers
and types of variant genomes in a
population; the specific infectivity
(infectious units divided by the total
amount of viral RNA) is indicative of the
interfering potential of a virus
Genome length (most
RNA viruses have a
genome of between 3
and 32 kb, with little
redundant
information)
A small genome size permits a more
effective occupation of sequence space, as
discussed in the text
Mutations needed for a
biological change
(variable, but one or
few mutations may
suffice for important
biological changes, as
discussed in the text)
If important phenotypic changes were not
dependent on limited numbers of
mutations, quasispecies distributions with
the levels of genetic heterogeneity
described here would not be important
for virus adaptability, and this review
would not have been written
Virus fecundity and
turnover (capacity of
generating new viral
particles to replace
those of previous
generations that are
catabolized)
It influences the capacity of exploration of
sequence space, with its implications for
adaptability (see the text and Fig. 8)
a Factors include proximity to a clonal origin, mutation rate, and environmental
heterogeneity (see the text for references).
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completed in a shorter time than that for the cognate full-length
genome (379, 585). A plausible mechanism is that deletions occur
essentially at random (at frequencies that depend on the replica-
tion machinery, particularly polymerase processivity) and that
when a combination of internal deletions compatible with com-
plementation arises, a segmented form can overgrow the mono-
partite, full-length genome. This possibility is also reinforced by
the fact that multiple FMDV genomes with a variety of internal
deletions arose during replication, and they were maintained at
low frequency in the evolving population (307). Thus, the results
with FMDV point to particle stability as a mechanism that can
trigger the evolutionary event toward genome segmentation
(618). It will be intriguing to explore whether following thismajor
transition, the segmented FMDV genome will maintain its bipar-
tite genome organization or will undergo some newmajor transi-
tion for fitness gain. The observed evolutionary pattern includes
ingredients of gradualism (accumulation of point mutations
[307]) and of evolutionary shifts (or “saltations”), rendering real-
istic at themolecular level the occurrence of punctuated equilibria
during viral genome evolution (244).
Population Equilibrium, Apparent Stasis, and Rapid
Evolution
Themutation rates for RNA viruses measured by genetic and bio-
chemical procedures (53, 220, 726) (Table 2) imply that most
template RNAs that are copied into a complementary strandmust
contain between 0.1 and 2 mutations. Therefore, unless the vast
majority of mutations were lethal (which is obviously not the case
[31, 101, 215, 272, 724, 725]), it should take only a few rounds of
template copying (despite initial differences in the distribution of
mutations, depending on the contributions of the stamping-ma-
chine and semiconservative replication modes [728, 730]) to pro-
duce a dynamic spectrum of mutants. In classical population ge-
netics, variation and constancy usually refer to the consensus
genomic nucleotide sequences (or deduced amino acid se-
quences) of the organism under study. Consensus sequences are
determined by standard sequencing techniques, often referred to
as Sanger sequencing. In virology, consensus sequences are those
most commonly determined, and they serve as the basis for virus
identification, to establish phylogenetic relationships among viral
isolates, or to interpret processes of selection and random drift in
virus evolution, assuming that such interpretation does not neces-
sitate information on the underlying mutant spectra (189, 333,
378, 721). The problem arises when the presence and composition
of a mutant spectrum affect relevant traits in virus biology (see
reference 652 and other sections of the present article).
Ever since the quasispecies nature of RNA virus populations
was unveiled, the inappropriate distinction betweenmutation rate
(in mutations introduced per nucleotide copied, a biochemical
value which is dictated largely by the template-copying fidelity of
the replication machinery), mutation frequency (the proportion
of mutations present in a viral population, which is the result of
mutation, competition, selection, and in some cases even random
events), and rate of evolution, to mean rate of evolution with a
time factor in it (for example, substitutions per site and year dur-
ing the evolution of a virus in the field) (Table 2) was considered a
conceptual flaw (203). Mutation rate continues being used incor-
rectly not only in general evolution but also in evolutionary virol-
ogy, thus contributing to the mistaken belief that an invariant
consensus sequence implies an absence of mutations. Another
misleading and amply used term is “fixation,” referring either to
genomes or to mutations. Given the concepts conveyed by quasi-
species dynamics, it is intrinsically contradictory to use the term
“fixation.” The reason is that genomes and mutations can at best
attain transient dominances, and they will unavoidably coexist
with a mutant repertoire. Fixation was frequently used during the
neutralist-selectionist controversy (now largely vanished) to dis-
tinguish “fixation” of mutations either by random drift of ge-
nomes or by positive selection of phenotypes associatedwith those
mutations (435, 437).
Population equilibrium is sometimes used to refer to viral pop-
ulations that maintain a constant consensus sequence (371, 376).
Near-equilibrium conditions can be approached experimentally
with large populations of simple RNAmolecules replicated by Q
replicase (64, 65, 68, 70, 71) and upon passage of large viral pop-
ulations in cell culture (215, 784). In the latter studies an invariant
consensus sequence was noted despite a complex, changing mu-
tant spectrum (Fig. 2). High mutation rates permit but do not
necessitate rapid evolution. The same virus can display either evo-
lutionary stasis or rapid evolution, depending on its biological
environment. A classical example is the evolutionary stasis fre-
quently observed with avian influenza viruses (IVs) in their natu-
ral avian hosts, where they do not cause disease, and rapid evolu-
tion of the same viruses when they replicate and cause disease in
alternative avian hosts or in mammalian hosts (324). Arboviruses
may also display relative evolutionary stasis despite the presence of
mutant spectra, probably reflecting a stabilizing selection for the
capacity to replicate efficiently in vertebrate and invertebrate
hosts. Although different studies on experimental evolution have
provided conflicting results, evidence of a trade-off to achieve rep-
lication in two different environments has been obtained (refer-
ences 142, 165, 404 to 406, 567, and 849 and references therein).
Remarkably counterintuitive outcomes may result from quasi-
species dynamics. In particular, biologically significant perturba-
tions can take place in a mutant spectrum without any modifica-
tion in the consensus sequence. An initial fitness gain of HIV-1
clones in cell culture may occur with an invariant consensus se-
quence (77). More dramatic is the transition toward extinction
due to increases in mutation rate, in which a virus undergoes a
replicative collapse without any alteration of the consensus se-
quence (see “Antiviral Approaches to Counteract Quasispecies
Adaptability: Lethal Defection and Lethal Mutagenesis” below).
In other words, an ultimate transition toward the disappearance
of a virus from infected cells would go unnoticed genetically if the
consensus sequence was the only one monitored!
Evolution is not always understood as a modification of the
consensus sequence; it can be viewed as a disequilibrium of a mu-
tant spectrum.When positive selection or stochastic events inter-
vene, subsets of genomes from the mutant spectrum increase in
frequency and replace the previous distribution, thereby leading
to a new consensus (Fig. 2). Disequilibria can come about by pos-
itive selection or by random events, and they may be durable or
short-lasting, depending on the tendency of the ensemble to re-
equilibrate mutant distributions (which is dictated by the relative
fitness or selection coefficients of parental and progeny distribu-
tions). Adaptation of a natural virus isolate to cell culture consti-
tutes an example of modification of a viral population due to the
growth of subpopulations in the new environment. This was pre-
sciently expressed by Andreas Meyerhans, Simon Wain-Hobson,
and their colleagues with the statement “to culture is to disturb,”
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in the first demonstration of the quasispecies nature of HIV-1 and
its biological implications (552). Adaptation of a natural viral iso-
late to cell culture will in most cases entail a modification of the
genetic composition of the viral population, even if the adaptation
period is short.
When a mutant spectrum harbors an ample repository of vari-
ants, selection of genome subsets in a new environment can be
very rapid. Astonishing rates of evolution of consensus sequences
in vivo, of 102 substitution per site per year or even higher, can be
attained (87, 136, 311, 341, 473, 698, 753). It should be appreciated
that such rates of evolution are 106- to 107-fold higher than the
average rates estimated for cellular genes during long-term evolu-
tion (the values and implications are reviewed in references 189
and 376). Thus, a dynamic mutant spectrum has a dual potential
to show either stasis (rates of evolution of around 104 substitu-
tion per site per year or lower) or rapid evolution of its consensus
sequence (even 101 to 102 substitution per site per year). Stasis
does not imply mutation rates lower than those usually operating
during RNA genome replication, nor does rapid evolution imply
higher-than-average mutation rates.
A distinction is made between directional selection and fluctu-
ating or cyclical selection that does not result in “fixation” of the
corresponding genetic traits (259, 343). Fluctuating selection,
judged by alternating nucleotide sequences, may be due to limita-
tions in the number of acceptable nucleotide or amino acid se-
quences at some loci. Alternation of amino acid sequences was
observed at major antigenic sites of FMDV strains of the same
serotype isolated over a period of 6 decades (525).
Population size, genetic heterogeneity, adaptive capacity, and
evolutionary rate are dependent on an interconnected set of pa-
rameters, some amenable to quantification and others difficult to
measure.Major parameters are the rate of genomemultiplication,
the mutation rate, and the tolerance of genomes to accept muta-
tions and remain functional. These parameters apply to all patho-
gens, be they cellular or subcellular. The mutation rate, tolerance
to mutations (nonlethal mutations with a range of fitness values),
and population size will determine the breadth of the mutant
spectrum and the landscape of minority mutations and their fre-
quency (Fig. 8A).
Exploration of Sequence Space and Virus Adaptability:
Fidelity Mutants
The amplitude of a mutant spectrum can also be viewed as the
extent of occupation of sequence space (Fig. 8B). The term se-
quence space refers to a theoretical representation of all possible
variants of a sequence, and it can concern nucleotide or amino
acid sequences (237, 243, 542, 741). The theoretical sequence
space of a virus (or any living entity) is extremely large, being equal
to the number of different unit digits used to construct the rele-
vant macromolecule to the power of the sequence length. The
total theoretical sequence space of a viral genome of 10,000 nucle-
otides is 410,000, a number that defies imagination (192, 238). The
gigantic dimensionality of sequence space prohibits its represen-
tation in two dimensions. In Fig. 8B the theoretical sequence space
is represented by a gray, punctuated, and diffuse background and
the space occupied by two actual viral populations as spheres. This
extreme oversimplification nevertheless allows us to make some
points on evolution: a large sphere has a vastly superior number of
possibilities to advance toward new regions of sequence space
than a small sphere (Fig. 8B).
The sequence space that can be actually occupied by a virus is a
very minor portion of the theoretical space for obvious biological
reasons: the viral genome must encode sequence-dependent reg-
ulatory signals, several secondary and tertiary structures in RNA
perform functional roles, and open reading frames must encode
FIG 8 Relevance of the complexity and size of the mutant spectrum in RNA
virus evolution. (A) Diagram of four virus populations of different sizes and
complexities. The blue and red curves represent populations that differ greatly
in size (ordinate). Populations on the right contain a larger average number of
mutations per genome than those on the left (abscissa). A large population size
and high numbers of mutations favor adaptation unless interfering interac-
tions or the threshold for virus viability intervenes.With an average number of
about 5 mutations per genome, a population of 2  1011 virus particles in-
cludes 3.3  109 single mutants and 2.6  103 genomes with 20 mutations
(calculation based on the Poisson distribution, ignoring fitness effects of mu-
tations). A population of 1 108 particles includes 3.3 106 single mutants
and only 26 genomes with 20 mutations. (B) An imaginary representation in
only three dimensions of a different occupation of sequence space. In the
background of a huge theoretical multidimensional sequence space (square)
(see text), viruses occupy a tinyminority that may require expansion to neigh-
bor points in an adaptation process. The two spheres with a 10-fold difference
in radius represent two viral populations that differ in sequence space occu-
pancy. In this drastic simplification to three dimensions, viruses in the large
sphere have a 100-fold-larger number of potential direct contacts in neighbor-
ing, unoccupied positions of sequence space than viruses in the small sphere
(based on the sphere surface). Such neighboring positions can be reached by a
limited number ofmutational steps. Several examples of adaptabilitymediated
by an increase of mutation rate or population size are described in different
sections of the text.
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functional proteins which interact with other viral or host pro-
teins, among many other limitations.
The comparison between a viral genome and a mammalian
genome serves to illustrate distinctive implications of quasispecies
depending on genome size. A viral genome of 10,000 nucleotides
has a maximum of 3 104 possible single mutants (a theoretical
figure that disregards fitness effects). This number is below the
population size of many natural viral populations, even within a
single infected organism (see “Viral Fitness and the Effect of Pop-
ulation Size: Bottleneck Events” above). In sharp contrast to the
case for a typical RNA virus, the total number of possible single
mutants in a mammalian genome is about 1010, a value which is
well above the population size (total or effective) estimated for
mammalian species. That is, the capacity to explore sequence
space (and therefore the adaptive capacity) within reach of viruses
is far greater than the capacity available to cellular organisms.
Other parameters that also favor the adaptive capacity of RNA
viruses are the number of mutations needed for relevant pheno-
typic traits and virus fecundity and turnover (Table 2) (see also
next section). These quantitative arguments reinforce the concept
that quasispecies dynamics is much more profitable to viruses
than to cellular organisms as an engine for adaptation. This does
not deny that important features of quasispecies dynamics, par-
ticularly those related to group selection, are displayed by subcel-
lular and cellular collectivities and even by some “nonreplicative”
biological macromolecules such as prions (65, 184, 483, 530, 619,
857) (see also Conclusions, Connections, and Prospects below).
At any given time, amutant spectrum can be considered a cloud
in sequence space (sphere in Fig. 8B). The cloud shifts its position
(and, of course, variant composition) in response to selective
forces, or a new cloud is started as a result of a bottleneck or
founder event. An essential feature of sequence space is its high
connectivity. Any two genotypes are separated by a number of
point mutations that never exceeds the genome length. In practi-
cal terms, this means that points separated by a fewmutations can
be rapidly reached when movements are guided by a fitness gra-
dient (238). Even in the case of a single mutation (or a small
number of mutations, depending on the mutation rate exhibited
by the replication machinery), neighboring points of sequence
space can be reached throughmeremutational pressure without a
guiding fitness gradient. An example is the occurrence of drug
resistance mutations that can be reached in the viral populations
that replicate in infected patients. Drug resistance mutations are
often selected in the presence of the drug, and in this case the drug
is the selective agent that drives the fitness gradient. However,
drug resistance mutations can be found in the mutant spectra of
viruses whose populations had never been exposed to the drug
(see “Selective Forces and EscapeMutants” and Specific Viral Sys-
tems below).
When a fitness value is assigned to each position of a portion of
sequence space, a fitness landscape is obtained, following the clas-
sical metaphoric visualization of evolutionary events depicted by
Sewall Wright (875, 876; see also reference 741 for limitations of
this display). Two points (that are not easy to capture in theoret-
ical models)must be emphasized with regard to fitness landscapes
in viral quasispecies: they are extremely rugged and transient.
These features are basically due to the rare occurrence of truly
neutral mutations in compact genomes and to the fact that vari-
able environments are the rule, and more so considering that the
viral population structure itself is part of the environment (192).
The extension and portion of sequence space occupied by a
virus during its replication may be relevant to its behavior, and
both depend on parameters of the virus (see the previous section)
and of the environment in which the virus replicates (738). The
host factors that may contribute to modify the amplitude of a
mutant spectrumhave not been identified, but theymay belong to
two broad categories, one based on constraints and the other on
participation. Stronger constraints in one host type versus another
may render a larger proportion of viral mutations lethal (i.e., they
occur, but they cannot be part of the mutant spectrum). Alterna-
tively, the participation of host proteins in complexes with the
viral polymerase may result in modifications of the template-
copying fidelity. At any given time, the multiple genetic and bio-
chemical factors involved in fidelity render the complexity of a
mutant spectrum largely unpredictable. Its quantification re-
quires empirical characterization through sampling of genomes
and calculation of genetic distances, mutation frequencies, and
Shannon entropies (see references 12, 31, and 289, among many
other analyses) or characterization ofmutant spectra by ultradeep
sequencing (see references 56, 94, 175, 252, 281, 359, 454, 515, 556,
780, 788, 846, 858, 874, and 889), among other analyses).
A broad mutant spectrum means higher accessibility to multi-
ple points in sequence space and, therefore, higher adaptability
reflected in fitness gain and its biological derivations, including
clinical outcome (130, 265, 404, 496, 705). Occupation of se-
quence space is multifactorial, but an important parameter is the
error rate exhibited by the viral replication machinery. Studies
with picornaviruses have contributed substantially to understand-
ing of the genetics and biochemistry of RNA genome replication
and to elucidation of the biological consequences ofmodifications
of template-copying fidelity (reviewed in reference 232). A polio-
virus (PV) mutant encoding amino acid substitution G64S in its
RNA-dependent RNA polymerase (termed 3D) was selected by its
decreased sensitivity to the purine nucleoside analogue ribavirin
(1--D-ribofuranosyl-1-H-1,2,4-triazole-3-carboxamide) (662).
The same G64S mutant was obtained independently in the Andi-
no’s andKirkegaard’s laboratories. Themechanism bywhich sub-
stitution G64S confers resistance to ribavirin is an estimated 3- to
5-fold increase of the general template-copying fidelity of the en-
zyme that in this manner restricts the incorporation of ribavirin
triphosphate (RTP) intoRNAduringRNA synthesis (33, 108, 660,
833). The limitation of ribavirin incorporation had as a trade-off
the generation of a narrower mutant spectrum, and the narrow-
ness restricted the tissue trophism of the virus, as evidenced by the
inability of the virus to cause neuropathology in a strain of mice
(660, 833). Neuropathology was restored when the mutant spec-
trum was expanded by mutagenesis (832, 833).
The studies with the G64S PV mutant and subsequent work
with other picornavirus fidelity mutants (476) have revealed a
number of implications of quasispecies dynamics (reviewed in
reference 832). They validated the concepts that the error rate of a
viral polymerase plays a key role in the observed heterogeneity of
the corresponding mutant spectrum, that a limited heterogeneity
can result in a selective disadvantage for the virus, that the ampli-
tude of the mutant spectrum can be a stable trait maintained after
several passages in cell culture, and that intramutant spectrum
complementation can occur in vivo. Resistance to ribavirin medi-
ated by substitution G64S in 3D had two related consequences: a
limited incorporation of ribavirin into viral RNA and a greater
tolerance to new mutational events (which could still occur as a
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result of ribavirin incorporation) by virtue of the higher-than-
averagemutant fidelity anddecreased averagemutation frequency
(i.e., its replicating further away from the error threshold than the
wild type) (153, 832).
It must be indicated that the adaptabilities of the high-fidelity
G64S polymerase mutant and wild-type PV might have been in-
distinguishable if the selective constraints had been less demand-
ing. For example, for a given virus population size, themutant and
wild-type viruses could be equally adaptable regarding generation
of antibody or drug escape mutants or replication in highly sus-
ceptible animal hosts, with no noticeable differences in the ensu-
ing pathogenesis (426). In contrast, when either constellations of
mutations or complementation between different mutant ge-
nomes is required for adaptation to a complex environment, a
broad mutant spectrum may prove to be advantageous or even
essential. Newfidelitymutants of RNAviruses are becoming avail-
able (48, 141, 180). Further biological studieswith fidelitymutants
should provide a more quantitative picture of the selective advan-
tage assignable to the complexity of the mutant spectrum. It has
been suggested that the long-term adjustment of high mutation
rates during RNA virus evolutionmight have been commensurate
with the advantage derived from generating an ample mutant
spectrum following a population bottleneck (466, 832, 833). As
reviewed in “Viral Fitness and the Effect of Population Size: Bot-
tleneck Events” above, bottlenecks are abundant in the course of
the natural life cycles of viruses, and mutants capable of adapting
to a complex environment following a population bottleneck
should overgrow thosemutants which can spread to only a limited
subset of surrounding cells. This is an important point that de-
serves additional experimental and theoretical studies.
High- and low-fidelity retroviral reverse transcriptases have
been described and characterized. Their study at the enzymologi-
cal level is an active field of research, but the biological effects of
fidelity on retrovirus adaptability have been only partially investi-
gated (546, 547). Some of the amino acid substitutions involved in
template-copying fidelity are related to resistance of HIV-1 to an-
tiretroviral agents (221, 412, 545, 548, 629, 690, 752). Increased
fidelity often resulted in decreased HIV-1 fitness (842, 860), and
the relevant mutants offer valuable materials to evaluate the bio-
logical impact of retroviral mutant spectra displaying differences
in complexity (see also “Human Immunodeficiency Virus Type
1,” “Hepatitis B Virus,” and “Hepatitis C Virus” below).
The term barrier is used to describe the limitations that a virus
must overcome to achieve a required phenotype. Genetic barrier
refers to the number of mutations needed for adaptation. A single
amino acid replacement can have either a low genetic barrier if its
occurrence requires a single transition mutation or a high barrier
if it requires twomutations (more so if transversions are needed).
Phenotypic barrier refers to the fitness cost that the amino acid
substitution imposes upon the virus. The concept of barrier is
further treated in connection with modifications of host cell tro-
pism and escape mutants in later sections, but here we want to
emphasize that a broad mutant spectrum can contribute to over-
come genetic barriers during selection of mutant viruses (Fig. 7
and 8).
The discovery of a functional 3=-to-5= exonuclease domain in
coronavirus nonstructural protein nsp14 (228, 555) is highly in-
formative with regard to the operation of the error threshold re-
lationship in RNA viruses. Coronaviruses are the largest RNA ge-
nomes characterized to date, with the number of genomic
nucleotides being between 28,000 and 32,000. No proofreading
function has been identified in the polymerases of other RNA
viruses with shorter genomes, although some indirect mecha-
nisms of RNA repair have been described (580). Significantly,
other Nidovirales which have a genome half the size of the coro-
navirus genome lack the exonuclease function (776). Coronavi-
ruses withmutations in nsp14 display either severe defects in RNA
synthesis (555) or a dramatic (12- to 15-fold) decrease in template
copying fidelity, as judged from the complexity of the spectra of
the mutant viruses in relation to the wild-type virus (180, 227,
228). Interestingly, nsp14-defective mutants are viable, and their
capacity to enhance the mutant spectrum complexity appears to
be a stable trait, at least in the course of several cell culture passages
(180, 227). A coronavirus with a functional 3=-to-5= exonuclease
and the same virus with an inactive exonuclease constitute an
attractive system to probe the biological consequences of mutant
spectra that differ more than 10-fold in mutational input. Impor-
tant questions such as adaptability in vivo or the effects of prox-
imity to an error threshold for two RNA genomes that differ only
in the proofreading activity are now amenable to investigation.
However, since most viral proteins are multifunctional, when a
fitness modification (typically a fitness decrease) is measured with
an exonucleasemutant, it must be ascertained that the trait can be
attributed to the modified fidelity and not to other roles of the
protein harboring the exonuclease function.
Replicative RNA-dependent RNA polymerases and DNA-de-
pendent DNA polymerases display multiple mechanisms tomod-
ulate their template-copying fidelity. Amino acid replacements
maymodify proofreading-repair activities or the intrinsic capacity
of the polymerases to discriminate among nucleotide substrates
during nucleic acid polymerases (363). The adaptive capacity of
viruses and the availability of molecular mechanisms to modify
polymerase fidelity suggest that high mutation rates have been
positively selected during RNA virus evolution.
The studies reviewed in the previous paragraphs argue in favor
of RNA viruses generally benefiting from an ample mutant spec-
trum. However, as predicted by the error threshold relationship
(Fig. 1) and further documented in later sections of this article, too
broad a spectrummay be deleterious to a virus. Mutant spectrum
complexity cannot be considered a neutral trait. Amid the intri-
cate network of cellular functions that contribute to (or oppose)
viral multiplication, quasispecies dynamics provides a general
adaptive strategy to respond to environmental requirements, in-
cluding the array of innate and adaptive immune responses. A
point of caution is in order here. When a complex mutant spec-
trum displays a selective advantage over a narrow one of the same
virus, it may be because of increased complementation among
components of a wider repertoire ofmutants or because subsets of
specific variants endowedwith adaptive potential (independent of
complementation) are represented in the complex (but not the
narrow) mutant spectrum. If, in contrast, a narrow mutant spec-
trum is found to bemore adaptable to a given environment than a
broad one, it may be due to exclusion of interfering genomes or to
enrichment in specific adaptable subpopulations in the narrower
repertoire.
Positive Selection and Molecular Memory: Deterministic
Features of Viral Quasispecies
Since positive selection (defined in “Levels and Mechanisms of
Genetic Variation, Competition, and Selection” above) involves
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replication of a viral subpopulation that expresses the selectable
trait and since replication generally entails fitness gain (254, 496,
600), selection permits an increase in the frequency of subsets of
genomes. The increase of fitness resulting from replication during
selection allows the subsequent maintenance of the selected sub-
population as memory genomes (707). They can remain present
in the mutant spectrum at frequencies higher than those dictated
by basal mutation rates (85, 707). The search for quasispecies
memory was inspired in the fact that mobilization of minority
biological elements in response to a stimulus is typical of complex
adaptive systems such as the immune system. In response to a
foreign antigen, the genomes of cells from the immune system
undergo recombination and localized hypermutation, and those
cells that manifest the highest affinity for the antigen are clonally
expanded. This course of events, which has parallels with a selec-
tion of viral subpopulations, generates long-lived memory T cells
that confer long-term immunity against the triggering antigen
(11, 268, 291, 397, 403, 640, 647). We postulated that genomes
present in the mutant spectra of viral quasispecies may include
genomes that represented a record of those that were dominant at
earlier phases of the same evolutionary lineage. Experiments with
FMDV documented that when subsets of genomes that had be-
come dominant in a viral lineage as a result of positive selection
were outcompeted by other genomes of the same population, they
did not reach their basal, standard mutation frequency. Rather,
they attained a frequency higher than the basal one. This higher
frequency was termed memory level, and it reflects the previous
dominance of the same or similar genomes in the population (32,
85, 707, 710).
Molecular memory in viral quasispecies is a consequence of
quasispecies dynamics, as suggested by the following observa-
tions. (i) Population bottlenecks eliminate memory, consistent
with the fact thatmemory is a feature of the quasispecies as awhole
(entire mutant distribution) and not of the individual genomes
independently of the ensemble (190, 707). (ii) The frequency at-
tained by amemory genome in a viral population is dependent on
the relative fitness of the virus destined to become memory. In
comparing memory levels of FMDV mutants, a 7.6-fold-higher
initial fitness of a mutant resulted in 30- to 100-fold-higher fre-
quency when the mutant became a memory genome (708). (iii)
When present in a replicating viral population, memory genomes
gained fitness in parallel with the most frequent genomes of the
same quasispecies (32), in agreement with the RedQueen hypoth-
esis (825). This hypothesis proposes that in competing popula-
tions there is a continuous selection of the most fit genomes in
both populations, and this hypothesis has found experimental
confirmation in studies with several RNA viruses (26, 132, 419,
487; reviewed in reference 652). (iv) The memory level can be
durable, but it is gradually lost in replicating populations. Mem-
ory decay followed strikingly identical courses in parallel lineages,
a fact that suggested a deterministic behavior of the virus popula-
tion (710).
An alternative mechanism proposed for maintenance of quasi-
species memory is complementation and phenotypicmixing-hid-
ing (862). For reasons previously discussed (710), we think that
complementation and phenotypic mixing-hiding did not partici-
pate in memory of the two genetic markers investigated with
FMDV, although their participation in other cases cannot be ex-
cluded.
The demonstration of the presence of memory genomes was
extended to HIV-1 in vivo (86). Two types of memory were dis-
tinguished and documented experimentally in HIV-1: a replica-
tive memory similar to that described for FMDV and a cellular or
reservoir memory derived from DNA integration into cellular
DNA, inherent to the retroviral life cycle (86). Memory genomes
influenced the evolution of HIV-1 in infected patients (84) and
may have favored the reemergence of ancestral genomes docu-
mented in several HIV-1 populations (151, 166, 318, 390, 418).
The hepadnavirus HBV, by virtue of it including a stable closed
circular DNA in its life cycle, can also display a memory reservoir
that has a number of implications for the intrahost evolution of
this important human pathogen (see “Hepatitis B Virus” below).
The presence of replicative and reservoirmemories in viral pop-
ulations as the result of quasispecies dynamics has been supported
not only by experimental studies but also by theoreticalmodels on
the behavior of evolving quasispecies (84, 86). It may be a wide-
spread feature of living systems, since the concept of a genetic
memory described for viruses was later extended to Drosophila
melanogaster (802).Memory genomes confer on viral populations
preparedness to respond to selective constraints already experi-
enced by the same evolutionary lineage (reviewed in references 85,
190, and 652). The dynamics ofmemory acquisition is expected to
operate in vivowhen an antiviral agent is used to treat an infection
and an antiviral-resistant mutant is selected and then outcom-
peted by other components of the mutant spectrum. Conversion
into memory may occur as a result of treatment interruption or
implementation of an alternative treatment regimen. This has
been evidenced in the case of HIV-1 (84), and it is expected to
operate in the case of new antiviral agents to treat chronic viral
infections. It is presently a debated issue whether it will be cost-
effective to subject viral populations tomicroarray screening or to
ultradeep sequencing analysis for personalized treatment plan-
ning. The administration of drugs whose resistance mutations are
present in the mutant spectrum could be avoided, thereby delay-
ing selection of resistant mutants and extending the benefits of a
treatment. The debate is reminiscent of the one that took place 3
decades ago regarding the benefits of standard sequencing infor-
mation tomanage HIV-1 infections, which was clearly resolved in
favor of using such information.
It was particularly interesting that memory decay followed
strikingly identical kinetics in four parallel lineages despite finite
population sizes and populations being far from equilibrium
(710). Two phenomena were proposed to underlie the determin-
istic kinetics of memory decay. One is an averaging effect of dif-
ferent mutations on fitness of the memory genomes relative to
other genomes of the same population. Similar effects of muta-
tions on fitness in independent lineages were also noted in biolog-
ical clones of FMDV subjected to plaque-to-plaque transfers (255,
467, 468, 509) (see “Viral Fitness and the Effect of Population Size:
Bottleneck Events” above). The second phenomenon that could
contribute to the deterministic behavior is the limited tolerance to
mutations of a compact picornavirus genome that would limit the
pathways toward discordant diversification (710).
Memory decay is not the only process for which a deterministic
behavior has been observed in RNA viruses. Two competing pop-
ulations of VSV gained fitness in parallel, in agreement with the
Red Queen hypothesis, and only occasionally a superior mutant
arose and excluded other mutants from the competition (132), in
agreement with the competitive exclusion principle of population
genetics (308, 350). Whether this principle is really of general va-
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lidity was a strongly debated issue decades ago. For example, Ayala
showed that two species of Drosophila coexisted for many gener-
ations despite competing for limited resources (38). The different
behaviors of Drosophila and VSV may reflect one of the salient
features of RNA genetics: the highly dynamic nature and large
population size of VSV—with opportunity for the generation of
perturbing high fitness variants—versus the genotypic and phe-
notypic inflexibility of the Drosophila population within the time
frame of the experiment.
This difference renders even more surprising a deterministic
feature that was identified in competitions between a VSV and a
neutral mutant derivative that was phenotypically marked (682).
At nearly constant periods of time (competition passages), a crit-
ical point was reached at which the wild type dominated over the
neutral mutant but never the converse. It was proposed that this
nearly deterministic behavior was mediated by an averaging of
mutational noise signals that occurred during the competition
process (682). This interpretation is related to the one proposed
for deterministic memory loss (710). Additional experiments
showed that environmental perturbations introduced during the
competitions between VSV and its neutral derivative (for exam-
ple, an increase of temperature, 5-fluorouracilmutagenesis, or the
presence of defective interfering [DI] particles) favored the dom-
inance of the wild-type virus (681). The consensus sequence of the
two competing viruses differed at six positions. It was proposed
that the six mutations that occurred when generating the marked
neutral mutant, and whichmoved the virus to a different position
in sequence space, rendered the mutant less adaptable. While the
mutantmaintained the same fitness as the wild type under normal
growth conditions, under environmental demands it could not
attain beneficial mutations as rapidly as the wild-type virus (681).
This led to a contingent neutrality that could explain the deter-
ministic behavior observed. These results are in agreement with in
silico competitions carried out with simple replicons (864).
The molecular basis for deterministic behavior of finite popu-
lations of RNA viruses will generally be difficult to resolve. What
the experimental results suggest is that stochastic or deterministic
features may dominate virus evolution and that it will be ex-
tremely interesting to define which parameters (tolerance to mu-
tations, virus population size, environmental homogeneity versus
heterogeneity, etc.) may favor one or the other (468, 704, 710).
Complementation and Defection: Quasispecies as a Unit of
Selection
Complementation is a process by which a genome expressing a
functional protein can promote replication of another closely re-
lated genome whose corresponding protein is defective (or sub-
optimal). Interference is the mirror image of complementation in
the sense that the defective protein impedes the functionality of
the competent partner.
The occurrence of complementation among components of a
mutant spectrum was suggested in the early studies that showed
that individual biological clones isolated from a virus population
displayed lower average fitness values than the entire population
from which they had been isolated (215, 224) (Fig. 9). Since then,
extensive evidence in favor of intraquasispecies complementation
has accumulated. The PV fidelity mutant G64S (see “Exploration
of Sequence Space and Virus Adaptability: Fidelity Mutants”
above) did not replicate efficiently in the brain of susceptiblemice.
However, when it was coinoculated with wild-type PV or with a
G64S mutant with an expanded mutant spectrum, the G64S mu-
tant entered the central nervous system (CNS) and replicated
(832, 833). This observation suggests that members of the more
diverse PV mutant spectrum complemented the more restricted
population derived from the G64S mutant, allowing the latter to
access the brain. It is not clear whether complementation was due
to coinfection of the same cells or to other, indirect mechanisms
(66, 832).
Complementation between viral mutants has been extensively
described, and it underliesmaintenance of defective genomes (de-
fective interfering particles or other defective types) in viral pop-
ulations (1, 312, 563, 618, 703, 867). The attractive extension to
quasispecies dynamics is that complementation may be exerted
not only among dominant genomes (as in the experiments to
define complementation groups and cistrons of classical genetics
or in an evolved bisegmented form of FMDV [618] [discussed in
“Fitness Gain and Genetic Change: Genome Segmentation”
above]) but also among components of a quasispecies, the result
of which is fitness enhancement (Fig. 10).
FIG 9 Early evidence of complementation within a viral quasispecies. The
average fitness of an uncloned population is higher than the fitness of viral
populations grown from individual viral plaques 1, 2, 3, and 4 (215, 224)
(fitness values are depicted as a triangle at the bottom).
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Related in origin but converse in its result on fitness, interfer-
ence is exerted by RNA genomes or their expression products on
replication of other components of the viral population. This in-
terference phenomenon is distinct from RNA interference by
small RNAs or from the high negative interference that concerns
the unexpected multiple template switches that may occur during
recombination (114, 384). De la Torre andHolland showed that a
VSV quasispecies could suppress VSV genomes that in isolation
displayed higher fitness than the suppressing population (171).
This result represented the first experimental observation that a
mutant spectrum could guide the behavior of specific mutants
included in the spectrum. That a lower-fitness genome can ac-
quire a selective advantage over a more fit genome by virtue of a
favorable mutant spectrum was predicted by an early computer
simulation based on quasispecies theory (238, 789). Suppression
of high-fitness antigenic variants by low-fitness antibody escape
populations was described for FMDV replicating in cell culture
(78). PV mutants delayed replication of drug-resistant mutants
(154).
As a counterpart to the complementation required for replica-
tion of the high-fidelity PV (832, 833), attenuated PV suppressed
the neurological disease in monkeys associated with virulent PV
(126). Also, the growth hormone deficiency syndrome in mice,
which is associated with replication of pathogenic lymphocytic
choriomeningitis virus (LCMV) strains in the animals, was sup-
pressed by nonpathogenic LCMV variants (801). Thus, a variety
of cell culture and in vivo virus-host systems have provided evi-
dence of suppressive and interfering effects within quasispecies.
An important challenge is to elucidate the molecular interactions
that lead to the interference. They may involve the same mecha-
nism displayed by dominant negative interactions of a virus mu-
tant on the corresponding wild type exerted by one of several
proposed mechanisms (886). Some may be parallel with interfer-
ence exerted by defective interfering (DI) particles (703), although
when viablemutants are involved, subtle interactions among viral
gene products might play a role. Coelectroporation of BHK-21
cells with wild-type RNA and an excess of specific capsid or poly-
merase mutants resulted in suppression of infectivity by mutants
that were competent in RNA replication (654). A single amino
acid substitution could convert an interfering mutant into a non-
interfering mutant and vice versa. Thus, small movements in se-
quence space can transform a complementing functional protein
into a defective, interfering counterpart so that mutational events
can modulate complementation and interference in quasispecies.
An excess of a mixture of interfering FMDV mutants synergis-
tically suppressed the infectivity of standard, infectious FMDV
(654). This result is in agreement with suppression of FMDV in-
fectivity by preextinction, heavily mutagenized FMDV RNA pop-
ulations (320). Indeed, sequence analyses show that preextinction
viral populations are enriched with multiple mutants that, al-
though present at low frequency, could give rise to interference as
a collective manifestation of low-frequency, functionally deficient
mutants (331, 392). Defective genomes in natural viral popula-
tions appear to be abundant, as judged by the identification of stop
codons within open reading frames. However, their biological
roles are largely unknown. APOBEC3 decreased the specific infec-
tivity of Friend retrovirus, and noninfectious particles stimulated
the neutralizing antibody response (773).
A number of theoretical models have introduced competition,
cooperation, and complementation in the description of quasi-
species and the error threshold (27, 729). These models offer re-
alistic elements that may provide them with a predictive value
(562). The collective behavior of viral quasispecies suggests that at
least at times amutant ensemble rather than an individualmutant
can be the target of selection. This has been and still is a hotly
debated topic in general genetics. Nevertheless, the evidence that a
viral quasispecies can be the target of selection provides an impor-
tant distinction from the classical Wright-Fisher formulations of
evolutionary dynamics, and it has been one of the reasons to rec-
ognize that quasispecies can embody evolutionary mechanisms
not always reconcilable with those of classical population genetics
(for papers and reviews on this topic, see references 95, 140, 530,
578, 619, and 861). The intraquasispecies interactions may be ex-
erted by mutants generated intracellularly within the same repli-
cative ensemble or by exogenousmutants that penetrate into a cell
together with the standard virus (and both will generate a corre-
sponding mutant cloud). Some virus-host systems display super-
infection exclusion, and therefore, potentially interfering and
standard genomes should coinfect cells simultaneously (562).
Polyploidy (the presence of several genomemolecules in the same
virus particle) has been documented for some viruses (59, 383,
498). Therefore, interactions among viral genomes and their ex-
pression products within a cell can occur with participation of
mutants generated within the cell or with mutants introduced
either by coinfection, by reinfection (when superinfection is not
excluded), or through polyploid particles.
The collective properties of mutant spectra represent an effect
of mutations present in different genomes of a given population.
This level of interaction in viruses has been explored to a lesser
extent than interactions among mutations present in the same
genomic viral RNA molecule. Such interactions are referred to as
positive epistasis, in which fitness of a multiple-mutant genome is
higher than those of the individual mutants. Conversely, negative
FIG 10 A schematic representation of interactions of complementation and
interference (or defection) within mutant spectra. Standard genomes are de-
picted as smooth blue spheres and interfering genomes as rough red spheres.
Each symbol (even of the same shape) portrays a slightly different genomic
sequence. Complementing interactions (thin arrows, left side) dominate when
an RNA virus replicates with standardmutation rates. Under such conditions,
the fitness of the population ensemble is higher than that of the individuals that
compose the population. When mutation rates increase, interfering interac-
tions (thick arrows, right side) dominate and viable individuals are more fit
than the ensemble. (Adapted from reference 212.)
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epistasis refers to lower fitness of the multiple mutant than of the
individualmutants (245, 446, 626, 695). Epistatic effects in viruses
may be obscured by the presence of a mutant spectrum, since the
genome under analysis is in reality a mutant cloud in which sub-
sets of genomes may increase or decrease their frequencies dy-
namically. The sequence indetermination may blur interactions
between twomutations unless epistasis in an individual genome is
strong (523). Compensatorymutations are an example of positive
epistasis that permit survival of escape mutants when the muta-
tion relevant for escape inflicts a fitness cost upon the virus (ref-
erences 591 and 632 and references therein). Compensatory mu-
tations are key to themaintenance of drug resistancemutations in
viral populations, as further discussed in the next sections.
BIOLOGICAL IMPLICATIONS OF QUASISPECIES DYNAMICS
Cell Tropism and Host Range Mutants: Biological
Alterations and Viral Emergence
The main features of viral quasispecies described in the previous
sections have several biological implications that affect the virus-
host relationship. The dynamics of selection of minority compo-
nents can play a role in the modifications of cell tropism and host
range, as documented with designed experiments and during vi-
rus evolution in vivo. The number of amino acid substitutions
needed and the genetic and phenotypic barriers involved are de-
terminant parameters of how likely a modification of cell tropism
or of host preference will be. The understanding of the dynamics
of modification of cell recognition is still fragmentary compared
with, for example, that of the dynamics of drug resistance or drug
dependence, although the underlying mechanisms involving se-
lection of viral subpopulations are likely to be parallel.
The capacity of a virus to productively infect a cell does not
depend only on recognition of a cellular receptor on the cell sur-
face but also on intracellular host factors that render a cell either
permissive or refractory to virus multiplication and to formation
and release of virions.Host cell specificity ismultifactorial. That is,
amino acid substitutions either in the viral capsid or surface pro-
teins (which interact with receptors or potential receptors) or in
nonstructural viral proteins (which interact with cellular compo-
nents and influence permissivity to virus multiplication) can re-
sult in modifications of cell tropism or host range.
The receptors used by viruses to recognize and penetrate into
cells belong to different families of macromolecules (proteins, li-
poproteins, glycoproteins, glycolipids, glycosoaminoglycans,
etc.), which are often organized as complex structures on the cell
surface (46, 61, 155, 517, 739, 866). These diverse molecules per-
form disparate cellular functions (adhesion, signaling, etc.) and
are often present in large numbers (103 to 104 per cell) on the cell
surface (155). The presence of the receptor is a necessary but may
not be a sufficient condition for infection.Molecules such as sialic
acid or heparan sulfate (HS) may function as bona fide viral re-
ceptors or may act as macromolecules that recruit viruses on the
cell surface to facilitate their reaching a true receptor which me-
diates penetration into the cell. Other molecules, often termed
coreceptors, might be needed for efficient entry (61). The absence
or blockage of any required receptor or coreceptor may impede
virus entry into a cell.
When a new virus emerges or is discovered in the field, it is very
difficult to predict the type of receptor molecule it might use. One
of the reasons for such unpredictability is that receptor usage does
not follow any obvious correlation with the phylogenetic position
of a virus, as determined by nucleotide and amino acid sequence
comparisons (436). The current system of virus classification, de-
spite serving as a fundamental guide to virologists, suffers from
serious limitations derived in part from the variable nature of
most viruses it intends to classify. Historically, virus classifications
were guided by physical properties, antigenic relationships, and
disease manifestations. More recently, comparisons of genomic
nucleotide sequences and amino acid sequences of viral proteins
have served as the basis for classification (references 464, 465, and
760 and references therein). With a phylogenetic relationship
based on comparing several genes of viruses (or ideally the entire
genomic sequence), a single nucleotide or amino acid change in
one of the viruses has no effect on its phylogenetic position. Yet, a
single or few amino acid changes can nevertheless profoundly al-
ter host cell tropism and other important phenotypic traits of
viruses, as covered in several sections of this article. A virus may
include in its mutant spectrum genomes that despite belonging to
the same phylogenetic group defined by the consensus sequence
may differ in salient biological properties. The ambiguous situa-
tion created is not easy to solve, but it has been suggested that
sequence data banks could be expanded to include characterized
minority sequences present in the mutant spectrum (see refer-
ences 193 and 208 for discussions of the limitations of the current
system of virus classification).
Related viruses (according to current classifications) may use
different receptors, unrelated viruses may share a receptor, and
viruses may display the same tissue tropism but using different
receptors. The majority of human rhinovirus (HRV) serotypes
bind to intracellular adhesion molecule 1 (ICAM-1), while a few
HRV serotypes bind members of the low-density lipoprotein re-
ceptor (LDLR) family. Subgroup C adenoviruses and group B
coxsackieviruses share the appropriately termed coxsackieviruses-
adenovirus receptor (CAR) (reviewed in reference 61). Binding to
decay-accelerating factor (DAF) is shared by phylogenetically di-
vergent clusters of enteroviruses (672). Although not all receptors
and coreceptors recognized by hepatitis viruses have been identi-
fied, the receptor for hepatitis A virus (HAV) (HAV receptor 1)
and the candidate receptors and coreceptors for HCV (the tetras-
panin CD81, scavenger receptor type B1 [SR-B1], epidermal
growth factor receptor [EGFR], ephrin receptor A2 [EphA2], and
the tight junction components claudin-1 and occludin) belong to
different protein families (49, 261, 417, 665, 668, 683) despite
these viruses sharing hepatotropism. The hemagglutinin esterases
(HEs) are glycoproteins present in coronaviruses, toroviruses, and
influenza virus (IV) type C. These proteins probably have a com-
mon origin and have evolved to confer on the viruses different
sialic acid recognition specificities (references 461 and 890 and
references therein).
Either mutations that lead to amino acid substitutions at exter-
nal residues of surface proteins (arrived at by either diversification
or convergence) or recombination events that result in an ex-
change of modules (encoding relevant protein motifs) may result
in modification of the host cell tropism. When mutations alone
can mediate a shift in receptor recognition, the mutant spectrum
(with minority genomes encoding altered proteins that have the
potential to use alternative receptors) can play a role. Passage of
FMDV in cell culture selected virus mutants that included amino
acid substitutions in the capsid surface that permitted infection
through the binding toHS at the cell surface (45–47, 61, 395, 715).
HS-binding variants of FMDV are present as minority compo-
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nents of FMDV that replicate in cattle tissues in vivo (874). A
severe acute respiratory syndrome (SARS) coronavirus with in-
creased replication in human proximal tubular epithelial cells
(PTEC) of the kidneywas selected after a fewpassages in these cells
(624). The availability of a given receptor molecule (be it HS in
cells in culture, DAF in epithelial cells lining the intestine, core-
ceptor CCR4 or CXCR5 in cells of the immune system, or others)
may favor selection of those components from mutant spectra
that can derive a productive infection fromusing an available (and
functional) receptor (46, 687). That new receptor might be differ-
ent from the one used by the majority of components of the mu-
tant spectrum (45, 46, 61). Selection dynamics of minority quasi-
species components was evidenced during IV adaptation to
different cell lines (699). Again, there is a biological implication of
the presence of minority subpopulations that can be selected in
response to a matching receptor molecule.
The concept of barrier, explained in “Exploration of Sequence
Space and Virus Adaptability: Fidelity Mutants” above, applies
also to modifications of cell recognition. A new functional recep-
tor-virus interaction may require the replacement of multiple
amino acids on the virus surface, thus rendering their occurrence
and the ensuing selection unlikely (836). While a single amino
acid substitution to eliminate receptor recognition is expected to
be a frequent event (not noticeable because the corresponding
virus will be eliminated by negative selection), generation of a new
receptor recognition site through multiple amino acid substitu-
tions is an event with a high genetic barrier (reference 688 and
references therein). The low probability of occurrence can be very
roughly estimated from the actual number of amino acid replace-
ments needed and the number and type of mutations involved.
The newly generated receptor recognition site should obviously
have a positive effect on fitness because it permits the virus to
penetrate in a new cell type. However, the required amino acid
substitutions may negatively affect some other trait such as capsid
or surface protein stability. In this case a large phenotypic barrier
may impede selection, and the order of appearance of each muta-
tion would be of importance for fitness at specific stages.
Minimal genetic change has proven sufficient tomodify the cell
tropism and pathogenic potential of a virus (several examples
were reviewed in references 45, 46, 82, 149, 539, 678, 820, and
879). This is the case for the modification of CCR5 or CXCR4
coreceptor usage by HIV-1 (82, 167, 355) or changes in the sialic
acid-binding preference of the hemagglutinin of IV (reference 822
and references therein). Mutations that abolish sugar-binding ac-
tivities of the coronavirus transmissible gastroenteritis virus
(TGEV) eliminate the enterotropism of the virus (448). The respi-
ratory tropism and absence of enteric tropism of porcine respira-
tory coronavirus are associated with a deletion at the N-terminal
domain of the coronavirus spike protein (see reviews and addi-
tional references on coronavirus receptor usage and its variations
in references 328 and 646). Structural studies have documented at
least three different mechanisms by which the surface glycopro-
tein of paramyxoviruses can establish functional interactions with
protein and glycan receptors, suggesting a great potential for the
emergence of new paramyxoviral pathogens (81).
HRV mutants adapted to using HS as receptor must either be
acid labile or acquire acid lability through mutation to compen-
sate for the absence of the uncoating activity of ICAM-1 (428,
837), which constitutes an example of a phenotypic barrier.
FMDVuses integrins to infect cells in vivo (54, 394, 396, 558, 586).
The integrin recognition amino acid triplet RGD is located on a
mobile loop of capsid protein VP1, protruding from the capsid
surface (2). Because the RGD is highly conserved among field
isolates, this triplet was considered universally essential for FMDV
infection. However, FMDV that was passaged multiple times in
BHK-21 cells did not require the RGD to infect cells, and instead it
used HS or a third, unidentified receptor (45–47).
The canyon hypothesis proposed that a receptor recognition
site should be shielded from the variation that occurs at antigenic
sites (702). Contrary to the canyon hypothesis, the VP1 loop in
which the integrin recognition site of FMDVresides is also amajor
antigenic determinant of the virus that includes multiple overlap-
ping epitopes (2, 533, 536–538, 829, 830). These studies showed an
intricate connection among the different epitopes and docu-
mented that some of the amino acids that determine integrin rec-
ognition are also involved in binding to neutralizing monoclonal
antibodies (MAbs) (533, 534, 538, 829). Thus, receptor recogni-
tion sites need not be separate from antibody recognition sites.
Any mutation that abolishes integrin recognition, for example,
mutations affecting the RGD, will be subjected to negative selec-
tion (like those affecting any other amino acid critical for a viral
function), and the corresponding virus will not survive unless it
can be rescued by complementation. In this view, the selective
advantage derived from hiding a receptor recognition site from
antibody recognition is largely irrelevant. Not only can receptor
and antibody recognition sites overlap, but some antibodies pen-
etrate deep into the picornavirus canyon (774).
Overlap of receptor and antibody recognition sites has been
documented with many other RNA and DNA viruses, and it now
appears to be the rule rather than the exception (46, 61, 391, 892).
One of its consequences is the potential of coevolution of host cell
tropism and antigenicity, two important traits in the life cycle of
viruses. Coevolution is defined as an interaction between two (or
more) biological entities by which they exert evolutionary effects
on one another (21, 297, 419, 873), as clearly documented with
viruses and cells during persistent infections in cell culture (see,
e.g., references 10, 172, 701, and 893). An alteration of receptor
specificity that entails a change in binding to antibodies or vice
versa can qualify as a coevolutionary event. An antigenic domain
that shares amino acid residues with a receptor-binding site will
lose part of its constraints for variationwhen the receptor ceases to
be functional, for example, because an alternative receptor is used
instead. When evolution of FMDV in cell culture rendered the
RGD dispensable, the repertoire of MAb escape mutants ex-
panded relative to the repertoire obtained with the wild-type vi-
rus. This was shownwith amajor neutralization epitope located at
amino acid residues 138 to 147 of capsid protein VP1 of FMDV
(Fig. 11). None of a total of 84 independently isolated MAb SD6-
resistant mutations of the parental FMDV C-S8c1 affected the
RGD sequence, because the sequence is needed for integrin recep-
tor recognition. In contrast, 26 out of a total of 46 SD6 escape
mutations obtained using C-S8c1p100 (the passaged C-S8c1 pop-
ulation that evolved to recognize alternative receptors) mapped
within the RGDL (47, 196, 526, 711) (Fig. 11). This specific exam-
ple illustrates how escape mutant repertoires present in mutant
spectra can vary depending on biological features that in this case
were recognized but that in other cases can go unnoticed.
A remarkable case of coevolution in vivo was revealed by the
analysis of the FMDV that replicated in cattle previously immu-
nized with a peptidic vaccine. Such vaccines generally confer par-
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tial immunity because they present the host immune system with
a limited repertoire of B- and T-cell epitopes. Exposure of a lim-
ited antigenic repertoire by a vaccine is against one of the princi-
ples of vaccinology, which asserts that for a vaccine to be effective
it should evoke an immune response which is similar to that
evoked by the authentic pathogen (72, 202, 260). Upon challenge
with virulent FMDV, some of the peptide-vaccinated animals de-
veloped viremia and vesicular lesions. Virus from several lesions
included amino acid substitutions at the RGD or neighboring res-
idues that resulted in altered host cell specificity (791, 795). Mod-
ifications such as those described for FMDV require very fewmu-
tations, and therefore, there is a tangible probability that these
classes of mutants are present in the viral quasispecies, either be-
cause the mutations do not inflict a significant fitness cost or be-
causemutants harboring them can bemaintained by complemen-
tation.
Other cases of modification of host cell tropism emphasize the
relevance of quasispecies dynamics in presenting collections of
mutants or recombinant genomes with the potential to interact
with alternative receptors (reviewed in references 45, 46, 61, and
192). Modification of antigenic sites can also affect the antibody-
dependent enhancement of viral infection, amechanismexploited
by several viruses (793), including FMDV (336, 531, 696).
Analysis of mutant spectrum composition, together with struc-
tural studies, may provide some hints about possible evolutionary
outcomes in relation to receptor recognition. Specifically, three-
dimensional structures of complexes between viral attachment
proteins and their cognate (standard) cellular receptors may be
informative in regard to how related viral proteins can adapt to
using alternative receptors (159, 783).
Host cell tropism and pathogenicity can depend on substitu-
tions at structural or nonstructural viral proteins. Amino acid
substitutions in the IV polymerase subunit PB2 can promote ad-
aptation to alternative hosts, and one of themechanisms probably
involves enhancement of viral replication and increases in viral
load through interaction with host proteins (299, 300, 357, 786,
881). In a laboratory study designed to investigate the events that
led to adaptation of a swine FMDV to the guinea pig, it was shown
that upon serial passage of the virus in guinea pigs, variants with
amino acid substitutions I248T in protein 2C andQ44R in protein
3A were selected (609). Only upon further passage was replace-
ment L147P in the antigenic loop of capsid protein VP1 selected.
The three amino acid substitutions were maintained upon repli-
cation of the virus in swine and suckling mice. Amino acid substi-
tution T248N in nonstructural protein 2C, not detectable in the
parental virus, was present as a minority genome in the guinea
pig-adapted virus and became dominant upon infection of pigs. A
minority variant arising in an unnatural host may become domi-
nant on reinfection of the original host species (610).
Cross-species transmission can be influenced by the ability of
the virus to selectmutants that overcomehost restriction elements
(438). An LCMV variant differing in two amino acids from the
wild type displayed altered cell tropism in spleen, induced a gen-
eralized immunosuppression, and established a persistent infec-
tion in mice (79). An amino acid substitution in encephalomyo-
carditis virus (EMCV) can render the virus diabetogenic (42).
Cardiovirulence of coxsackievirus B3 can be determined by a sin-
gle site at the 5= untranslated region (UTR) (815). (For additional
studies on coxsackievirus B pathogenesis and evolution and the
relevance of quasispecies for enteroviruses in general, see several
chapters of references 232 and 812).
Phenotypic plasticity and, in particular, coevolution of anti-
genicity and cell tropism can promote host range alterations of
viruses and therefore contribute to viral disease emergence.
New human viral diseases have emerged at the rate of about one
per year over the last decades and in some cases with a monu-
mental impact on public health, such as with the current AIDS
pandemic. Several studies have dissected a number of contrib-
uting sociopolitical and environmental influences, including
the zoonotic origin of many human viral diseases (reviewed in
references 24, 41, 185, 337, 387, 447, 503, 565, 638, 658, and
775). Pangenome analyses using ultradeep sequencing are cur-
rently unveiling the presence of multiple virus types in a num-
ber of biological habitats (583). The results have confirmed
previous evidence that rodents are a source of multiple viruses,
some of which are yet to be classified (reference 663 and refer-
FIG 11 Modification of the repertoire of antibody escape mutants of a virus associated with dispensability of a host receptor for infectivity. The picornavirus
FMDV genome (displayed at the top) includes a major antigenic determinant (amino acid sequence written with the single-letter code), with an epitope
recognized by neutralizing antibody SD6 (underlined sequence) which includes the sequence RGDL (boxed) also involved in recognition of integrin receptors.
FMDV C-S8c1 SD6 escape mutations map around but not within the RGDL (top gray box). Subscripts indicate the number of times that a given escape mutant
was obtained in independent selection events. The repertoire of SD6 escapemutants of FMDVC-S8c1 passaged 100 times in cell culture (C-S8c1p100) expanded
to include substitutions at residues G142, D143, and L144 (bottom gray box). The expansion of the escapemutant repertoire was due to integrin receptors being
dispensable for the multiply passaged FMDV. (Adapted from reference 653 with permission.)
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ences therein). Viruses that replicate in rodents will generate
mutant spectra that may reach new hosts as a result of animal
movements and increases of rodent populations due to agricul-
tural practices. Rodent populations offer a typical example of
the evolutionary and environmental influences on viral disease
emergence, but many additional animals (notably bats and pri-
mates) can be a potential source of multiple variant forms of
many viruses (185, 447, 587). The detection of a viral sequence,
however, does not imply that an infectious virus is present.
Diversiﬁcation and Self-Organization of Viral Quasispecies
In previous sections of this article we have provided evidence of
virus behavior being the result of interactive genome ensembles,
as in the presence of a genetic memory that is erased by bottleneck
events. Here we describe the evolution of quasispecies toward en-
sembles that display new phenotypic traits. A significant example
of how viral quasispecies can self-organize tomodulate cell killing
was observed with FMDV replicating in BHK-21 cells, a stable
biological environment (616). A clone of FMDV (C-S8c1, the
progeny from a single genome) was passaged at a high MOI to
ensure that multiple viral particles infected the same BHK-21 cell.
At passage 143, a MAb-resistant variant termed MARLS was se-
lected (113). This variant displayed high fitness and killed BHK-21
cells efficiently (here called “high virulence” despite referring to a
trait in cell culture) (364). Surprisingly, the sequences that were
the signature of MARLS (32 mutations relative to the parental
genome C-S8c1) did not become dominant even after 460 pas-
sages. When viral samples from several passages were subjected to
three low-MOI passages, MARLS-like populations were rescued.
Moreover, biological clones isolated from those populations seg-
regated into two classes: those similar to the uncloned populations
(termed p200 clones) and those that were MARLS-like. This evo-
lutionary pattern suggested that the high-fitness, high-virulence
MARLS subpopulation was suppressed by subpopulation p200.
Cell killing measurements and cell killing interference assays in-
deed distinguished between the MARLS-like clones, which were
termed the colonizers, and the p200 clones, whichwere termed the
competitors. Both subpopulations exhibited a competition-colo-
nization dynamics similar to that previously recognized in classi-
cal ecological systems (806). A theoretical model of coinfection
dynamics was developed, and it predicted a density-dependent
(MOI-dependent) selection of either colonizers or competitors, a
point that was confirmed experimentally (616). The experiments
indicated that a single clone of FMDV can diversify into geneti-
cally distinct subpopulations that exhibit a competition-coloniza-
tion dynamics in which the killer colonizers are suppressed by the
competitors that act as modulators of virulence. The study with
FMDV has stimulated theoretical simulations of virulence modu-
lation through the interaction of viral subpopulations in coin-
fected cells (174).
Coinfections of cells by multiple viruses, perhaps preferentially
in coinfection-prone cell subsets (122, 129, 177),must be frequent
as judged by the generation of recombinant viruses in vivo (1, 4, 5,
157, 414, 766, 769, 804). Thus, coinfections may play a role in
modulation of virulence in addition to being a source of recom-
binant viruses. Specifically, in experiments with serial passages of
FMDV inmice, attenuated strainswere isolated in organs inwhich
coinfection was more likely (compare references 616 and 727).
Thus, molecular memory, positive interactions of complemen-
tation to facilitate survival ofmutant subsets, negative interactions
that favor virus extinction, diversity thatmodulates virulence, and
density-dependent selection (90, 171, 604, 750, 816, 817) are fea-
tures than depend on mutant spectra and that can critically influ-
ence virus behavior.
Selective Forces and Escape Mutants
Escape mutants are the subset of mutants present in a viral popu-
lation that can replicate despite the action of a selective constraint
that impedes replication of the genomes that represent themajor-
ity of the population. The selective constraints can be antiviral
drugs, components of the innate or the adaptive immune re-
sponse, or interfering RNAs, among others. The first descriptions
of escape mutants to antiviral inhibitors were by Tamm, Barrera-
Oro and their colleagues (230, 544). The ample occurrence of
escape mutants of different viruses under a variety of environ-
mental conditions in vivo and in cell culture is yet another mani-
festation of the presence of relevant variants in themutant spectra
of viral populations.Herewe summarize only some representative
quantifications and the implications of escape mutants for viral
persistence.
The frequency of inhibitor-resistant mutants of viruses is gen-
erally in the range of 103 to 105 (reviewed in references 188,
202, 212, and 693). Relevant considerations that determine the
actual frequency are the number of amino acid substitutions re-
quired for resistance, the genetic barrier (number and type of
mutations needed for the amino acid substitutions), and the fit-
ness cost that the mutations entail. Resistance to inhibitors often
requires one or a few mutations, and there are multiple, alterna-
tive mutations that can confer resistance to a drug. Those muta-
tions that confer resistance with a limited fitness cost are likely to
be represented inmutant spectra. If 20 ormore definedmutations
were needed simultaneously to escape a selective constraint, a
quasispecies with the range of complexities of mutant spectra en-
countered in infected organisms would be largely irrelevant. No
escape mutants would be selected, but the survival of viruses
would be incompatible with the environmental challenges posed
by our biosphere. A demonstration of the adaptive capacity of a
virus is not only that escape mutants are readily selected but also
that virus replication may even become drug dependent (44, 173,
229).
All genetically variable viruses display similar positive selection
events conducive to single-drug and multidrug resistance associ-
ated with one or several point mutations and, less frequently, with
insertion-deletion or recombination events. Resistance within in-
fected individuals or at the epidemiological level has been de-
scribed for each of the drugs that have been used to treat human
influenza infections. Multiple amino acid substitutions in the
neuraminidase (NA) have been associated with resistance to the
NA inhibitors used in anti-influenza virus type A drug therapy
(I117V, E119V,D198N, I222V,H274Y, R292K,N294S, and I314V
for oseltamivir and V116A, R118K, E119G/A/D, Q136K, D151E,
R152K, R224K, E276D, R292K, and R371K for zanamivir), and
resistance mutations have been detected in multiple avian, swine,
and environmental isolates of the virus (622). SubstitutionH275Y
in the NA of the 2009 pandemic IV confers resistance to oseltami-
vir; ultradeep sequencing revealed the presence of thismutation in
5% of clinical samples, the majority from patients subjected to
oseltamivir treatment (179). Substitutions E119G and E119V
conferred multidrug resistance to several NA inhibitors at a con-
siderable fitness cost for the virus. I222Vhad a synergistic effect on
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the oseltamivir and permivir resistance conferred by H274Y and
compensated for the reduction of viral fitness (667).
Several families of inhibitors of picornaviruses are available,
and drug resistance and sometimes drug dependence have been
reported (173, 181, 210, 212, 229). Tamm and Eggers were pio-
neers in showing that combination therapy had an advantage over
monotherapy (796).
New, effective inhibitors are often claimed to offer great prom-
ise because they can inhibit mutant viruses which are resistant to
other drugs. This transient optimism generally ends with the ob-
servation that the new drug can itself select for additional resistant
mutants and that multidrug resistance becomes increasingly fre-
quent when several drugs are used in clinical practice. Drug resis-
tance for HIV-1, HBV, and HCV is reviewed in Specific Viral
Systems below. The course of events is similar for all pathogenic
viruses and can be summarized as follows. (i) Drug resistance is a
general phenomenon, and selection of a drug-resistant mutant is
taken as evidence of specificity of an antiviral drug (188, 366, 666,
693). (ii) Multiple different mutations or combinations of muta-
tions and, thus, mutational pathways can lead to drug resistance.
There are several reasons for this, one being that multiple short-
range and long-range interactions occur within a protein mole-
cule (782, 818). As a consequence, a decrease of affinity for a ligand
drug can come about through multiple amino acid replacements
at different sites in the protein that binds the drug. A protein that
forms a complex with the one targeted by the drug can also affect
drug binding. (iii) High-level resistance to a drug may entail mu-
tations different from those involved in low-level resistance, and
thus, genomes displaying low and high resistance to the same drug
occur at different frequencies (8, 360, 361, 828). (iv) As a general
rule, substitutions that confer drug resistance increase viral fitness
when fitness is measured in the presence of the drug and decrease
fitness measured in the absence of the drug. (v) When multiple
substitutions are involved in drug resistance in a givenmutational
pathway, some mutations may be selected for their fitness-en-
hancing effect, but they may not contribute directly to decreasing
the affinity for the drug. These features should become more de-
fined at the molecular level with the advent of ultradeep sequenc-
ing techniques, combined with additional fitness measurements
in vivo.
Parallel arguments of Darwinian selection of mutant viruses
apply to the immune response. The innate immune response
against viruses has several components, some established on a
permanent basis and others recruited as a consequence of virus
infection. Permanent components include proteins of the com-
plement system and cytokines and chemokines that gather cells
(neutrophils, monocytes, macrophage, dendritic cells, natural
killer cells, etc.) at the sites of infection. Systems recruited as part
of the immune response against viruses are editing activities that
perform important cellular functions. Among them, the adeno-
sine deaminase acting on RNA (ADAR) proteins are a family of
adenosine-to-inosine editing enzymes that act on double-
stranded RNA (594). One of the isoforms of ADAR 1 is a restric-
tion factor for several (but not all) RNA viruses (848). Little is
known about viral antagonists of ADAR restriction, but hypermu-
tated viral genomes generated by ADAR can contribute to anti-
body escape (521, 522) or to the generation of pathogenic hyper-
mutated genomes (such as hypermutated measles virus genomes
associated with subacute sclerosing panencephalitis [109]). Other
cellular functions can modulate susceptibility to viral infections.
This is the case of murine proteins Fv1 and Fv4, which are the
products of expression of endogenous retroviruses; Fv1 blocks the
entry of preintegration complexes into the nucleus, and Fv4 acts as
a competitor of env for receptor binding. Other examples for ret-
roviruses are the tripartitemotif protein 5 (TRIM5), zinc finger
antiviral protein, or the APOBEC family of editing proteins (see
“Human ImmunodeficiencyVirus Type 1” below formechanisms
used byHIV-1 to counteract immune responses and reference 186
for a discussion on how cellular functions can either contribute to
or interfere with viral replication).
The adaptive immune response poses multiple selective con-
straints to virus replication, including neutralizing antibodies,
several subsets of virus-specific T cells that can eliminate infected
cells either by direct contact or through soluble cytokines (gamma
interferon [IFN-	] and tumor necrosis factor alpha [TNF-]).
The latter effectors also participate in the recruitment of innate
immune components, thus contributing to the clearing of the in-
fection. Viral escape mutants, which permit virus survival and
replication in the face of the host immune response, can play an
important role in either the establishment ormaintenance of viral
persistence (3, 131, 311, 388, 479, 643, 748, 749) (see also the
discussions of the immune responses for HIV-1, HBV, and HCV
in Specific Viral Systems below).
Vaccinationmay be an important evolutionary force for viruses
(124). Vaccine escapemutants have been reported for HAV, a fact
which is particularly relevant because a single serotype has been
described for this virus (271, 440). HAV needs to maintain rare
codons in the capsid-coding region, probably to regulate ribo-
some traffic to achieve an adequate folding of the capsid proteins
(26). The requirement of rare codons might prevent the genera-
tion of antigenic variants that are sufficiently distant to qualify as
a new serotype (25). Despite such likely restrictions, antigenic
variants of HAV that probably escaped the immune response
evoked by the available vaccines were isolated among immuno-
compromised individuals (656). This study reinforces the concept
that partial immunization due either to low immunogenicity of a
vaccine or to limited capacity of the vaccinees to evoke an immune
responsemay allow continued viral replication and sufficient viral
loads to promote the emergence of antigenic and cell tropism
variants (46, 185) (see “Cell Tropism and Host Range Mutants:
Biological Alterations andViral Emergence” above). The observa-
tions on vaccine escape mutants of HAV agree with the presence
of complex mutant spectra despite limited variation of the con-
sensus sequence of HAV populations (152, 723).
It is tempting to invest in immunotherapeutic approaches
based on the induction of immune responses against highly con-
served epitopes or on administration of neutralizing antibodies
directed to conserved regions of viral proteins (23, 598). However,
it is unlikely that a virus will yield to such pressures. A conserved
viral domain may have a cellular counterpart for which immune
tolerance has developed (e.g., the RGD motif present in the cap-
sids of some picornaviruses, which is an integrin recognition site
for cell adhesion [598]). Even if a cellular counterpart is not pres-
ent, once subjected to selection, a hitherto-invariant viral site may
find escape routes through substitutions that affect long-term in-
teractions within the target protein and compensatorymutations.
Despite this, new drugs designed to target highly conserved sites
within mutant spectra (revealed by application of ultradeep se-
quencing)may be included as part of antiviral treatments that take
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into consideration quasispecies dynamics, as discussed in the next
section.
An independent line of research that bears on evolutionary con-
straints of viruses has been the preparation of poliovirus with
deoptimized codon usage and codon pair frequencies (96, 146,
569). Codon-deoptimized viruses are attenuated, with an ex-
tremely low probability of reversion due to the number of muta-
tions needed to restore part of the codons to those of the original
virus. The authors refer to this situation as “attenuation by a thou-
sand cuts.” If we turn the phrase into “fitness decrease by a thou-
sand cuts,” it becomes a fascinating evolutionary question how
such a codon-deoptimized virus will find fitness recovery path-
ways. These multiply modified viral genomes constitute a means
to study routes of virus escape from deep fitness valleys that can-
not consist of the mere reversion of the original lesion or limited
numbers of compensatory mutations.
Antiviral Approaches to Counteract Quasispecies
Adaptability: Lethal Defection and Lethal Mutagenesis
The need for new paradigms to approach infectious diseases has
been expressed from different points of view, including the appli-
cation of Darwinian concepts of evolutionary ecology (105, 865).
The problems that quasispecies dynamics pose for viral disease
prevention and control have been amply recognized (for over-
views, see references 134, 135, 187, 188, 201, 202, 279, and 599 and
several chapters in reference 211). The current aim of antiviral
interventions is to achieve a low viral load, which often results in
decreased pathogenicity and can provide the immune systemwith
an opportunity to clear the virus or to prevent disease manifesta-
tions. A low viral load is linked to low replicative fitness, and new
antiviral strategies can be directed to viral fitness, reducing the
chances of fitness recovery during viral replication in the host
organisms (134, 135).
Five main strategies have been implemented or proposed to try
to minimize or delay the selection of antiviral-resistant mutants:
(i) combination therapy, successfully achieved with the highly ac-
tive antiretroviral therapy (HAART) for HIV-1-infected patients;
(ii) splitting of the treatment between an induction regimen and a
maintenance regimen; (iii) the use of drugs directed to cellular
functions, alone or in combination with drugs that target viral
functions; (iv) the combined use of immunotherapy and chemo-
therapy; and (v) lethal mutagenesis or virus extinction mediated
by accumulation of mutations in the viral genome.
The advantage of combination therapy over monotherapy is a
consequence of quasispecies dynamics, due to the decreased prob-
ability of generating a viral variant with two or more mutations
required to escape to a drug combination (76, 188, 192, 201, 202,
368, 475, 573, 592, 670, 692, 824). Although prolonged, low level
replication will often lead to selection of multidrug-resistant mu-
tants and treatment failure, combination therapy remains the
standard of care to treat diseases associated with highly variable
viruses. A recent model study in cell culture of the interplay be-
tween a mutagenic agent and an inhibitor of viral replication sug-
gested that a sufficiently low viral loadmay impede the selection of
inhibitor-resistant viral mutants (649). Despite several factors
contributing to the probability of selection of drug-resistant mu-
tants (mutation rates, genetic and phenotypic barriers, etc.), a low
viral load is at present a major aim of a combination therapy.
Amore recent proposal is a proactive treatment, divided in two
steps: an induction treatment aimed at reducing the viral load and
the number of viralmutants, followed by amaintenance regime to
sustain a low viral load (840). This strategy has been proposed on
the basis of theoretical considerations of viral dynamics, but to our
knowledge it has not yet been tested in experiments.
Many cellular functions are essential to sustain the multiplica-
tion of virus in the infected cell. Therefore, targeting of cellular
proteins with drugs can result in inhibition of viral multiplication
(305, 313, 381, 451). Two potential problems may arise: (i) toxic-
ity for the cell resulting from the inhibition of a cellular function
and (ii) selection of viral mutants either that can use a host pro-
tein-drug complex or that render ineffective the inhibition of the
cellular target. The latter possibility may seem unlikely, but it is
due to the fact that some cellular proteins participate in the repli-
cation cycle of viruses through complexes with viral proteins. As
an example, amino acid substitutions T17A, E295K, and V44A in
protein NS5A and T77K, and I432V in NS5B of HCV confer re-
sistance to the cyclophilin inhibitor SCY-635 because cyclophilins
interact with NS5A in the course of the virus replication cycle
(reviewed in references 115, 169, 456, 733, and 831).
A low viral load could be also achieved though a combined
strategy that involves administration of neutralizing antibodies
(or other means of adaptive immune response stimulation) to-
gether with antiviral agents (484, 745, 850). Despite being strate-
gies that should help in suppressing mutant spectra, their explo-
ration still needs in vivo experiments and clinical trials.
Lethalmutagenesis is based on the concepts of violation of error
threshold (Fig. 1) (see Theoretical and Experimental Origins of
Quasispecies above) and of negative interactions among compo-
nents of a mutant spectrum (Fig. 10) (see “Complementation and
Defection: Quasispecies as a Unit of Selection” above). This new
antiviral strategy aims at extinguishing viruses through an excess
of mutations introduced in viral genomes upon replication in the
presence of mutagenic agents, notably nucleotide analogues (re-
viewed in references 20, 191, 287, and 325) (Fig. 12). The first
experiments that demonstrated a negative consequence of mu-
tagenesis for virus adaptability and survival were performed by
John Holland and colleagues, who examined the effects of several
mutagenic agents on PV and VSV (375, 472). The term lethal
mutagenesis was coined by Lawrence A. Loeb, James I. Mullins,
and colleagues to describe the loss of replicative potential of
HIV-1 in cell culture caused by the pyrimidine nucleoside ana-
logue 5-hydroxydeoxycytidine (490), and they proposed that
mutagenic ribonucleotide analogues could be investigated as anti-
HIV-1 agents (491). The exploration of base or nucleoside ana-
logues as antiviral mutagenic or nonmutagenic agents is currently
an active field of research that has linked antimicrobial therapy
with anticancer therapy (57, 99, 226, 315, 316, 323, 330–332, 356,
375, 495, 576, 633, 634, 637, 676, 869). It involves both the design
of new compounds and the search for an application to viral mu-
tagenesis of previously described analogues (125, 326, 327, 351–
354).
Several studies with cell culture have documented the extinc-
tion of RNA viruses that employ different replication strategies
upon infection in the presence of base or nucleoside analogues
(12, 128, 148, 153, 162, 164, 293, 330–332, 459, 501, 561, 633, 634,
747, 761, 762, 799, 838; see also several chapters in references 187,
192, 211, and 232). This is the case for the pyrimidine base ana-
logue 5-fluorouracil, which is used in anticancer therapy (6, 7, 57,
99, 226, 315, 316, 323, 330–332, 356, 375, 495, 576, 633, 634, 637,
676, 869).
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The transition into error catastrophe can be viewed in the case
of viruses as the loss of the superiority of the master sequence and
a drift in sequence space that would lead to nonfunctional viral
genomes (Fig. 1 and 12). Experimentally, the events in viruses that
are a parallel to violation of the error threshold and entry into
error catastrophe have been investigated using a number of virus-
host systems (reviewed in several chapters of references 187 and
232). From these studies, the current picture of the molecular
basis of lethal mutagenesis is that an initial increase in mutation
rate generates defective but RNA replication-competent viral ge-
nomes, termed defectors, which interfere with the replication of
the standard virus, thus contributing to the suppression of repli-
cation of the entire ensemble (Fig. 13). This model is termed the
lethal defection model of virus extinction, and it is supported by
both experimental results and in silico simulations (212, 320, 331,
392, 506, 654). Following this initial phase of the action of defec-
tors, if mutagenesis continues or its intensity increases, lethal mu-
tations can become prominent and participate in virus extinction
(29, 331) (Fig. 12 and 14). Although the kinetics of accumulation
of interfering and lethal mutations is largely unknown and partic-
ipation of other viral and host mechanisms in extinction is likely,
the current lethal defection model is coherent with well-estab-
lished features of viral quasispecies (187, 211, 232, 651).
In addition to experimental evidence, the loss of replicative
competence of viruses associated with an excess of mutations is
supported by several theoretical models (17, 67, 91, 233, 506, 593,
611, 742, 794). A point to underline regarding models that deem-
phasize a role of mutagenesis is that extinction could not be
achieved by the decreases in viral load due to nonmutagenic in-
hibitors, while extinction occurred by the same decreases in viral
load due to a mutagen (633, 634, 649). Thus, the decrease in viral
load that impedes progression of the infection (a reproductive
ratio Ro of
1 at the level of cell-to-cell spread) is a consequence
of mutagenesis, not the primary mechanism of extinction. The
transition of viruses into error catastrophe or lethalmutagenesis is
a newparadigm in antiviral therapy that has as itsmain features (i)
the requirement of mutagenesis, (ii) the presence of an invariant
consensus nucleotide sequence during the transition (321, 330),
and (iii) at least in some cases a movement in sequence space with
the early occurrence of hypermutated genomes (330, 651) (Fig.
14) (see also the next section).
The efficacy of lethal mutagenesis may be favored by the multi-
functional nature of the great majority of viral proteins (207) and
domains within proteins (51, 829). The same amino acid substi-
tution may have multiple negative effects on different steps of the
virus life cycle, thereby accelerating its replicative collapse. Evi-
dence that lethal mutagenesis can be effective in vivo (709) and a
promising first clinical trial in which a mutagenic pyrimidine an-
alogue affected the mutational pattern of HIV-1 in AIDS patients
(574) offer interesting prospects. However, as summarized in the
next section, protocols involving nonantagonic mutagenic agents
and nonmutagenic antiviral inhibitors should be explored.
An encouraging aspect of lethal mutagenesis is that its princi-
ples operate in nature as amechanism to combat viruses and other
molecular parasites. Notably, some members of the APOBEC
(apolipoprotein B mRNA editing complex) family of editing pro-
teins are diverted from their physiological editing roles in the cell
to become part of antiviral functions, in particular antiretroviral
activities exerted via hypermutagenesis, as discussed in “Human
Immunodeficiency Virus Type 1” below. The RIP (repeat-in-
duced point mutations) system in some filamentous fungi is a
FIG 12 Schematic representation of our present assessment of the events
involved in virus extinction by increased mutagenesis. The picture is based on
the concept of error threshold of quasispecies theory (Fig. 1), modified by
experimental findings with RNA viruses. The error threshold is depicted here
as a region of template-copying fidelity where the transition from a quasispe-
cies distribution to random sequences (loss of information) occurs. Before
entering the threshold domain, at least two transitions occur: lethal defection
followed by overt lethality. Interference and lethal mutations drive viral pop-
ulations toward extinction, while selection of mutations that confer resistance
to the mutagenic agent used preserves quasispecies identity. See the text for
experimental evidence and references.
FIG 13 Schematic representation of interference exerted by a trans-acting
viral protein. (A) A viral genome and two mutants (with tan, blue, and red
genomic regions) encode a wild-type (tan, functional) and two mutant (blue
and red, increasingly defective and interfering, respectively) proteins as a con-
sequence of mutagenesis acting on a viral genome. (B) The relevant protein
acts as a hexamer in the virus life cycle. An increasing proportion of mutant
proteins will accentuate interference (defection) by decreasing the activity of
the protein. It is worth noting that the samemutant protein can act to interfere
or to complement, depending on the biological context. A blue protein may
rescue some activity when the red protein is dominant but may decrease ac-
tivity when the wild-type (tan) protein is dominant. This is one of the mech-
anisms postulated tomodulate viral fitness inmutagenized populations (com-
pare with Fig. 10; see text for references).
Domingo et al.
182 mmbr.asm.org Microbiology and Molecular Biology Reviews
defensemechanism consisting of the introduction ofmutations in
repeatedDNA sequences of genetic parasites (138, 302). Editing is
part of the replication cycles of several viruses, including
Paramyxovirinae. The polymerases of these viruses stutter in a
controlled fashion to edit the viral phosphoprotein mRNA. It has
been proposed that these viruses have evolved to possess a genome
of polyhexameric length (a fact known as “the rule of six”) to
prevent the deleterious effects of hypermutagenesis that may re-
sult from uncontrolled editing (443). The observation that several
biological systems exploit mechanisms to produce or prevent
“natural error catastrophe” events suggests that enhanced mu-
tagenesis has the correct conceptual foundations to become an
effective antiviral strategy.
An increase in mutation rate caused by nucleoside analogues
may not be disadvantageous to a virus. The mutagenic nucleoside
5-azacytidine (AZC) enhanced the replicative ability of bacterio-
phage Q during plaque development in the presence of AZC
(107). In contrast, Q populations were driven to extinction by
AZC during growth in liquid medium, unless mutagen-resistant
phage was selected (34, 107). Evidence suggests that the determi-
nant element of adverse versus beneficial effects of increased mu-
tagenesis may lie in the proximity to an error threshold for main-
tenance of genetic information, and this argument may be valid
for viral and cellular systems (160, 779, 781).
Mutagen-Resistant Mutants and the Molecular Basis of
Virus Extinction
Ribavirin-resistant mutants have been described for several vi-
ruses (269, 661, 662, 734, 885). However, in many cases it is not
clear whether ribavirin acts as a mutagenic agent, as a nonmuta-
genic inhibitor, or as both. Consequently, it is not knownwhether
resistance refers to its mutagenic activity or inhibitory activity or
both. It has not been established either whether resistance to a
mutagenic agent will be as easily selectable as resistance to non-
mutagenic inhibitors. Since the same ribavirin-resistant PV poly-
merase mutant G64S (described in “Exploration of Sequence
Space and Virus Adaptability: Fidelity Mutants” above) was ob-
tained independently in two laboratories (108, 660, 662), it was
thought that picornaviruses may have available very few alterna-
tive mechanisms to achieve ribavirin resistance. However, an
FMDV passaged in the presence of ribavirin did not select substi-
tutionG62S (the one equivalent toG64S in PV), and it selected 3D
substitution M296I instead (761). Substitution M296I increased
viral fitness in the presence of ribavirin and decreased the incor-
poration of RTP into viral RNA, without a significant alteration of
the general template-copying fidelity of the enzyme (30, 761).
FMDV with a G62S substitution in its 3D was constructed by
site-directedmutagenesis. It displayed a strong selective disadvan-
tage relative to FMDV encoding the wild-type polymerase; pas-
sage of the mutant virus in cell culture resulted in reversion to the
wild-type polymerase, contrary to the case for the M296I mutant,
whichwas stable (277). Thus, a substitution that waswell accepted
and conferred PV resistance to ribavirin was highly detrimental to
a closely related virus encoding a similar polymerase molecule
such as FMDV (276, 277). M296 is located on a loop close to the
active site of the polymerase, while G62 is in the fingers sub-
domain of the enzyme. Comparison of the three-dimensional
structures of the polymerases including either substitution G62S,
M296I, or both documented that despite the two residues being
13.1 Å apart, they are connected through a network of interactions
that reach the polymerase active site (277). An effect of substitu-
tionG62Swas to restrict the flexibility of the loopwhereM296 lies
and the ability of the enzyme to bind to the RNA template. Thus,
despite the potential of G62S in the FMDV polymerase to reduce
incorporation of ribavirin into RNA, the altered enzyme inflicted
upon FMDV such a selective disadvantage that substitution G62S
could have never been selected unless compensatory substitutions
(which have not been found) were introduced in the polymerase
(277).
The polymerase mutants described for PV and FMDV display
two distinct mechanisms of ribavirin resistance with different im-
plications regarding the adaptive potential of the viruses: while
G64S in PV resulted in a general increase of template-copying
fidelity that impaired virus adaptation to complex environments
(660, 833), M296I in FMDV resulted in the specific restriction of
ribavirin incorporation. The mutant virus could incorporate ad-
ditional replacements at the standard rate to achieve high-level
resistance to ribavirin (8, 30, 761). The alternative mechanisms of
picornavirus resistance to ribavirin suggest again that due to the
many subtle interactions among distant sites of proteins in general
(782, 818), multiple pathways for drug resistance are probably
possible in most cases (as discussed in “Selective Forces and Es-
cape Mutants” above), but only a subset of them are compatible
with the virus maintaining sufficient fitness. The results under-
FIG 14 Effect of increasedmutagenesis in a viral population. In the top panel,
mutagenesis increases 100-fold the average mutation frequency of a mutant
spectrum, resulting in a decrease of the amount of infectious RNA. The second
panel indicates that high mutation frequencies result in a decrease of the pro-
portion of infectious viral RNA in a population, with loss of infectivity preced-
ing loss of viral RNA replication. The bottom box stresses three major events
associated with enhanced mutagenesis, as discussed in the text.
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score the interest of targeting viral fitness as a general approach to
antiviral interventions (134, 135).
Mutant clouds need not be symmetrical in an imaginary (mul-
tidimensional) representation of sequence space (Fig. 8B). FMDV
mutants displaying high levels of ribavirin resistance offer a rele-
vant example.When FMDVwithM296I in 3Dwas passaged in the
presence of increasingly larger concentrations of ribavirin, two
additional replacements, P44S and P169S, were sequentially
added to yield the triple polymerasemutant termed SSI (8). These
three substitutions inflicted a modest decrease in FMDV fitness
quantified in BHK-21 cells in the absence of ribavirin and a re-
markable fitness gain in the presence of ribavirin. The mutant
polymerases were compared with the wild-type enzyme function-
ally and structurally. The most salient biochemical feature found
was that substitution P44S restricted ribavirin incorporation
more strongly opposite C than opposite U in the template-primer
combinations tested in vitro (8). A consequence of this misincor-
poration bias was that during replication in the presence of
ribavirin, the triple mutant could maintain a balance among the
four transition mutation types [ratio of (G¡A)  (C¡U) to
(A¡G) (U¡G)] which was very similar to the balance attained
by the wild-type enzyme in the absence of ribavirin. The excess of
G¡A and C¡Umutations associated with ribavirinmutagenesis
proved deleterious for FMDV, and the mutational bias was pre-
vented in the case of the triple SSI mutant, resulting in escape of
extinction by ribavirin (8). Examination of the mutant spectra of
wild-type and SSI mutant viruses indeed documented a higher
frequency of deleterious mutations due to G¡A and C¡U tran-
sitions, supporting a selective advantage of a virus capable of
avoiding a mutational bias. Yet, the wild-type and mutant SSI
FMDVs produced mutant spectra of similar complexities. Modu-
lation of transition types represents a third mechanism of ribavi-
rin resistance that did not involve obvious modifications of gen-
eral copying fidelity.
The critical amino acid substitution to maintain the FMDV
mutational balance in the presence of ribavirinwas P44S, a residue
conserved among picornaviruses that lies in a loop that connects a
-strand and a -helix in the fingers domain (8, 276). A local
reorganization of amino acid residues at the amino-terminal re-
gion of the enzyme was noted. This region, together with amino
acids of motifs G and F of 3D, binds the 5=region of the template,
driving the RNA toward the active site. Substitution P44S trig-
gered the conformation change at the amino-terminal region of
the enzyme, reoriented template nucleotides, and most probably
led to a template residue-dependent alteration of ribavirin recog-
nition (8, 275). Ribavirin resistance in FMDV has been described
here in detail to illustrate the capacity of amino acid substitutions
near or far from a polymerase active site to modulate replicative
parameters for the benefit of a virus. Our current knowledge with
polymerases in general suggests that any virus has the potential to
invent an array of molecular “tricks” for survival. In the words of
Joshua Lederberg: “Abundant sources of genetic variation exist for
viruses to learn new tricks, not necessarily confined to what hap-
pens routinely or even frequently” (471).
From the point of view of occupation of sequence space, what
the triple SSI FMDVmutant achieved was to limit the occupation
of regions with genomes with high frequencies of A andU. FMDV
populations passaged in the absence or presence of ribavirin were
analyzed using differential DNA denaturation PCR (3D-PCR), a
procedure that selectively amplifies A- and U-rich genomes from
aDNApopulation (787). Interestingly, FMDVgenomeswith high
frequencies of A and U (termed hypermutated genomes) were
present in both ribavirin-treated and ribavirin-untreated popula-
tions, again documenting the presence of a deepmutant spectrum
in nonmutagenized, multiply passaged populations of FMDV
(651). Amajor effect of ribavirin was to generate an A- andU-rich
repertoire of genomes in a single passage. In the absence of riba-
virin, a statistically significant increase of genomes enriched in A
and U was not obtained until passage four (651). The high fre-
quency of hypermutated genomes after one passage in the pres-
ence of ribavirin was not maintained at subsequent passages, a
conclusion that was also reached in a previous analysis using phy-
logenetic procedures and partition analysis of quasispecies (616).
We interpret this quasispecies compaction as a consequence of
negative selection that operates on genomes rich in A and U, fol-
lowing their abundant but transient presence as a result of ribavi-
rin mutagenesis (8, 615, 651).
FMDV polymerase substitution P44S, the one responsible
for high-level ribavirin resistance (8), was present in the mu-
tant spectra of FMDV populations passaged in the absence of
ribavirin (651). This is probably a consequence of the modest
effect of P44S on viral fitness (8). The P44S frequency increased
as a result of ribavirin treatment, as expected (651). Its pres-
ence in FMDV populations never exposed to ribavirin is related
to a wealth of observations on the presence of inhibitor-resis-
tant viral mutants in natural isolates from patients who have
not been exposed to the relevant inhibitors (156, 358, 409, 452,
470, 581, 582, 697, 733).
The 3D-PCR study with FMDV was also revealing from the
point of view of the molecular basis of lethal mutagenesis. The
accelerated presence of hypermutated genomes associated with
ribavirin treatment represents a shift in sequence space which is
compatible with the main observations previously described as a
hallmark of lethal mutagenesis: increased frequency of defector
genomes and an invariant consensus sequence (321, 330, 392).
Movements in sequence space may prove relevant to lethal mu-
tagenesis, and the new-generation sequencing techniques may
contribute in the planning of new antiviral protocols based on
administration of mutagenic agents.
The investigations summarized in this section suggest that se-
lection of viruses resistant tomutagenic agents is not a rare occur-
rence. To what extent such mutagen-resistant mutants may jeop-
ardize antiviral treatments based on lethal mutagenesis remains
an open question.
The Interplay between Mutagenesis and Inhibition in the
Design of Antiviral Protocols
Ever since quasispecies dynamics was recognized as a key feature
of pathogenic RNA viruses, the need to use combinations of com-
patible inhibitors to suppress viral replication was acknowledged
(see “Antiviral Approaches to Counteract Quasispecies Adapt-
ability: Lethal Defection and Lethal Mutagenesis” above). The
widely accepted and amply supported advantage of combination
therapymay, however, not be always applicable when amutagenic
agent enters the picture, as in the case of lethal mutagenesis-based
antiviral designs. Although several mechanisms of mutagenesis-
based extinction have been proposed (89, 91, 158, 233, 331, 506,
794, 861), very few experimental and theoretical studies have ap-
proached combination therapies involving mutagenic agents
alone or mutagenic agents and nonmutagenic inhibitors. The few
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studies that have been carried out suggest that this is likely to
become a fertile domain of antiviral research.
The mutations that conferred resistance of FMDV to ribavirin
prevented the extinction of the virus by high doses of ribavirin (see
the previous section). However, the ribavirin-resistant virus was
extinguished by a combination of the mutagenic base analogue
5-fluorouracil and the inhibitor of RNA replication guanidine
(648). This observation suggests that the availability of two or
more mutagenic agents with different mechanisms of action (i.e.,
purine versus pyrimidine analogues, resembling one or other pu-
rine or pyrimidine type) can provide expanded antiviral possibil-
ities provided the analogues are virus specific and toxicity for the
host is limited. The use of twomutagenic agents (sequentially or in
combination) is conceptually parallel to the administration of two
inhibitors. Investigations on the use of multiple mutagenic agents
are needed.
An alternative approach is the use of combinations of muta-
genic agents and antiviral inhibitors. Since the early studies on
lethal mutagenesis, it was found that a low viral load and low
viral fitness favor extinction (762), as expected from the pa-
rameters that enter into the error threshold relationship (233,
243) (Fig. 1). High-fitness HIV-1 was not extinguished by the
mutagenic analogue 5-hydroxydeoxycytidine, but systematic
extinction was achieved by a combination of 5-hydroxydeo-
xycytidine and the antiretroviral inhibitor 3=-azido-3=-de-
oxythymidine (AZT) (799). This result would seem a reason-
able extension of the preferred combination therapy over
monotherapy, involving a mutagenic agent and a nonmuta-
genic inhibitor. The extension, however, proved to be far less
straightforward than anticipated.
The following considerations are relevant to the use of muta-
gens in combination with inhibitors. First, a mutagenmay display
a mutagenic activity and an inhibitory activity that may be related
or unrelated. 5-Fluorouridine triphosphate (FUTP) inhibits the
uridylylation of FMDV primer protein VPg, a critical step in the
initiation of picornaviral RNA synthesis (867), and 5-fluorouri-
dine monophosphate is incorporated into RNA, causing misin-
corporations (7). In this case, the inhibitory and mutagenic activ-
ities of FUTP appear to be unrelated. Ribavirin was considered to
be an inhibitor of arenavirus replication (250, 399, 424, 430, 497,
709, 736, 770). When this issue was reexamined using LCMV, it
was found that concentrations of ribavirin that allowed viral rep-
lication were mutagenic, while no evidence of mutagenesis was
obtained with ribavirin concentrations that suppressed viral rep-
lication (561). This result is not unexpected, because expression of
a mutagenic activity associated with incorporation of an analogue
into RNA will be dependent upon RNA replication. It cautions,
however, against considering nucleoside analogues inhibitors of
viral genome replication without testing a possible mutagenic ac-
tivity by lower concentrations of the analogue. It is not known
whether the inhibitory activity of ribavirin on LMCV is indepen-
dent of or related to its mutagenic activity (see further discussion
in reference 561). There is also evidence that some antiretroviral
treatments that have been used in clinical practice can be muta-
genic (510).
Whether a base or nucleoside analogue acts as an inhibitor or as
a mutagen during therapy is relevant because interactions be-
tween a mutagen and an inhibitor can influence the effectiveness
of an antiviral treatment, in particular sequential versus combina-
tion inhibitor-mutagen administration. The activity of amutagen,
present simultaneously with an inhibitor, can increase the fre-
quency of inhibitor-resistant mutants, resulting in higher viral
production. A mutagen can also help in finding a position in se-
quence space in which multiple mutations can provide resistance
to the inhibitor and sustain high viral fitness (compensatory mu-
tations) (349). Increased mutagenesis can have beneficial effects
through enhancement of genotypic and phenotypic diversity but
deleterious effects when excess mutations jeopardize viral func-
tions. Furthermore, the viral load can be a determinant factor of
the effect of mutagenic agents and antiviral inhibitors. Despite a
history of enhancedmutagenesis of FMDV, a sufficiently low viral
load allowed continued viral replication, without selection of gua-
nidine-resistant mutants (649). Thus, multitudes of environmen-
tal factors (viral load, population bottlenecks, environmental het-
erogeneities, compartmentalization of infection, etc.) can all affect
the consequences of mutagen-inhibitor interactions for viral sur-
vival. In general, the combined action of any two drugs (be they
mutagenic or not) cannot be reduced to the sum of their indepen-
dent effects (282, 393, 809).
Extinction of FMDV by a combination of a mutagenic agent
and an antiviral inhibitor was more effective than extinction by
themutagenic agent alone (633, 634).When a sequential protocol
involving first inhibition by guanidine and then mutagenesis by
ribavirinwas comparedwith the corresponding combination pro-
tocol (simultaneous administration of guanidine and ribavirin),
the former proved to bemore effective to achieve the extinction of
FMDV in BHK-21 cells (650) (Fig. 15). Two main factors were
identified as being responsible for the advantage of the sequential
protocol. One is the enhancement of generation of guanidine-
resistant mutants by ribavirin when present together, and this was
supported by a theoretical model in which the mutagenic activity
is a key parameter. In the absence ofmutagenic activity, themodel
predicts an advantage of combination (over sequential) therapy
(650), in agreement with previous models of virus dynamics (see
“Antiviral Approaches to Counteract Quasispecies Adaptability:
Lethal Defection and LethalMutagenesis” above). A second factor
that could contribute to the superiority of the sequential treat-
ment is that the defectors that are generated by ribavirinmutagen-
esis, and that contribute to viral extinction, may have their inter-
fering action inhibited by the presence of guanidine. This was
demonstrated experimentally by coelectroporation of BHK-21
cells with an interferingmixture of FMDVmutants andwith stan-
dard RNA. Interference of the expected intensity was exerted ei-
ther in the absence of drugs or in the presence of ribavirin, but it
was strongly diminished in the presence of guanidine (650).
Therefore, at least two different manifestations of the simultane-
ous presence of a mutagen and an inhibitor may render subopti-
mal the transition toward extinction.
The results with FMDV raised the important prospect that new
antiviral protocols involving amutagenic agentmay not necessar-
ily follow the classical combination-therapy paradigm. The theo-
retical generalization of the FMDV findings came with a model of
viral dynamics that described the viral response (progeny infectiv-
ity and frequency of guanidine-resistant mutants) in the presence
of different doses of ribavirin and guanidine (393). One of the
main predictions of the model is that an advantage of the sequen-
tial versus the combination protocol is manifested at a high con-
centration of the inhibitor, a point thatwas confirmed experimen-
tally (393). The general model furnishes information with which
to reduce the number of preliminary experiments to be carried out
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prior to the design of an antiviral protocol. The obvious challenge
now is to explore the applicability of the results to other virus-host
systems in cell culture and in vivo, to open the way to a possible
clinical application.
We wish to emphasize the consequences that an understanding
of quasispecies dynamics can have in the design of antiviral inter-
ventions. In this case, theory is closely interconnected with prac-
tice.
FIG 15 A sequential administration of first an inhibitor and then a mutagenic agent can be more effective than the corresponding combination of drugs. In this
model experiment with FMDV in cell culture, guanidine hydrochloride (GU)was used as the inhibitor and ribavirin (R) as themutagen. (A) Scheme of four drug
administration protocols involving five virus passages in BHK-21 cells: only GU, only R, a combination of GU and R (GUR), or first one passage with GU and
then four passages with R (GU, R). (B, C, and D) Virus titer and viral RNA molecules at different passages as a function of treatment regimen and drug
concentrations (given in the box above the panels and below the abscissas). Note that the lowest titers and viral RNA levels are attained with the sequential
protocols. (E) Reverse transcription-PCR (RT-PCR) amplifications used to detect viral RNA in the corresponding cell culture supernatants to monitor viral
extinction. The upper part of each panel identifies the drug treatment and passage number.  or  below the panels indicates positive or negative RT-PCR
amplification and extinction. M, molecular size markers; C and C, positive and negative controls, respectively. Note the earlier extinction with sequential
treatment at the two highest GU concentrations. (Adapted from reference 650, in which experimental details are described.)
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Viral Quasispecies Dynamics In Vivo: Long-Term Virus
Evolution
In previous sections, concepts related to quasispecies dynamics
have been elaborated based both on designed protocols of exper-
imental evolution (using cell cultures, the natural host organism,
ormodel host organisms) and on observations of viral population
dynamics in the field. Two questions arise: (i) to what extent the
conclusions of the studies on experimental evolution reflect the
population dynamics of viruses in their natural environments and
(ii) what are the consequences of quasispecies dynamics for the
understanding of long-term virus evolution. Concerning the first
question, an overall comparative assessment suggests that no fun-
damental contradiction has been found between the behavior of
viruses in model experiments and in natural infections with re-
gard to genetic variation, competition and interference among
components of a mutant spectrum, and selection of genome sub-
sets. Concerning the second question, increasing evidence sug-
gests that quasispecies dynamicsmust be taken into consideration
to interpret long-term virus evolution. It is not possible to list all
results in support of such assertions, but we list a few.
The presence of mutant spectra of FMDV in virus-infected cat-
tle was one of the early observations on quasispecies in vivo (194),
and it has been amply supported by many subsequent studies
(102, 103, 311, 609, 778, 791, 795, 874). The FMDV population
heterogeneity and dynamics—including fitness variations and bi-
ological effects of bottleneck events—revealed by these studies are
perfectly coherent with the behavior of the virus in cell culture
(777; also see many subsequent studies reviewed in references 195
to 197, 212, and 214). Likewise, several observations on VSV pop-
ulation heterogeneity and dynamics (reviewed in references 376
and 596) had counterparts in vivo (512).
Quasispecies memory was described in a designed experiment
using FMDV (707), and it was shown to occur also with HIV-1 in
vivo (reviewed in reference 85).Memory probably underliesmany
reemergences of ancestral sequences recorded in several studies
(see “Positive Selection and Molecular Memory: Deterministic
Features of Viral Quasispecies” above). The frequency of drug,
antibody, or cytotoxic T-lymphocyte (CTL) escape mutants and
the effects of population size on the repertoire of virus variants can
best be quantified in experiments designed in cell culture. Virtu-
ally allmajor conclusionswith important pathogens in cell culture
had a counterpart in vivo (see references 80, 136, 252, 281, 454,
and 494, amongmany other studies). Parallel quasispecies behav-
ior in cell culture and in vivo is expected because its roots lie in
error-prone replication, which is increasingly recognized as a
shared feature of several viruses and retroelements both in cell
culture and in vivo (192, 400, 408).
Shared features also make it likely that antiviral approaches
(such as the ones based on lethal mutagenesis described in the
previous section) can be of general applicability (see Conclusions,
Connections, and Prospects below).However, the possible advan-
tage of sequential versus combination therapies that require intro-
duction of specific parameters (discussed in the previous section)
has been predicted for nonretroviral RNA viruses. Extensions to
retroviruses or DNA viruses that have a latency step will require
analogous models and parameters adapted to the corresponding
replication strategy (393). Additional examples of the behavior of
viruses in vivo that fit the expectations from model studies are
given in the next section of this article, which is concernedwith the
impact of quasispecies dynamics for HIV-1, HBV, and HCV.
Quasispecies dynamics relates to long-term virus evolution be-
cause mutant spectra provide the types of genomes that will be
transmitted from infected into susceptible hosts. For some vi-
ruses, concepts derived from molecular quasispecies have been
integrated to the epidemiological level, notably in the case of PV
by Vadim Agol and colleagues (309). Multitudes of formation
cycles of quasispecies swarms and transmission, together with
changes in the composition ofmutant spectra, are determinants of
long-term evolution patterns. Rapid evolution of some viral lin-
eages in the field has been related to pathogenic potential relative
to that of slower-evolving related lineages (891). Genetic diversity
derived from a higher polymerase error rate has been shown to
underlie norovirus pandemic potential (92). Enhanced viral fit-
ness may also contribute to dengue disease severity, an increas-
ingly important, still unsettled issue (614).
Viruses diversify into genotypes and subtypes, and it is the gen-
eral course of events that as increasing numbers of isolates are
analyzed, the number of subtypes becomes too large for subtyping
to be justified (for example, subtyping of FMDVwas stopped dur-
ing the second half of the 20th century because refined tools such
as monoclonal antibody-based subtyping showed that virtually
each new isolate was a new subtype [195, 535]). A genotype of a
virus can be viewed as a set of related genomes that have found a
high fitness domain and acquired epidemiological relevance asso-
ciatedwith replicative or nonreplicative traits. Initially, a genotype
tends to abound in a given geographical area, although for socio-
economic reasons (increasing migration, traveling, and trade),
geographical clusters tend to be blurred. For viruses with active
recombination, mosaic genomes from different parental geno-
types or subtypes may be an additional important source of
genomic variation, adaptability, and diversification.
A corollary of themechanisms involved in quasispecies dynam-
ics is that RNA viruses do not evolve as a result of a linear (or
nearly linear) accumulation of mutations but rather evolve as a
result of disequilibria of mutant distributions. The uncertainty of
how divergent the transmitted genome will be relative to the one
that initiated the infection, together with the alternation of peri-
ods with and without active viral replication subjected to positive
and negative selection, renders unlikely the operation of a molec-
ular clock in the case of virus evolution. John Coffin expressed
skepticism about extrapolating from phylogenetic analyses the
date of the common ancestor of retroviruses or the year of diver-
gence of HIV-1 and HIV-2 (144). Additional extrapolations to
date ancestral viruses have been made based on strict or relaxed
clock models, often resulting in conflicting results. In particular,
despite rates of evolution for viruses being in the range of 1 101
to 3  105 substitution per site per year (with some exceptions
such as the simian foamy viruses) (reviewed in reference 189), for
the same virus a higher rate of evolution is obtained when the
compared sequences correspond to viruses isolated within a short
time span than when they correspond to isolates separated by a
long time interval (189, 778). For closely related isolates from the
same disease episode, it was suggested that a steady accumulation
ofmutationsmight result from the random sampling of sequences
from the quasispecies followed by amplification in successive sus-
ceptible hosts (834). The operation of a molecular clock follows
the tenet of the neutral theory of molecular evolution, implying
that rates of evolution reflect mutation rates. This is untenable
considering our current understanding of quasispecies dynamics.
Several contradictions have now become apparent, including not
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only the dating of viral ancestors, but also rates of codivergence of
viruses and their hosts (reviewed in references 754 and 768). The
reasons for such gross discrepancies are not known, but they
might relate to the inadequacy of extrapolating short-term quasi-
species evolution based on population disequilibria into long-
term evolution under the assumption of a linear accumulation of
mutations.
The term epidemiological fitness has been proposed to describe
the relative selective advantage that some natural viral isolates
manifest over other related (but distinguishable) isolates in the
field (189, 559). The epidemiological advantage of a given virus
has many replicative and nonreplicative components, including
infection dynamics in any individual host, transmissibility, virion
stability, and others. Such variable parameters render even less
plausible the operation of a molecular clock.
Another potentially misleading calculation is the ratio of non-
synonymous to synonymousmutations (dN/dS) as an indicator of
positive selection versus negative selection and random drift in
virus evolution. Despite being an extensively used parameter, its
implications regarding evolutionary forces are questionable on at
least two grounds. First, the dN/dS ratio was initially developed to
be applied to distantly related genomes, not to closely related se-
quences as is the case in quasispecies evolution (450). When a
selective constraint is applied to a quasispecies swarm, many
genomic sites unrelated to the selective constraint may be sub-
jected to negative selection, while only one or a few sites may
respond with dominance of an amino acid substitution that re-
flects a positive selection event. Thus, a minority of amino acid
replacements accompanied by an excess of synonymous substitu-
tion that will produce a low dN/dS ratio may nevertheless drive
virus evolution.
Thus, evolution through disequilibria of mutant swarms has
important immediate effects for short-term, intrahost evolution,
but the present evidence has started to indicate that it may also
condition long-term events. Classical tenets of population biology
may have to be reconsidered for rapidly replicating, error-prone,
collectively integrated biological entities.
SPECIFIC VIRAL SYSTEMS
Several viruses contributed decisively to establish the quasispecies
nature of viral populations and to unveil its biological implica-
tions, and they have provided the current picture of viral quasi-
species dynamics summarized in previous sections. However, ac-
celerated Darwinian evolution found maximal clinical impact in
persistence and treatment strategies for three major human
pathogens, HIV-1, HBV, and HCV, for which the presence of
complex mutant spectra as the fuel for adaptability was soon rec-
ognized (references 100, 416, 518, and 552, followed by many
other studies). The lack of vaccine efficacy and failure to maintain
a low viral load by antiviral drugs were understood as a conse-
quence of quasispecies dynamics. In the next sections we review
some of the major implications of quasispecies for these three
human pathogens.
Infections by HIV-1, HBV, and HCV share a number of fea-
tures. They affectmillions of humansworldwide, with estimates of
nearly 40 million people infected with HIV-1, 2,000 million sero-
positive for HBV (with 350 million chronic carriers), and around
210million people infectedwithHCV. These infections constitute
a true insidious pandemic, with remarkable numbers of coinfec-
tions, in particular with HIV-1 and HCV, that reach about 7 mil-
lion people. The viruses replicate continuously in their hosts, al-
beit at different rates, from fulminant outbursts to a seemingly
controlled, slow pace. Bottleneck events are frequent during
transmission of these viruses, which occurs mainly through the
parenteral route (blood-to-blood contact). The viruses share er-
ror-prone replication, attributed partly to the absence of a proof-
reading-repair activity in the corresponding polymerases, and re-
markable genetic heterogeneity. They have diversified into
multiple genotypes and subtypes that sometimes represent a ge-
netic signature that affects virus behavior. Some biologically rele-
vant features are common to different types and subtypes, and
these general features are addressed here. Also, they have in com-
mon very high rate of virion production, with a number that can
reach 1011 to 1012 per infected individual per day (590, 607, 852).
Despite these shared traits, HIV-1, HBV, and HCV differ in fun-
damental biological aspects of their replication and interaction
with their host organisms, sometimes affecting the interpretation
of the observed population heterogeneities.
Human Immunodeﬁciency Virus Type 1
Viral dynamics. The mutation and recombination rates and fre-
quencies, the virion production rate, and a short generation time
all contribute to HIV-1 exhibiting quasispecies dynamics (refer-
ences 145, 369, 385, 407, 478, 511, 552, 588, 589, 639, 655, 674,
675, 735, 800, 804, 844, and 852, among numerous other studies).
The interpretation of the origin ofHIV-1 heterogeneity and diver-
sification of viral sequences is complicated by the compartmental-
ization of the infection, the presence of viral reservoirs (and there-
fore replicative and nonreplicative quasispecies memory), and
reactivation of latent provirus (85, 110, 127, 176, 296, 390, 458,
488, 706, 835, 872). Retroviral sequences integrated into cellular
DNA will be subjected to the relative evolutionary stasis typical of
cellular genes (except in the case of potential integration at sites
undergoing cellular hypermutational events). Proviral activation
will contribute new replicating genomes that correspond to virus
that was actively replicating at an earlier phase of the infection.
Thus, the generation of millions of mutant and recombinant
HIV-1 variants and competition among them in the compart-
mentalized and continuously changing host environment create a
dynamic diversity that defies imagination. HIV-1 population
complexity is increasingly documented and quantified by applica-
tion ofmassive sequencing techniques (370, 513, 516, 570, 846), as
summarized in the next paragraphs.
Major questions related to HIV-1 quasispecies evolution that
remain only partially understood are (i) the effect ofmutations on
the response to antiretroviral treatment, with an ever-increasing
catalogue of mutations and combination of mutations that confer
different degrees of resistance to one or several antiretroviral
agents, (ii) the interaction of the virus with the different branches
of the adaptive immune response, with its many implications for
vaccine design, and (iii) dynamics of coreceptor switching in re-
lation to viral pathogenesis and disease progression. These funda-
mental questions cannot be approached without considering viral
parameters interconnected with host factors. One of the key pa-
rameters that influences HIV-1 behavior and response to selective
constraints is fitness (684), a measure of replication capacity of
general relevance for RNA viruses (see “Viral Fitness and the Ef-
fect of Population Size: Bottleneck Events” above). HIV-1 fitness
is closely related to viral load, which is an important element in
virus adaptability and in turn is connectedwith viral pathogenesis.
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Current strategies to controlHIV-1 infection either pharmacolog-
ically or by immune stimulation (or combinations of the two
strategies) should aim at decreasing viral loads and sinking dimin-
ished HIV-1 populations into deep fitness valleys without escape,
at least with the genetic variation and exploration of sequence
space accessible to the virus. The question is whether such valleys
can be reached through antiviral interventions, given the provirus
stage in the replication cycle.
Drug resistance. Multiple mechanisms of HIV-1 drug and
RNA interference resistance have been described (545, 843, 859).
The dynamics of the generation and increase in frequency of
HIV-1 drug-resistant mutants adheres to the basic principles es-
tablished experimentally for a variety of RNA viruses, which have
the support of theoretical models (188, 692, 693) (see “Selective
Forces and EscapeMutants” above). Due to the continuous input
of new genomic sequences during HIV-1 replication, mutations
that diminish sensitivity to antiretroviral agents often preexist in
infected humans, even if they have never been treated with the
relevant drugs (358, 409, 470, 581, 582, 808, 814). This phenom-
enon must be distinguished from primary resistances due to in-
fection by HIV-1 harboring resistance mutations selected in the
infected, previously treated donor individual. Nonprimary resis-
tance mutations are a consequence of the elevated mutation fre-
quencies, since mutations are expected to affect codons related to
drug resistance as much as any other sites in the genome (581).
No list of antiretroviral resistance mutations will be presented
here, since periodic updates can be found in the literature and on
websites (137, 411). HIV-1 treatment has mobilized unprece-
dented resources to develop new antiretroviral agents, with (at the
time of this writing) 25 inhibitors available that target reverse
transcriptase, protease, fusion, virus entry, or proviral integration.
For themajority of them,multiplemutational pathways leading to
resistance have been described. The general picture emerging
from drug and multidrug resistance in HIV-1 is very similar to
that described for RNA viruses in general, with the added ingre-
dient of the presence of the proviral reservoir. Even if a drug re-
sistancemutation or set of multidrug resistancemutations inflicts
a fitness reduction on the virus, compensatory mutations are fre-
quently selected to restore fitness (231, 349, 386, 527, 529, 549,
591). Moreover, and pertinent given the potential impact of de-
fective genomes on the replicative capacity of a virus, multidrug-
resistant variants can exist in cells as defective quasispecies and
may be rescued by recombination to yield infectious progeny
(679).
Recombination can contribute to generatemultidrug-resistant
strains by bringing together genomic sequences that each confers
resistance to an inhibitor (292, 423, 442, 445, 568, 570, 887). It is a
debated issue whether the presence of minority subpopulations
with mutations that decrease the sensitivity to antiretroviral
agents, independently of their origin (transmitted, memory, or
mutational pressure), should help to determine the treatment reg-
imen or not. According to some studies, low-frequency baseline
drug resistance is associated with a higher risk of treatment failure
(43, 314, 322, 409, 550, 630, 764). Other studies have not found an
influence of minority resistance mutations on the treatment re-
sponse (551, 659). Different views on the usefulness of ultradeep
sequence analysis of HIV-1 from treatment-experienced patients
have been also expressed (163, 469, 826). Previous experience sug-
gests that the more detailed the molecular information on the
virus populations present in a patient, the better for treatment
management.
Development of drug resistance requires a minimum replicat-
ing load to explore sequence space in search of the relevant muta-
tions (649). It is a common experience that to succeed in selecting
a drug-resistant viral mutant, it is best first tomultiply the virus in
the presence of limited drug concentrations to ensure a sufficient
replicative load and then to increase the drug concentration grad-
ually (8, 55, 662, 761). This probably reflects gradual selection,
first of mutations with a low barrier and that display a limited
degree of resistance, followed by other mutations that express
more firmly the resistance trait. In agreement with these observa-
tions in cell culture, drug resistance is less frequent in patients who
adhere toHAART andmaintain a low viral load than in those who
sustain high-level virus replication (368). Resistance may develop
very quickly when treatment is suboptimal and viral replication is
only partially suppressed.
When fitness recovered through compensatory mutations is
only fragmentary, resistant virusmutants will be replaced bywild-
type genomes upon treatment interruption. These rebound vi-
ruses may originate from virus that had been archived in latently
infected cells before the start of therapy (413) or from the com-
petitive advantage of true revertants that arise during replication
(439, 631).
It is difficult to anticipate whether treatments with only limited
side effects will be found to decrease HIV-1 fitness without possi-
bility of fitness and viral load recovery. The treatment options
presently accessible are those that have been discussed in “Antivi-
ral Approaches to Counteract Quasispecies Adaptability: Lethal
Defection and Lethal Mutagenesis” above (313, 393, 574, 819,
840). A major challenge is to target the pool of resting memory
CD4 T lymphocytes and other cells that act as a latent reservoir
of HIV-1 genomes and that do not respond to antiretroviral treat-
ment. Reservoir cells have a long half-life, estimated at an average
of 14 days for macrophages and 4 years for memory CD4 T cells.
The administration of mutagenic agents specific for the HIV-1
RT, sequentially or in combination with antiretroviral inhibitors
(354, 574, 799) is worth exploring. Perhaps a combined pharma-
cological and immunotherapeutic approach could offer some en-
couraging prospects, provided that the effects of the immune re-
sponse against HIV-1 come to be better understood.
Coping with the immune response. In contrast to antiretrovi-
ral agents that generally target a single viral protein (reverse trans-
criptase, protease, integrase, etc.), the host immune response gen-
erates multiple and diverse constraints that act simultaneously
upon the virus. This is true of the multiple branches of the innate
immune response (52, 645) and acquires an additional dynamic
component in the adaptive immune response (multiple B-cell and
T-cell epitopes located at different sites in viral proteins subjected
to variation). The immune response imposes several selective con-
straints to all viral infections, but in the case ofHIV-1 there are the
added complications that subsets of cells that take part in the im-
mune response can also be infected and that infection-mediated
immunosenescence (273) modifies the immunological environ-
ment over time.
HIV-1 has evolved both interaction and evasion strategies to
cope with the innate immune response. One of the functions of
Vif is to counteract the antiretroviral activity of somemembers of
the APOBEC family of cytidine deaminases (362, 504).
APOBEC3G and APOBEC3F hypermutate negative-strand re-
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verse transcripts, which results in multiple G¡A mutations in
positive-sense cDNA. This mechanism can be regarded as a natu-
ral counterpart of lethal mutagenesis as an antiviral strategy based
on compromising viral survival through an excessive mutational
load (see “Antiviral Approaches to Counteract Quasispecies
Adaptability: Lethal Defection and Lethal Mutagenesis” above).
Editing activities can contribute to HIV-1 variation (716). Several
mechanisms for HIV-1 to evade activated natural killer cells have
been described (16, 267, 389).
HIV-1 escapemutants contribute exuberantly to virus survival
in the response to neutralizing antibodies and to cytotoxic T cells.
Current evidence suggests that HIV-1 is continuously evading the
neutralizing response of antibodies to the point that the effect of
virus neutralization in plasma viremia is minimal (694, 851). In
this antibody-virus arms race, the virus seems destined to be the
winner unless massive amounts of polyclonal neutralizing anti-
bodies could be delivered (410). Escape from neutralizing anti-
bodiesmay be facilitated by the limited fitness cost inflicted by the
amino acid substitutions needed to elude neutralization (823) (see
“Selective Forces and Escape Mutants” above). Fitness effects are
expected to be more pronounced in the case of cytotoxic T lym-
phocyte (CTL) escape mutants because T-cell epitopes can be lo-
cated at conserved regions of nonstructural and structural pro-
teins. CTL escape HIV-1 mutants play a key role in viral
persistence (80, 106, 218, 664). As in the case of escape from neu-
tralization, the relevance of quasispecies dynamics is evidenced by
multiple escape routes tested in a continuous process of variant
generation and selection with viral fitness as a contributing factor
(281).
The rate of viral escape from a CTL response depends on the
magnitude of the response (which itself is dependent on associ-
ated HLA alleles), the diversity of the CTL response, the viral load
to which the response is directed, and the fitness cost associated
with the amino acid substitutions needed for escape (304, 415,
528). The rate of CTL escape may slow down in the chronic phase
of infection. Escape mutants can be transmitted, and the mutants
may revert depending on their fitness level in the new host (295).
Fitness is an environment-dependent parameter (205), and the
rate of epitope evolution is expected to vary in different individual
hosts. A rapid intrahost evolution need not be reflected in rapid
evolution at the population level (the one resulting frommultiple
interhost transmissions [295]). (This is analogous to high muta-
tion rates not necessitating high rates of evolution [compare with
“Population Equilibrium, Apparent Stasis, and Rapid Evolution”
and “ViralQuasispeciesDynamics InVivo: Long-TermVirus Evo-
lution” above].)
In contrast to the neutralizing antibodies evoked during infec-
tion, the cellular immune response can partially control the initial
HIV-1 replication and viral load, whose decrease may depend on
the fitness decrease associated with CTL escape (528, 673, 737,
895). In some elite controllers, (a small proportion of HIV-1-
infected individuals who maintain a low viral load in the absence
of antiretroviral treatment), a broad CTL response and mainte-
nance of low-fitness CTL escape mutants may contribute to the
control of the infection (612). A reasonwhy theHIV-1 infection is
often not controlled by the cellular immune response may be the
functional impairment of HIV-1-specific CD8 T cells, and con-
tinued viral replication may lead to their exhaustion. In this view,
HIV-1 often emerges as the winner in the arms race between the
viral quasispecies and the diverse array of immune cells that in
itself is highly heterogeneous (183, 623). From the point of view of
adaptability of a mutant spectrum and its ensuing diversification,
heterogeneity of the major target host cells marks a difference
between HIV-1 and the hepatotropic HBV and HCV, to be dis-
cussed in the next two sections.
A fitness increase of retroviral immune escape variants need
not affect directly the genomic regions related to immune escape
(B-cell or T-cell epitopes or their neighborhood in the relevant
viral proteins). Rather, fitness may be compensated for by en-
hancement of other, unrelated traits such as cell-to-cell spread
(878). Exploitation of different pathways for fitness recovery has
been observed with other viral systems (254), it is expected from
quasispecies dynamics and from the connectivity of sequence
space (see “Exploration of Sequence Space andVirusAdaptability:
Fidelity Mutants” above), and it is highly relevant to vaccine de-
sign and to the mechanisms underlying progression of HIV-1 in-
fection toward AIDS.
The capacity of HIV-1 to overcome the host immune response
andpersist for extensive timeperiods constitutes amajor difficulty
for the design of effective vaccines. The well-established concept
that multiple B-cell and T-cell epitopes should be targeted using
sequences that can cover a broad spectrum of circulating viruses
should be followed for the design of anti-HIV-1 vaccines (120,
188, 202, 425, 441, 579). From the results summarized in previous
paragraphs, it appears that the focus should be on targeting the
immune response toward those epitopes whose variation inflicts a
high fitness cost upon the virus (134, 135, 161). Again, a combi-
nation of immunological and pharmacological approaches could
be considered in attempts to submerge HIV-1 and other highly
variable viruses into deep fitness valleys.
The rate of progression to AIDS appears to result from a com-
plex interplay of viral andhost factors (references 19, 474, 557, and
753, among many other studies). Concerning the influence of
HIV-1 dynamics, it has been difficult to associate global features of
the viral population (genetic diversity, number of positively se-
lected sites, and recombination rate) with disease progression
(104). Patterns of HIV-1 evolutionary change, defined as the rate
of divergence of the viral population relative to the founder virus,
and the degree of heterogeneity of the evolving population have
produced conflicting results andmultiple interpretations. During
the asymptomatic period in moderate progressors, Shankarappa
and colleagues distinguished three phases. An early phase involved
a rapid linear increase of divergence and heterogeneity of the
C2-V5 region of env. At the time of emergence of X4 variants, a
second phase was characterized by a continuing increase of diver-
gence but not of heterogeneity. Coincidentwith a decline of CD4
T cells, a third phase was marked by an invariance or decline of
both divergence and heterogeneity (753). This consistent pattern
contrasts with those from other studies, which found positive and
negative relationships between viral diversification and disease
progression (quoted and discussed in reference 753).
A procedure to infer the HIV-1 genomic sequence of transmit-
ted/founder virus has been developed (720). In the cases studied,
the transmitted viruses wereCCR5-tropic. Characterization of the
viruses in ensuing months revealed a few adaptive mutations that
were explained mainly, but not exclusively, by CTL responses. An
analysis of the CD8 T-cell response during early stages of the
acute infection suggested that the total T-cell response was asso-
ciated with selection of escape mutants (274). This study also
showed that the capacity of T-cell epitopes to tolerate amino acid
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substitutions correlated with the emergence of escape mutants, in
agreement with fitness cost being an important element in im-
mune escape, as discussed in previous paragraphs.
Ultradeep sequencing is currently providing new information
on the dynamics of modification of coreceptor usage (94, 788,
814). In one of the studies, V3 env sequences predicted to be
X4-tropic were identified at least 3 months prior to such se-
quences being detected in a phenotypic assay (94). The transition
between CCR5- and CXCR4-tropic variants followed stepwise
mutational pathways involving multiple, low-frequency interme-
diate mutants. Individual patients varied regarding the number
and diversity of variants with any given predicted phenotype. One
of the problems in trying to anticipate disease progression from
general evolutionary parameters of the relevant viral populations
is that disease progression may relate specifically to some genetic
changes (for example, the determinants of host cell tropism) and
not to global features of a viral population. This argument was
already expressed regarding the difficulty of associating phyloge-
netic groupings with biological features that depend on limited
genetic change (see “Cell Tropism and Host Range Mutants: Bio-
logical Alterations and Viral Emergence” above). Despite the con-
tribution of multiple host factors, HIV-1 evolution within in-
fected patients recapitulates most features of viral quasispecies in
relation to pathogenicity and the challenge of finding means to
limit the progress of the infection.
Hepatitis B Virus
Viral dynamics. Quasispecies dynamics of HBV has been pro-
fusely documented, with processes of mutation, competition, and
selection occurring as part of the natural life cycle of the virus, with
evidence of past recombination events (769). Multiple types of
HBV variants are selected by antiviral treatments or by the host
immune response, which arises more slowly than in the case of
HIV-1 (for a review, see references 73, 178, 334, 402, 421, 489, 683,
and 894).Despite operation of universalDarwinian principles, the
HBV genome and those of other, related animal hepadnaviruses
have unique features that modify some of the consequences of the
acquisition of mutations.
HBV shares withHIV-1 the presence of a genetic reservoir that
in the case of HBV is a covalently closed circular DNA (cccDNA)
found in the nuclei of infected hepatocytes. During infection, the
relaxed circular DNA (RC-DNA) present in virions is converted
by cellular enzymes into the cccDNA,which is the template for the
synthesis of pregenomic RNA (pgRNA) and viral mRNAs (re-
viewed in references 421, 477, and 744). The cccDNA constitutes a
genetic archive of the virus in the same cells where active viral
replication takes place. This has evolutionary implications similar
to those of proviral DNA in retroviruses. Due to its high stability
(long half-life), cccDNA serves as a repository of ancestral HBV
genomic sequences in liver tissue. In addition, viral DNA can in-
tegrate into host DNA by an unknown mechanism in what ap-
pears to be an unregulated process. Because of the necessary pres-
ence of cccDNA, HBV can display both a replicative memory and
a cellular (or reservoir) memory. Sequences that had been domi-
nant at an earlier phase of the evolution of the same HBV lineage
can be reintroduced in the pool of actively replicating HBV (85,
463) (see “Positive Selection and Molecular Memory: Determin-
istic Features of Viral Quasispecies” above).
Multiple copies of cccDNA organized as minichromosomes
can be found in the nuclei of a single infected hepatocyte. The
capacity of cccDNA to contribute to actively replicating HBV de-
pends on the “replication space” available, whichmeans the num-
ber of cells that can be productively infected in the liver (not to be
confused with sequence space of a virus [compare with “Explora-
tion of Sequence Space and Virus Adaptability: Fidelity Mutants”
above] [683, 743, 894]).HBV cccDNA is responsible for the occult
HBV infection (OBI) in patients with low or negative surface an-
tigen (HBsAg) and anticore antibodies and who may have a low
level of or undetectable HBV DNA in serum (118, 717, 758). Per-
sistence of HBV DNA and possibly its integration into cellular
DNA are probably involved in the development of hepatocellular
carcinoma (HCC) (751, 797, 871). An alternative model of HBV
carcinogenesis involves a virus-mediated increase in the cellular
mutation rate. According to this model, the HBVX protein acts as
a potent transcriptional activator and stimulates generation of
reactive oxygen species that enhance the cellular mutation rate,
evoking malignant transformation (813).
HBV has some features that distinguish it from HIV-1 regard-
ing short-term, intrahost evolution. One feature concerns the het-
erogeneity of the cells that support viral infection, due to suscep-
tible cells belonging to different lineages or sublineages. Despite
hepatocyte heterogeneity within a liver (or liver “zonation” asso-
ciated mainly with differences in metabolic activity [810]), HBV
encounters amore homogeneous intracellular biological environ-
ment than HIV-1 (183, 623). The intracellular environment and
the receptors expressed on the host cell constitute powerful con-
straints for the selection of viral subpopulations, such as those
associated with coreceptor usage switch in HIV-1 (see the previ-
ous section). The dynamics due to coreceptor shift that operates in
HIV-1 is unlikely to have a parallel in the case of HBV. Despite
this, extrahepatic replication of HBV cannot be excluded. Distinct
HBV populations can be found in the liver, peripheral blood
mononuclear cells (PBMC), and plasma up to 15 years post-liver
transplant. Antiviral drug-resistant variants were more frequent
in liver than in PBMC, and both compartments were potential
sources for reinfection (143). Thus, some HBV compartmental-
ization, with implications for selection of viral subpopulations,
may occur.
Another distinct characteristic of HBV is the remarkable num-
ber of overlapping reading frames in its genome. The pre-S1- and
pre-S2-coding regions, which precede the surface antigen
(HBsAg)-coding region, overlap the spacer domain of the poly-
merase (P) gene, while the region encoding HBsAg overlaps with
the polymerase domain involved in nucleic acid synthesis (421,
894). Gene overlaps can amplify the phenotypic consequences of
mutations. In particular, some drug-resistant mutations that map
in theHBVpolymerase can give rise to amino acid substitutions in
the surface antigen that can decrease the affinity of the virus for
antibodies. It is generally accepted that the presence of overlap-
ping open reading frames restricts virus variation, because any
single mutation has some probability of adversely affecting two
proteins and, consequently, viral fitness. This is certainly true, but
nevertheless, HBV can manage quite successfully to overcome se-
lective constraints, be they of immunological or pharmacological
nature. An argument against overlapping reading frames being
responsible for a substantial decrease of virus adaptability is that
current virology is teaching us that most (if not all) viral proteins
perform multiple functions in the life cycle of viruses. Thus, any
amino acid substitution will in effect be responsible for the alter-
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ation of multiple functions even if the viral genome lacks overlap-
ping genes.
Despite important differences between HIV-1 and HBV, the
basic Darwinian principles of genetic variation, competition
among variants displaying different phenotypic traits, and domi-
nance (often transient) of the most fit variants in a given environ-
ment obviously apply to HBV, as extensively documented with
clinical studies involving each of the viral genotypes (143, 178,
339, 421, 434, 683, 685, 894). The dynamics ofmutant generation,
competition, and selection is noted in vivo even in the absence of
external selection pressures such as drug administration or immu-
notherapy (see “Coping with the immune response” below).
Drug resistance. After the implementation of lamivudine
(LMV) for treatment of HBV infections, it became apparent that
the virus had the capacity to become resistant to antiviral agents,
following basically the same course of events described for HIV-1.
Resistance of HBV to small interfering RNAs in cell culture and in
mice has been described (877). Resistance to nucleotide analogues
occurs in a considerable proportion of treated patients, albeit with
different kinetics of dominance (reviewed in references [178 and
894]). Antiviral drug-resistant mutants emerge as a function of
host determinants and at least six viral factors: the viral mutation
frequency, the capacity to toleratemutations of the antiviral target
site, the selective pressure exerted by the drug (effective drug con-
centration at the viral replication site), the magnitude and rate of
virus replication, the overall replication fitness of the resistant
mutant relative to that of the wild type, and the availability of
replication space (50, 225). Some drug resistance mutations con-
fer cross-resistance to other drugs or prepare the virus for acqui-
sition ofmutations that confer resistance to other drugs, compen-
satory mutations permit fitness recovery following a fitness
decrease associated with acquisition of a primary resistance mu-
tation, mutations that confer resistance can preexist in viral qua-
sispecies, and the cccDNA is responsible for the reactivation of
viral replication upon therapy interruption (178, 401, 434, 489,
894). This course of events is similar to that documented for
HIV-1.
HBV virological breakthrough to lamivudine (LMV) is pre-
ceded by the emergence of quasispecies variants bearing amino
acid substitutions at polymerase (RT) position 204, i.e., within the
YMDD catalytic motif (abbreviated rtM204V/I). Patients tend to
have a gradual switch fromaYMDDwild-type population at base-
line to a 100% lamivudine-resistant population. Careful analysis
of amino acid substitutions located outside domain C of HBVRT,
including those known to partially restore replication capacities in
vitro, show that the in vivo replication ofHBV variants is driven by
multiple forces, including replicative advantages conferred by
mutations accumulating outside domain C and the changing en-
vironment in which these variants replicate (628). In patients who
interrupt lamivudine treatment, reversion (partial or complete) to
wild-type virus is often observed after only a few months (97).
The distribution of genetic variability of HBV shows different
patterns in antiviral-treated and untreated subjects, and the qua-
sispecies divergence of different regions ofHBVmay vary substan-
tially even within a single host. Antiviral-treated subjects show
amino acid changes within the known T-cell or B-cell epitopes in
the surface or core antigen, most of which are accompanied by
mutations in the RT region. In patients who received lamivudine
as initial antiviral therapy, nucleotide polymorphism and nonsyn-
onymous divergence decrease at lamivudine breakthrough but in-
crease after rescue therapies. Patients treated with adefovir-tel-
bivudine sequential therapies showdistinct changes in divergence.
When untreated subjects have an alanine aminotransferase (ALT)
flare, they exhibit an increase in heterogeneity and divergence in
the precore-core region (798).
The quasispecies complexity and diversity do not appear to
differ between responders and nonresponders to lamivudine at
baseline, but both parameters are significantly lower in responders
than in nonresponders after 4 weeks of therapy. The dynamic
changes of quasispecies complexity and diversity during the first 4
weeks correlate with lamivudine antiviral efficacy and antiviral
resistance (119).
Edited HBV sequences with G¡A hypermutations are present
in infected individuals at different stages of liver disease (787,
827). This innate immune mechanism, initially identified as a de-
fense against retroviruses, may also promote HBV variation. Us-
ing ultradeep sequencing technology and a classification model
that measures excess G¡A mutations, host-mediated G¡A hy-
permutations have been identified. Interestingly, 2.9% of se-
quence reads from 45 untreated chronically HBV-infected pa-
tients were classified as hypermutated, and of those, the majority
included two of the most common drug resistance mutations,
A181T and/or M204I in HBV RT, that arise from G¡A changes
(515, 689).
It is well established that viral load is a key parameter to allow
the virus to explore sequence space to find pathways for drug or
multidrug resistance, while maintaining adequate fitness levels.
Insufficient viral suppression, such as that associatedwith sequen-
tial monotherapy with nonmutagenic inhibitors, can promote se-
lection of drug-resistant variants (883). It is anticipated that com-
bination treatments with three or more inhibitors directed to
different steps of the virus life cyclemay achieve viral suppression,
which is essential to prevent disease progression (485). If muta-
genic agents specific for HBV RT were developed, current models
suggest that a strong reduction of viral load followed immediately
by mutagenesis should be an effective protocol to prevent selec-
tion of drug-resistant mutants (393). However, these strategies
necessitate the development of new anti-HBV inhibitors and spe-
cific mutagenic agents. Furthermore, they will be faced with the
cccDNA reservoir unless means to deplete this DNA pool or ren-
der it inactive are found.
Liver transplantation offers a situation in which residual virus
of the acceptor or donor individual finds a new environment (the
grafted liver under immunosuppression) tomultiply and generate
fit quasispecies. A challenge is to suppress HBV viral loads to pre-
vent recurrence of the infection after liver transplantation. Com-
binations of nucleoside analogues with specific anti-HBV immu-
noglobulins are currently used with some success (123).
Coping with the immune response. HBV can escape immune
pressure, as evidenced by selection of HBs antigen mutants in the
presence of actively generated or passively administered anti-HBs
antibodies (641). As a consequence of the production of antibod-
ies against theHBeAg, anti-HBe escapemutants are selected. Since
HBeAg expression is not essential for HBV replication, the virus
can evade the anti-HBe response by reducing or turning off
HBeAg expression. Precore point mutations, insertions, and dele-
tions occur with high frequency. The introduction of stop codons
(such as the frequent G¡A transition at nucleotide 1896) may
prevent HBeAg production. This mutation also affects the struc-
ture of a highly conserved encapsidation signal (termed epsilon),
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sinceG1896 base pairs with nucleotide 1858 at the stem-loop of an
RNA secondary structure.Mutation G1896¡A is favored inHBV
of genotypes B, D, E, and G and some representatives of genotype
C, as in these viruses nucleotide 1858 is thymidylic acid and the
stop codon stabilizes the RNA structure involved in encapsidation
(reviewed in reference 755).
Other common HBeAg variants are core promoter mutants,
characterized by pointmutations in the promoter for bothHBeAg
mRNA and core protein mRNA (807). The core promoter mu-
tants decrease HBeAg expression through transcriptional down-
regulation. The frequent double A1762T and G1764A nucleotide
exchange results in a substantial decrease inHBeAg expression but
enhanced viral genome replication, again mediated by reduced
precore RNA transcription. These virological properties lead to
enhanced pathogenicity of core promoter mutants in vivo. In-
creased replication capacity and reduced virion secretion may
raise the viral load in the liver, which triggers liver damage directly
or indirectly through the immune response (485). Massive liver
damage during acute infection leads to fulminant hepatitis. Dam-
age during chronic infection increases hepatocyte turnover, in-
duces fibrosis, and increases the chance of hepatocellular transfor-
mation and malignancy (807). As opposed to precore variants,
core promoter variants can be detected in patients who are either
HBeAgpositive or negative. The prevalence of core promoter vari-
ants is about 40%, and they are evenly distributed among the
major HBV genotypes.
The term HBeAg seroconversion refers to HBeAg becoming
undetectable while anti-HBe antibodies are present. When ac-
companied by low viralDNA levels in serum, undetectableHBeAg
is indicative of a reduced risk of liver disease.HBsAg positivity and
high DNA serum levels, however, denote viral persistence and
elevated alanine aminotransferase (ALT) (a marker of liver dis-
ease). Thus, HBeAg negativity can be associated with different
disease outcomes, the most negative of them signaled by elevated
viral loads (340). The core antigen-coding region appears to be
stable prior to seroconversion, but mutations are rapidly selected
as a consequence of the anticore immune response (13, 334). Fit-
ness enhancement of HBV can follow after mutations in the basal
core promoter that increase binding of liver-specific transcription
factors are selected, leading to enhanced viral replication (335,
792).
The S protein contains an exposed major hydrophilic region
(residues 110 to 155) which encompasses the antigenic “a” deter-
minant that is important for inducing immunity. The “a” deter-
minant of HBV is a loop with immunological and evolutionary
implications similar to those of the RGD-containing loop of
FMDV (discussed in “Cell Tropism and Host Range Mutants:
Biological Alterations and Viral Emergence” above). Amino acid
substitutions at this site can lead to conformational alterations
that may affect the binding of neutralizing antibodies or mediate
failure to detect hepatitis B virus surface antigen (HBsAg) in diag-
nostic assays. The most frequent amino acid substitutions in S are
G145R and D144A (74, 377). HBV “a” mutants have been shown
to escape vaccine-induced or passively transferred neutralizing
responses, leading to the development of a true, HBs antigen-
positive HBV infection in the presence of high titers of anti-HBs
antibodies.
The overlap between the S and polymerase genes has as a
unique consequence for HBV that drug resistance mutations may
result in a modification of the antigenic behavior of the virus and
vice versa. Polymerase (RT) substitutions associated with lamivu-
dine resistance produce changes in the overlapping S gene that
result in reduced antigenicity of the HBsAg protein. Escape mu-
tations, present as a result of vaccination or immunoglobulin
treatment, map in the fingers subdomain of the polymerase.
When combined with lamivudine resistance mutations in the
YMDDdomain, the S escapemutations have the incredible ability
to behave as compensatorymutations that can restore the replica-
tion of LMV-resistantHBV (74, 755). The situation faced is that of
a man-made coevolution established between treatment response
and antigenic variation, which may be accentuated as new immu-
nological or chemotherapeutic interventions are implemented.
The availability of variant databases for HBV should contribute to
monitoring of the prevalence of mutations and perhaps anticipat-
ing their effect on HBV adaptability (691).
In conclusion, quasispecies dynamics is deeply rooted in the
natural life cycle of HBV, even in the absence of external interven-
tions. When immunological or pharmacological pressures occur,
an extremely complex interplay of mutual influences between vi-
ral proteins is triggered. The system offers a fascinating field of
research to understand the intricate set of molecular interactions
that ensure fitness gain. Again, the challenge is to find means to
sink the virus in deep fitness valleys and to deplete or render non-
functional the cccDNA reservoir.
Hepatitis C Virus
Viral dynamics.Quasispecies dynamics ofHCV, first proposed by
the Vall d’Hebron group in Barcelona (518), is now a well-estab-
lished feature of its biology. In infected patients, continuous evo-
lution of HCV takes place, and viral persistence, disease progres-
sion, or response to treatment appears to be influenced by HCV
population heterogeneity (88, 116, 200, 319, 643, 683). Patrizia
Farci has thoroughly reviewed the implications of the quasispecies
nature of HCV for evasion of the adaptive immune response and
viral persistence, disease progression, liver transplantation, and
response to therapy (264). Therefore, here we only underline
some aspects of HCV quasispecies, mainly to compare this virus
with HIV-1 and HBV and to illustrate some concepts covered in
previous sections.
The vast heterogeneity of theHCV that replicates in an infected
patient has been amply documented by molecular cloning and
Sanger sequencing and recently by application of ultradeep se-
quencing (543, 584). HCV evolves at rates that are in the range of
102 to 103 substitution per site per year (499). These evolution-
ary rates rank among the highest reported for RNA viruses (189).
In interpreting data on the mutant spectrum diversity and con-
sensus sequence evolution of HCV, some differences between its
replication cycle and those of HIV-1 and HBV are worth empha-
sizing. One is the absence, from all evidence, of a DNA reservoir
that could play a role as a repository of ancestral genomic se-
quences, similar to proviral DNA in HIV-1 or cccDNA in HBV.
This implies that a replicative memory, but not a reservoir mem-
ory, can operate during HCV evolution subjected to sequential
selective constraints (see “Positive Selection andMolecularMem-
ory: Deterministic Features of Viral Quasispecies” above and the
previous sections onHIV-1 andHBV, for which a reservoir mem-
ory plays a role). Ancestral sequences might be introduced into
replicatingHCV if there are subsets of infected cells in whichHCV
replicates at a much lower rate than in the bulk of infected cells. A
mechanism of delayed replication relative to the major liver qua-
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sispecieswould be through extrahepatic replication in organs such
as blood or brain. Despite some evidence for extrahepatic replica-
tion, compartmentalization of HCV quasispecies is not a settled
issue (reviewed in reference 264). If a slow, extrahepatic replica-
tion occurred, a replicative memory could in effect act as a reser-
voirmemory, thus introducing a new element of complexity in the
understanding of HCV quasispecies evolution. Features that are
common to HCV andHBV are a strong preference for replication
in liver cells and a delayed adaptive immune response. Hepatot-
ropism should, in principle, provide for HCV a relatively constant
biological environment compared with HIV-1 (see discussion of
this point in “Hepatitis B Virus” above). Again, extrahepatic HCV
replication would introduce compartmentalization of viral sub-
populations and environmental heterogeneity (286, 502, 627).
The dynamics of a continuous generation of mutant swarms,
competition among variants, and selection of the most fit in each
of the environments follow the same tenets expounded through-
out this article (264). The availability of cell culture systems that
sustain extended multiplication of the entire HCV or genomic
replicons has mirrored selective events documented in vivo, with
clear evidence of adaptability under experimentally controlled
conditions. Evidence includes introduction of fitness-enhancing
mutations, selection of drug- and interferon-resistant mutants
(264, 344, 420, 669, 845), and selection of more stable virus parti-
cles (431). A virus-host coevolution in the course of a persistent
infection in cell culture (893) reinforces the Darwinian behavior
of HCV in interaction with its host cells, as documented with
other viruses (see “Cell Tropism and Host Range Mutants: Bio-
logical Alterations and Viral Emergence” above). Bottleneck
events contribute to diversification of HCV (93, 462, 680). HCV
genotype 4a dominates in Egypt, presumably due to poorly steril-
ized needles in a nationwide parenteral treatment of schistosomi-
asis in the middle of the 20th century, implying transmission with
bottlenecks of different intensity (290). The observed genetic vari-
ation along theHCV genome is not distributed in a uniformman-
ner. There are relatively conserved regions such as the 5= and 3=
untranslated regions (UTRs), where specific sequences and RNA
secondary structures are required for replication and translation
functions. The E1 and E2 glycoproteins and the nonstructural
protein NS5A show more variability, in particular some hyper-
variable regions that also display rapid amino acid sequence
change over time. Part of this variability arises through selection
events associated with immune escape (264, 765).
Most acute HCV infections evolve to chronicity, and a signifi-
cant proportion of chronically infected patients will develop se-
vere liver disease (380, 756). Once liver function is compromised,
the only reliable therapeutic intervention is liver transplantation.
However, HCV recurrently infects the liver graft in almost all
HCV-infected patients following orthotopic liver transplantation
(OLT), and the progression of HCVdisease posttransplantation is
generally accelerated compared with that in nontransplanted pa-
tients (60). Although HCV quasispecies diversity in most of the
patients decreased in the first week after OLT, it was more pro-
nounced in the patients with a lower fibrosis 1 year afterOLT (28).
In patients with severe HCV recurrence, evolution of HCV quasi-
species was also more pronounced, and HVR1 divergence oc-
curred earlier following transplantation (657). Neutralization es-
cape mutants that display an efficient entry into liver cells may
play an essential role in reinfection of the graft following liver
transplantation (262). HCV quasispecies have been extensively
studied both before and after OLT. During the first days following
transplantation, there is generally a rapid decrease in the HCV
quasispecies diversity, resulting in a more homogenous viral pop-
ulation. These very early changes in the quasispecies composition
strongly suggest that attachment and entry of HCV into hepato-
cytes constitute a bottleneck contributed by selection and random
sampling events from the viral population (519). The homogene-
ity of the HCV quasispecies continued to increase, being at its
highest value 4 weeks after OLT, coincident with high levels of
immunosuppression; therefore, relative homogeneity might be
explained by a deficient immune response against HCV (270).
As the demand for liver transplants exceeds the organ supply,
one approach to expand the pool of organs for transplantation is
to use grafts from extended-criterion donors, such as HCV-posi-
tive donors. Superinfection with different HCV strains within a
single patient is common under these circumstances. Competi-
tion between different strains can lead to the exclusion of one
strain by the other as soon as the first day after OLT, with no
preference as to whether the donor or recipient HCV prevails
(263, 686). These observations are analogous to the competitive
exclusion principle described for cell culture studies with other
RNA viruses (see “Positive Selection andMolecular Memory: De-
terministic Features of Viral Quasispecies” above). The level of
HCV genetic heterogeneity in pretransplant patients predicted
disease severity after transplant (481).
Regarding the connection between the pathogenic potential of
a virus and quasispecies complexity, it is worth stressing again that
the advantage of a broad mutant spectrum lies in the increased
capacity of the viral population to find portions of sequence space
in which to increase its fitness. Once a genome with a good fitness
level is found, a relative homogeneity can be associated with the
replication-competent, disease-provoking subpopulation. In
other words, enhanced pathogenesis can be associated with high
heterogeneity in the process of searching for the adequate subpop-
ulation or with relative homogeneity when selection has occurred.
The time at which population complexity is examined can be crit-
ical.
Treatment response anddrug resistance.Bothhost genetic de-
terminants and properties of the viral population determine the
response of HCV to alpha interferon/ribavirin (IFN-/R)-based
therapies. An increasing number of host genetic factors, with a
well-characterized one being the allelic forms of the IL28B site
(310), together with population characteristics of HCV, can affect
treatment success. In addition, the viral genotype, a trait that re-
sults from long-termHCV evolution, also determines response to
therapy. HCV genotype 1 is the most difficult to treat, with ap-
proximately 50% patients responding IFN-/R combined ther-
apy, compared to 80 to 90% for genotype 2 or 3 (505). Similar
differences have been found in patients coinfected with HIV-1
(317). Extensive research has been done to correlate nucleotide
and amino acid substitutions with the genotype-specific IFN-
response, for example, domains and specificmutations in the E2-,
core-, andNS5A-coding regions (116, 249, 644). Analysis ofNS5A
has been amain focus, especially a 40-amino-acid domain situated
in the central part of the NS5A, termed the IFN sensitivity-deter-
mining region (ISDR). This region has been described as a focal
point of quasispecies variation that can predict treatment out-
come. In an initial report, Enomoto and coworkers found a cor-
relation between particular amino acid variations inHCV subtype
1b with sensitivity to IFN- (249). Japanese patients infected with
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HCV genotype 1b who had at least 4 mutations in the ISDR con-
sensus sequenceweremore likely to achieve a sustained virological
response to IFN--based therapy than those who had fewer than 4
mutations. While some studies confirmed these results (117, 455,
577), other studies with genotype 1b-infected patients from Eu-
rope and theUnited States did not (644, 718, 731, 868). One of the
most relevant interactions of NS5A is with proteins of the IFN
signaling pathway, through direct inhibition of the IFN-inducible
protein kinase R (PKR), which is normally activated by double-
stranded RNA (dsRNA) to trigger a cellular antiviral state. The
portion of NS5A interacting with the cellular PKR is known as the
PKR-binding domain (PKRBD), which includes the ISDR. Thus,
PKR inactivation through a direct interaction of the ISDRmay be
one mechanism by which HCV avoids the antiviral effects of IFN
(303). A larger number of mutations in V3 and the interferon/
ribavirin resistance-determining region (IRRDR) of virus from
pretreatment serum in early virological responders than in that
from non-early responders was quantitated in a cohort of patients
infected with HCV of genotype 1b (247). A single amino acid
substitution in NS5A might be associated with a sustained viral
response and ALT normalization (595). However, a possible rela-
tionship between specific mutations in the NS5A and IFN- ther-
apy outcome remains an open question. In addition to dominant
mutations that may relate to treatment outcome, several studies
have addressed the role of quasispecies complexity in response to
treatment, without uniform conclusions. Puig-Basagoiti and col-
leagues observed that the complexity and diversity of HCV NS5A
quasispecies before treatment were lower in isolates from re-
sponders than in those from nonresponder patients, particularly
in the domain V3. These differences became more apparent dur-
ing IFN-/ribavirin therapy, where complexity and diversity re-
mained stable or tended to increase in nonresponders and to de-
crease in responder patients (677). Figlerowicz and colleagues
found that in children with chronic HCV infection, nonre-
sponders included a restricted number of closely related variants
while sustained responders included more distant variant classes
present in similar proportions (280). The E2 envelope gene has a
hypervariable region (HVR1) that expands over the first 417 nu-
cleotides of the E2-coding region and evolves more rapidly than
the rest of the genome (771). Many studies have shown that this
region has an important role in immune escape (reviewed in ref-
erence 264). Patients chronically infected with HCV usually har-
bor multiple variants with distinct HVR1 sequences that are pres-
ent at different frequencies, whereas newly infected patients tend
to display virus with lower quasispecies complexity than the virus
in the donor (462, 680). Acute resolving HCV maybe a result of
the transmission of a minor variant that prevails as the dominant
species, which generates a mutant distribution that can be cleared
by the immune response (486). In a study using ultradeep pyro-
sequencing (UDPS), samples from four recently diagnosed HCV-
positive individuals (with elevated ALT levels consistent with
acuteHCV infection)were analyzed (847). Lowdiversity inHVR1
was seen during the first 5 weeks after diagnosis, probably as a
result of transmission of only a few virions. Over time, certain
variants became dominant whereas others tended to decline in
number (847), a pattern of mutant replacement (543) typical of
quasispecies dynamics. Relatively little variation is seen in individ-
uals with deficient humoral immune response (62, 613). It has
been suggested that given its tolerance of variations, HVR1 can
mediate both the enhancement of cell entry and protection of
virions from neutralizing antibodies, rendering this region essen-
tial for persistence ofHCV (51). This constitutes an example of the
biological implications of the overlap between antigenic sites and
cell receptor recognition sites (see “Cell Tropism and Host Range
Mutants: Biological Alterations and Viral Emergence” above).
Low heterogeneity of the HVR1 is generally associated with
normal ALT levels (36, 83), and several groups have described that
a higher genetic complexity of the HVR1 quasispecies in pretreat-
ment samples is related to low or no response to IFN--based
treatment (280, 329, 642, 671, 722, 732, 757). No such correlation
was observed in telaprevir (TPV)-based treatments (460). A re-
duction in genetic diversity in HVR1 is likely to be the result of a
more successful and balanced cellular and humoral immune re-
sponse (266, 642). In nonresponders, Farci and colleagues dem-
onstrated that the initial dominant strain persists for at least the
first 12 weeks without changes in viral replication levels. This ar-
gues in favor of the hypothesis that inherently IFN--resistant
HCV variants are present in these patients before initiation of
therapy. The reappearance of the original dominant strain seen in
patients who had a breakthrough suggests either a temporary viral
suppression by IFN--modulated immune-mediated mecha-
nisms or a partial degree of sensitivity to IFN-. However, in pa-
tientswhohad a relapse, new viral strains emerged, suggesting that
most of the baseline variants were sensitive to IFN-. These new
variants could represent new mutants or preexisting minor vari-
ants present at undetectable levels that may have been less acces-
sible to IFN- (266). Despite the disappearance of viremia, HCV
appears to be able to persist for weeks tomonths at very low levels,
providing a reservoir for virus reactivation after IFN- treatment
(266).
Core is the most conserved protein of the HCV genome, with
96% amino acid sequence homology among subtypes (767).
However, amino acid substitutions in the core-coding regions of
different genotypes appear to be related to insulin, oxidative
stress, or steatosis resistance, variable responses in IFN-/ribavi-
rin combination therapy, and hepatocellular carcinoma (HCC)
(427). Core amino acid 70 and 91 polymorphisms have recently
been used to predict IFN- treatment response; for example,
Q/H70 andM91 in patients with genotype 1b predict a slow or no
response to IFN-, whereas patients infectedwithHCVharboring
R70 and L91 are more likely to obtain a rapid sustained response
(246, 453, 722).
HCV therapy has entered into a new era with direct-acting
antivirals (DAAs) (with boceprevir and TPV licensed in 2011, to
be followed by others) (449). As explained for HIV-1 and HBV,
the initial results suggest that emergence of viral resistance to
DAAs in chronically infected patients will be a significant prob-
lem. Again, a central issue is whether drug-resistant mutants pre-
exist in HCV populations. Sanger sequencing, as well ultradeep
sequencing, has identifiedmutations that confer resistance to pro-
tease inhibitors in patients not exposed to the drugs (156, 733,
828). Verbinnen et al. assessed the dynamics of variants emerging
in vitro under low, high, or stepwise-increasing concentrations of
a potent macrocyclic NS3/4A protease inhibitor (TMC380765).
Distinct concentration-dependent mutation patterns were iden-
tified. Low-resistance level patterns, initially observed in the pres-
ence of low concentrations of TMC380675, were replaced by high-
resistance mutational patterns when the concentration of the
compound was increased (828). Resistance level-dependent mu-
tations were first described for picornaviruses (see “Selective
Viral Quasispecies
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Forces and Escape Mutants” above), and this is probably a wide-
spread occurrence. This confers relevance to the drug concentra-
tions that reach the sites of viral replication, a parameter which is
rarely quantified.Hiraga and colleagues investigated emergence of
TPV-resistant mutants by ultradeep sequencing using an HCV
infectious model in human hepatocyte chimeric mice (367). Mice
were injected with HCV genotype 1b (with or without the TPV
resistance mutation A156S), and subsequently mice were treated
with TPV. Mice infected with the A156S HCV variant developed
lower-level viremia than those infected with the wild-type strain
but showed strong resistance to TPV. Althoughmice injectedwith
wild-typeHCV showed a rapid decline in viremia at the beginning
of therapy, a high frequency (11%) of TPV-resistant V36A vari-
ants emerged 2 weeks after the start of treatment, suggesting that
rapid emergence of de novo TPV resistance was induced by viral
mutation and selection (367). Again, no attempt is made here to
list the steadily increasing number of mutations related to drug
resistance because periodic compilations are published (344, 345,
429, 733).
As extensively documented with many viruses, HCV break-
through is associated with selection of minor subpopulations
present in HCV quasispecies (264, 880). Due to functional con-
nections among HCV proteins, mutational linkage has been ob-
served (880), and it has been suggested that amino acid covariance
networks can have a predictive value regarding treatment re-
sponse (37). Thus, there are at least three major predictors of
response to HCV treatment: (i) the alleles at different polymor-
phic sites in the human genome, (ii) viral population size and
mutant spectrum complexity, and (iii) amino acid covariance in
the consensus sequences of HCV in patients at the time of treat-
ment.
Coping with the immune response. Escape from the host im-
mune response is generally considered a major mechanism of
maintenance of HCV persistence (264, 643). The establishment of
persistence is probably influenced by several virus and host fac-
tors, and the participation of mutant generation in this step has
been questioned (643). Similarly to HIV-1, HCV displays a dy-
namics of continuous escape from neutralizing antibodies (217,
839). Likewise, escape from cytotoxic T cells plays a role in persis-
tence (251, 854; reviewed in reference 264). In a chimpanzee
model,HCVcontrol and clearancewere determined by the level of
HCV-specific IFN-	-producing T cells in the liver (803), which is
suggestive of an arms race between virus and cellular immunity as
well described for HIV-1, but for HCV it may lead to clearance or
persistence.
Some themes are recurrent in the quasispecies biology of
HIV-1, HBV, and HCV, as in probably most RNA viruses as they
interact with their hosts. One is the arms race in which viral qua-
sispecies and a correspondingly dynamic immune system engage.
An active immune responsemay have two opposite effects. It may
complete viral clearance or itmay enhance viral heterogeneity and
adaptability, thereby jeopardizing treatment efficacy, with good
evidence in the case of HCV (264, 564). Both in the immune
response to viruses and in external interventions such as antiviral
therapy, there seem to be a number of variables that can tip the
balance for or against the virus. Thus, from the point of view of
achieving virus clearance, the challenge is to understand what are
those critical variables so as to act appropriately once the nature of
the viral populations we aim to control begins to be understood.
CONCLUSIONS, CONNECTIONS, AND PROSPECTS
The multiple viral traits that are influenced by the genetic and
phenotypic heterogeneity of RNA viruses demonstrate that qua-
sispecies dynamics stands as a major biological feature that affects
virus behavior in decisive manners. Although it is probable that
not all the implications of quasispecies dynamics have yet been
appreciated, some general consensus can be stated. (i) The pres-
ence of complex mutant spectra in viral populations is a reality,
and it is not the result of artifactual mutations introduced during
in vitro nucleic acid amplification reactions or of inadequate pro-
cessing of nucleotide sequencing data. Each of the procedures re-
quires appropriate controls, and the results may need correction
of heterogeneity values, but sequencing errors are not the source
of the observed heterogeneities. (ii) Most of the biologically rele-
vant variation observed in vivo is the result of genetic variation and
competitive selection, together with random events acting on
multiple replicative units. (iii) The composition, complexity, and
amplitude of the mutant spectrum can exert an influence on the
biological behavior of a virus, including medically relevant traits
such as disease potential or response to antiviral treatments. (iv)
When adaptation to a new environment requires only one or few
mutations that do not inflict a high fitness cost, adaptation will be
achieved with a virus displaying the usual range of mutation rates,
rounds of replication, and population size. Compensatory muta-
tions will often be incorporated in an evolving population. In
contrast, when a large number of precisely defined mutations are
needed for a phenotypic change, the presence of a mutant swarm
will generally be irrelevant, and adaptation to the new environ-
ment will not take place. A limited range of adaptability imposed
by the portions of sequence space readily available to a virus is
what keeps virus identity in our biosphere and justifies taxonom-
ical groupings. (v) Quasispecies dynamics has explained the fail-
ure of monotherapy and synthetic antiviral vaccines but has
opened new possibilities for antiviral interventions.
Processes of adaptation anddeadaptation are brought about by
events that affect the composition and complexity ofmutant spec-
tra, at times with an invariant consensus sequence. Such events
have two complementary aspects: (i) the variation of adaptive
capacity depending on the population size and complexity of the
mutant spectrum and (ii) fitness modulation through internal
interactions established among genomes and expression products
within a mutant spectrum. From the mechanisms and specific
examples described in previous sections of the present article, it is
clear that adaptability is linked to four closely related parameters:
replication rate, viral load, genetic heterogeneity, and viral fitness.
Under conditions of unperturbed virus multiplication, enhance-
ment of one of these parameters generally goes together with en-
hancement of the others (Fig. 16). Indeed, as already predicted by
the very early formulations of quasispecies theory, when a small
amount of virus displaying a mutation rate typical of RNA viruses
is allowed unrestricted replication (no limitation of space or re-
sources) in a constant environment, competition among contin-
uously arising variants will result in increasing viral load and viral
fitness. If population size has to remain constant but replication
can proceed (because of variable host cells and a compensatory
turnover of virus generation and degradation), the virus will be
enriched in progressively higher-fitness components. This course
of events can bemodified by threemajor influences: environmen-
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tal changes, population bottlenecks, and modification of the mu-
tation rate.
An environmental change can produce deadaptation of a virus
that had acquired high fitness in the previous environment.When
confronted with an environmental change (immune and other
physiological responses), the virus population size confers on the
virus the capacity to explore sequence space, an essential ingredi-
ent of adaptability (Fig. 8). In connectionwith viral disease viewed
as an adaptation event from the virus side, increased exploration
of sequence space often results in disease progression. A general
association between viral load and disease severity has been estab-
lished in many cases, and it can be interpreted as an increased
capacity to find a viral subpopulation capable of altering host
functions (Fig. 16). Also, the absence of a rapid virological re-
sponse (decrease in viral load) following treatment initiation is a
predictor of virus relapse upon treatment discontinuation (554);
host factors may modulate the correlation between viral load de-
crease and probability of relapse (811). An early start of an antivi-
ral treatment, before the virus increases its intrahost fitness, is the
best option for a successful therapy (18, 368). There are exceptions
to this picture. Specific viral strains can be particularly pathogenic,
independently of any prior or further exploration of sequence
space. In the case of PV there are virulent and attenuated strains
with genetic signatures associated with these traits, as well as se-
quence space-dependent virulence determinants, as documented
with polymerase fidelitymutants. Itmay not be easy to distinguish
whether a genomic sequence confers high virulence per se or be-
cause it embodies a capacity to reach neighbor populations of
sequence space which constitute disease-associated swarms. We
anticipate that application of massive nucleotide sequencing to
viral populations as they produce disease in animal models may
contribute to clarifying this point.
Exploration of sequence space may result in selection of virus
variants that achieve a controlled replication in the face of the host
immune response, without disease symptoms. This is the case of
chronic, inapparent infections with limited or absent cell damage.
What tips the balance between inapparent and overt, disease-
causing infections is largely unknown and is probably host depen-
dent anddifferent fromvirus to virus. Inmany cases of viruses that
tend to produce overt disease, viral load, viral fitness, and explo-
ration of sequence space are interconnected parameters associated
with disease progression. Some models of viral ecology suggest
that long-term virus survival may select for virus attenuation and
persistence strategies. Yet, when acute disease is the outcome of an
infection, antiviral therapy should aim at decreasing the values of
any of the interconnected parameters implicated in disease pro-
gression (Fig. 16).
Bottlenecks can influence the course of events depicted sche-
matically in Fig. 6 and 7 by introducing a stochastic component in
which subsets of genomes have to initiate a new cycle of evolution-
ary events. A third relevant parameter is the mutation rate. Too
low a valuemay limit population heterogeneity and exploration of
sequence space, which are in turn connected with fitness gain and
viral load. If an infection was initiated by a high-fidelity virus
mutant, the prediction is that in successive generations lower-
fidelity mutants would be selected, provided that fidelity modifi-
cations did not imply impairment of other viral functions. The
dominance of lower-fidelity mutants should be more rapid when
the virus is confronted with a large environmental heterogeneity
during its replication. Tools are now available to test these predic-
tions.
In contrast to low mutation rates, higher-than-basal mutation
rates lead to generation of defector genomes which can be detri-
mental for fitness of the ensemble. Current data suggest a transi-
tion between regions of sequence space inwhich positive, comple-
menting interactions dominate and regions where defection
becomes prominent, previous to overt lethality with even higher
mutation rates (Fig. 10, 12, and 13). The transition from domi-
nance of complementation toward dominance of defection has
been easily observed with modest increases of mutation rate be-
cause, from several lines of evidence, RNA viruses replicate close
to the error threshold for maintenance of replicative competence.
The error threshold is not only an abstract corollary of quasispe-
cies theory; it sets a limit to virus viability when damage to viral
genomes and their expression products is no longer compatible
with completion of the virus replication cycle. This meaning of
error threshold approaches the original formulation by Leslie Or-
gel, who defined the error threshold in connection with the min-
imumaccuracy of protein synthesis in relation to aging (620, 621).
Because of the proximity of virus replication to an error thresh-
old for virus viability, lethal mutagenesis is a realistic antiviral
strategy that can have antiviral effects associated with modest in-
creases of the mutation rate. One of the challenges is to under-
stand the molecular basis of the positive and negative interactions
experienced by mutant spectra in order to learn about molecular
mechanisms of fitness gain and fitness loss to advance antiviral
protocols. Interference was studied extensively with defective in-
terfering (DI) particles, mainly with negative-strand RNA viruses,
and those pioneer studies half a century ago can now be applied to
understand the consequences of negative interactions within qua-
sispecies exerted by many classes of defective and defector mu-
tants. It is suspected that most interfering interactions at the pro-
tein level occur because most viral proteins function as homo- or
FIG 16 Interconnected parameters that contribute to disease progression.
Replication rate is directly related to the viral load. Viral load, together with
population genetic heterogeneity, permits exploration of sequence space for
fitness increase. One of the elements of viral pathogenesis is cellular perturba-
tion by virus that displays effective interactions with cells, tissues, and organs,
which is increasingly likely when the virus is enriched in potentially functional
mutants. Therefore, a major aim of therapy is to oppose increases of viral load
or viral fitness. See the text for experimental evidence and exceptions.
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heteropolymeric complexes that display decreased activities when
some of the monomeric components have amino acid substitu-
tions at sites critical for protein-protein interactions (Fig. 13).
While interference exerted either by specific viral mutants or by
unfractionated mutagenized viral RNAs has been demonstrated
experimentally, the proposedmechanismofmalfunctioning poly-
meric complexes has yet to be proven. Obviously, not only viral
proteins but also viral RNA can participate in interference by vir-
tue of its involvement in many RNA-RNA and RNA-protein in-
teractions.
When the implications of quasispecies dynamics were under-
stood, it became clear that synthetic vaccines or antiviral agents
used as monotherapy were doomed to failure. It is paradoxical
that important advances in biotechnology during the second half
of the 20th century have pushed antiviral interventions in the
direction contrary to what is required to control diseases associ-
atedwith viruses that formquasispecies swarms. Indeed, synthetic
vaccines consisting of antigenic peptides or proteins expressed
from biological vectors became amenable to biotechnological
production with the advent of peptide synthesis technology and
recombinant DNA methods. Conceptual oversimplifications, to-
gether with the ease of production of synthetic antigens, led to
hundreds of projects without prospects of being able to effectively
prevent diseases associated with quasispecies swarms. Complexity
cannot be fought with simplicity. Unless a new paradigm in vac-
cinology is developed, whole-virus attenuated or inactivated vac-
cines remain the only ones with some chance to confer protection
against infection by highly variable viruses.
Lethal mutagenesis was stimulated by the need to counteract
the quasispecies adaptive abilities. A further development has
been theoretical and experimental evidence that the efficacy of
antiviral treatments can be improved by a judicious use of antivi-
ral inhibitors and mutagenic agents, administered sequentially or
in combination, ideally in a personalizedmanner. Treatment pro-
tocols are expected to take into account choice of drugs and drug
doses depending on the patient profile, pharmacokinetics, drug
compatibilities, viral genotype, and mutant spectrum composi-
tion of the virus to be controlled. In using drug combinations, an
understanding of possible interactions among drugs is essential,
since the effect of two drugs often cannot be accounted for by the
effects of the individual drugs (282, 553, 809, 882). This is partic-
ularly true in the case of interaction between inhibitors and mu-
tagens, since the former can impede the activity of defectors and
the latter can contribute to generate inhibitor-resistant mutants
(393, 649, 650) (Fig. 15). Drug interactions that can affect viral
deadaptation constitute yet another manifestation of quasispecies
acting as a unit of selection.
New developments in the interphase between theory and ex-
periment can be expected in coming years. One important aspect
studied theoretically by Manrubia and her associates is the effect
of spatial interactions or proximity relationships among replicat-
ing quasispecies, in relation to host cell availability, and defense
responses. Together with the permissivity or limitation in the
spread of genomes, they can affect the outcome of competition
among genomes and their survival (9, 98, 158). Although some
connections between theoretical models of virus spread and the
effects of MOI in experimental infections have been made (508),
additional studies in cell culture and in vivo are needed. Spatial
effects are likely to influence viral survival, and, in principle, this
should be approachable through genome comparisons at different
sites in an infected host. Subpopulation frequency should be in-
terpreted in relation to local concentrations of components of the
immune response or antiviral agents.
Quasispecies theory had its major impact in interpreting the
behavior of RNA viruses, but the theory can be applied to other
biological systems due to two related facets of the theory: (i) the
impact of high mutation rates and (ii) the collective behavior of
biological ensembles. The extension to DNA viruses is obvious,
since DNA viruses whose replication is catalyzed by a low-fidelity
DNA-dependent DNA polymerase will display quasispecies dy-
namics with the consequences described in previous sections. A
less clear situation is encountered with the complex DNA viruses
whose replication is catalyzed by high-fidelity polymerases. De-
spite all viruses displaying adaptability to different environments,
it is not obvious whether complex DNA viruses form mutant
swarms. Among other issues, to what extent cellular postreplica-
tive repair pathways can cope with the repair needs in viral DNA
accumulated in replication factories needs to be investigated. A
point to be stressed is that the larger the complexity of a genome,
the lower its relative capacity of exploration of sequence space.
Thus, the majority of consequences of quasispecies dynamics for
virus adaptation and deadaptation will have a higher temporal
impact for short RNA genomes than for largeDNAgenomes, even
if they display comparable mutation rates (additional discussion
of quasispecies for DNA viruses can be found in references 192,
197, and 204).
A similar argument applies to cells, which have genomes orders
ofmagnitude larger than those of viruses. However, the advantage
of high mutation rates for biological systems has been docu-
mented with selection of mutator subpopulations of bacteria, of-
ten associatedwith increased pathogenesis (reviewed in references
192 and 619). Bacterial collectivities display cooperative interac-
tions that canmodulate their virulence. Genetic heterogeneity and
population complexity of cancer cells are important determinants
of their adaptability, including the capacity to invade distant or-
gans inmetastasis (121, 348). Even if the term quasispecies is used
mainly in the field of virology, cells in which a heterogeneous
ensemble is the target of selection follow the same conceptual
principles of quasispecies theory (for reviews of extension of the
quasispecies concept to cell populations, see references 530 and
619 and references therein).
The connection between evolution of viral quasispecies and of
early life forms in an RNAworldmay have yet another remarkable
confluence. In the discussions on the tree of life and a putative
cellular RNA world (285), a mode of precellular evolution remi-
niscent of complementary intramutant spectrum interactions has
been proposed (870). In this view, early cellular evolution in-
volved frequent exchanges of genetic material at a stage prior to
the establishment of those barriers that defined the genetic lin-
eages that evolved toward the ones we see today. This model pro-
poses a rapid Darwinian evolution, with high rates of lineage ex-
tinction and generation, close to mechanisms described in this
article.
An intriguing extension of quasispecies to a non-nucleic acid
system has been to conformation heterogeneity in prions as a de-
terminant of host range (482, 483, 759, 857). Strains of prions are
defined by differences in conformation of the same host prion
protein (PrPC). Recent data onDarwinian behavior of prions sug-
gest that a prion consists of a “quasispecies” of conformers and
that the conformer that “replicates” (that is, converts into the
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aggregated pathological form [PrPSC] of PrPC) is more efficiently
selected. In this extension of quasispecies, “mutation” is not an
inheritable change in a nucleic acid but a change of conformation
of the prion protein. According to this model, a prion consists of a
major conformation and a spectrum of conformation variants
(147, 482, 857). The quasispecies behavior of prions encompasses
selection of inhibitor-resistantmutants and preexistence of inhib-
itor-resistant mutants in prion populations never exposed to the
inhibitor, a remarkable parallelism with viral quasispecies behav-
ior. Rather than being separated bymutation, substrains of prions
are separated by the activation energy barrier needed to convert
one conformation into another. Adaptation can be viewed as a
movement in “conformation space.” As in the case of viruses,
recognition of quasispecies in prions may open new therapeutic
approaches to prion disease, although no effective therapy is yet
foreseen (857).
Conversion among conformations in a protein originates in
alterations of actions among amino acids, dependent on environ-
mental conditions.Quantummechanical fluctuations in chemical
bonds that determine mutations in genetic systems may also de-
termine conformations in proteins.
The extensions of concepts conveyed by quasispecies to dispa-
rate systems such as viruses, cell collectivities, and prions speak of
the power of the theory. Despite this review having fundamentally
addressed experimental quasispecies evolution, there are ongoing
developments in quasispecies theory, with a remarkable cross talk
between theory and experiment.
Eigen stated that “Theory cannot remove complexity, but it
shows what kind of ‘regular’ behavior can be expected and what
experiments have to be done to get a grasp on the irregularities.
This is more true in biology than in any other field of the physical
sciences” (233). In this area of research, theory has inspired exper-
iments and vice versa. There is much to be gained from the study
of biological and macromolecular entities as spectra or related
variants, since in such spectra lie their adaptedness.
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